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ABSTRACT
PI3-kinase mediates cSrc Activation and Podosome Formation through the Adaptor
Protein, AFAP-110, in Response PKCα Activation.
Valerie Glynis Walker
Significant evidence indicates the existence of cross-talk between PKCα, cSrc and
PI3-kinase signaling pathways. Activation of each of these kinases results in substantial
changes in actin filament concomitant with increased cell motility and invasive potential.
The ability of PKCα to induce cSrc activation requires the adaptor protein, AFAP-110. This
results in the disruption of the actin cytoskeleton and the formation of motility structures.
Activation of PI3-kinase has been shown to direct up-regulation of PKCα activity. However
the ability of PKCα to activate PI3-kinase remains controversial. Further, the integrity of
the PH1 domain was required for PMA induced colocalization between AFAP-110 and
cSrc, and PH domains are known to interact with PI3-kinase generated lipid products. In
this work, we wanted to determine whether PI3-kinase signaling played a role in PMA
induced colocalization between AFAP-110 and cSrc. Thus, we hypothesize that PKCα
directs AFAP-110 to colocalize with cSrc in a manner dependent upon PI3-kinase activity,
subsequently activating cSrc and directing changes in actin filament integrity. Chapter 1 of
this dissertation was a literature review of cSrc, AFAP-110, PI3-kinase and PKCα signaling
pathways. Chapter 2 examines the role of PI3-kinase activity in mediating the ability of
AFAP-110 to active cSrc in response to PKCα activation. Chapter 3 discusses the ability of
PI3-kinase activity to mediate AFAP-110 directed cSrc activation and podosome formation
in response to PKCα activation. Chapter 4 examines the role of AFAP-110 in PI3-kinase
mediated cell motility in ovarian cancer.
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CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW
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INTRODUCTION
The complexity of cell signaling pathways in regulation of various cellular
functions has proven to a complicated. Several known signal proteins have been
shown to interact directly and indirectly in mediating physiological and
pathological processes, such as bone remodeling and tumor cell invasion.
Several key signal proteins continue to resurface in playing key roles in these
processes, including PKCα, cSrc, and PI3-kinase. There is significant evidence
to indicate the existence of cross-talk between PKCα, cSrc and
phosphatidylinositol-3-kinase (PI3-kinase), and disruption of these pathways
result in atypical cell signaling. The cross-talk between cSrc and PKC is well
supported; however the intercommunication between PKC and PI3-kinase
pathways remains debated. Activation of each of these kinases results in
substantial changes in actin filament integrity and cell morphology concomitant
with increased cell motility and invasion.
While it is well established that PKCα, cSrc and PI3-kinase participate in
many of the same signaling pathways, it is unclear as to how these kinases work
together to regulate normal cell processes. Although PKCα was able to
phosphorylate cSrc in vitro, studies indicate that PKCα does not activate cSrc
directly. We have shown that the adaptor protein AFAP-110, was able to interact
with both Src family kinases and PKC isoforms to facilitate signaling between
these two proteins. However, the mechanism by which phosphorylated AFAP110 colocalized with inactive cSrc has remained elusive. Thus we hypothesized
that a lipid signal may fulfill this role. Studies have shown that PI3-kinase
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generated lipid products can result in the activation of PKC. Further, activation of
certain PKC isoforms, such as PKCδ and PKCε can promote activation of PI3kinase. In addition, it has been well established that cSrc can promote the
activation of PI3-kinase through inactivation of the D3 lipid phosphatase, PTEN.
Previous work by our laboratory indicated that AFAP-110 might act as an adaptor
protein to link cSrc and PKC signaling pathways with PI3-kinase. The focus of
this literature review is to highlight the important studies involving PI3-kinase,
cSrc and PKC signaling, and to explain the link between these kinases and how
this cross-talk can promote cancer formation and progression.

THE STRUCTURE AND FUNCTION OF SRC FAMILY MEMBERS.
The Src family of non-receptor tyrosine kinases (SFK) is essential in multiple
cellular processes including cell cycle regulation, proliferation, apoptosis,
survival, adhesion and motility. These kinases function to relay extracellular
signals to specific effectors through tyrosine phosphorylation. The Src kinase
family consist of nine members based on sequence similarity of the catalytic
domain, and includes Src, Yes, Blk, Lyn, Fyn, Yrk, Fgr, Hck, and Lck (239).
Each member shares a common domain structure consisting of four Src
homology regions (SH1-4), a unique domain, and a carboxy terminal regulatory
region (Figure 1) (25; 238). The highly conserved catalytic domain (SH1) is
responsible for substrate binding and tyrosine phosphorylation and is essential
(27). This domain includes an activation loop that contains a conserved tyrosine
residue at position 416 (Y419 in humans) which regulates kinase activity. The
tyrosine 416 is autophosphorylated and induces a conformational change
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“unfolding”, which exposes the catalytic domain to substrates (27; 238). Further,
the carboxy terminus of Src plays a major role in regulating the kinase (232). All
family members have a 15-19 amino acid carboxy terminal tail which contains a
tyrosine at position 527

(530 in humans). Phosphorylation of this tyrosine residue is done by C-terminal
Src kinase (Csk) resulting in significant reduction (greater than 98%) in kinase
activity and suppresses the effects of the activating Y416 phosphorylation.
Constitutive kinase activity and cellular transformation can result from a point
mutation of tyrosine 527 residue to a phenylalanine (Src527F)(27).
The localization of SFK members to the plasma membrane is regulated by
the SH4 domain. This domain is 12 amino acids in length and contains a
myristoylated glycine at position 2 that is found in all SFK members that allows
the protein to be anchored to lipid membranes. The lack of this myristoylation
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signal does not alter kinase activity but fails to induce cell transformation.
Further, membrane localization is aided by a palmitoylation sequence in SFK
members other than cSrc, Blk and the p61 isoform of Hck (27). In replacement of
this palmitoylation, these kinases contain a series of basic residues in the amino
terminus that contact acidic membranes. The SH2 and SH3 domains of SFK
members have been identified in several other classes of cellular proteins and
are necessary for mediating protein-protein interactions. These domains bind to
phosphotyrosine (P-Tyr)-containing sequences or proline-rich sequences,
respectively (226). The optimal binding consensus sequence for the Src SH2
domain is pYEEI (183); however, the phosphotyrosine sequence recognized by
each individual Src family member is specific. Several proteins have been shown
to be Src SH2 binding partners, including focal adhesion kinase (FAK), p85
subunit of PI3-kinase, p130Cas, and AFAP-110 (80; 204; 235);(169; 170; 211).
Tyrosine phosphorylation of FAK by Src results in an increase in cell survival and
anchorage-independent growth in transformed cells. Further, this
phosphorylation event has been shown to regulate calpain-dependent turnover of
focal adhesions and cell migration (37; 258). The SH3 domain of Src is important
for the regulation of kinase activity, localization, substrate identification and
association (185). Known Src SH3 binding partners include the p85 regulatory
subunit of PI3-kinase, AFAP-110, and paxillin (80; 151; 204; 211).

The Regulation Of Kinase Activity Of The Src Family.
The numerous roles that Src plays in cellular processes which makes
strict regulation necessary, because continuous kinase activity could have
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detrimental effects leading to cellular transformation and tumor formation. In
resting cells, Src family kinases are inactive and exist in a folded “closed”
conformation. This conformation is the result of intramolecular interactions where
the SH2 domain contacts the phosphorylated tyrosine 527 and surrounding
amino acids in the carboxy terminal tail. In addition, the SH3 domain binds the
SH2-kinase linker region and the amino terminal portion of the catalytic domain
(27; 226). These intramolecular associations prevent ATP and substrate binding
to the catalytic domain, but also the binding of the SH2 and SH3 domains to
binding partners. Full activation of SFK was the result of dephosphorylation of
tyrosine 527 and subsequent autophosphorylation of tyrosine 416. Further,
binding of high affinity ligands or modification of essential residues of the SH2 or
SH3 domain disrupts this intramolecular association will also promote an
increase kinase activity. Examples of high affinity binding partners for the Src
SH2 domain include FAK and SH3 binding partners such as AFAP-110 (5; 97;
169).
Src family kinases have been shown to localize to distinct cellular
compartments in a manner that is dependent of cell type and activation state. In
fibroblasts, cSrc is normally found associated with calcium-independent (cationindependent) mannose-6-phosphate receptor perinuclear vesicles, near the
microtubule organizing center (MOC) of the cell and the plasma membrane (60;
124). The distinctive localization patterns of Src in different cell types suggest
that specific localization was more complex than simply that regulated by the
SH4 domain. Several studies examined the ability of cSrc to associate with
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various cellular structures, and which amino acids of cSrc regulated this
localization. The association of Src with the cytoplasm appears to be the
responsibility of the amino terminal amino acid 1-14. However, amino acids 55111 along with amino acids 1-14 promoted Src association with both the plasma
membrane and perinuclear vesicles. Interestingly, amino acid residues 204-259
of the SH2 domain in cooperation with amino acids 1-14 promote localization
mainly to the perinuclear vesicles. Kaplan et al. determined that Src mainly
associates with endosomal membranes in fibroblast cells expressing cSrc, and
that these vesicles are distinct from lysosomal, Golgi apparatus and plasma
membrane vesicles (124). Consistent with these studies Redmond et al.
determined that these vesicles were actually part of the endocytic pathway (202).
Further the majority of Src was located on these vesicles which allowed Src to be
transported back to the plasma membrane during vesicular recycling. The signals
that initiate the movement of perinuclear Src to the plasma membrane remained
elusive. To address this, work by Fincham et al. indicated that translocation of
Src to the cell periphery was mediated by the actin cytoskeleton and regulated by
RhoA in response to growth factor treatment. Further, disruption of the actin
cytoskeleton abrogated the ability of PDGF stimulation to promote translocation
of Src to the plasma membrane (78). Thus we hypothesized that an adaptor
protein, such as AFAP-110, with the ability to contact the Src SH3 domain and
bind actin may be responsible for this translocation (82). It is known that
translocation and membrane association are required for complete activation of
Src, and we have previously identified that AFAP-110 fulfills this role (89; 253).
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Therefore comprehension of this pathway will provide a better understanding of
the mechanism of constitutive Src activation in cancer formation and progression.

The Role Of Src In Cancer Formation And Progression.
Several studies have linked Src to the progression and metastasis of
several types of cancer. Elevated cSrc protein levels and kinase activity have
been observed in several cancer types including breast and ovarian, and kinase
activity appears to correlate with disease progression (111; 234). This
unregulated activity appears to be linked to an increase in tumor motility and
invasive potential, resistance to apoptosis, and tumor associated angiogenesis.
To date, only one naturally occurring activating mutation in the src gene has
been described in a small subset of advanced human colon cancers (111).
Therefore, elevated Src kinase activity in cancer cells is most likely contributed to
reduced tyrosine phosphatases activation or the absence of regulatory proteins,
such as Csk. Interestingly, this increase in activity was not always mirrored with
an elevation in protein levels and was hypothesized to be associated with posttranslation modification. The correlation of cancer progression with Src activity
was observed in highly malignant adenomas which display the highest levels of
kinase activity and the greatest metastatic potential (39; 40). Ottenhoff-Kalff et al.
observed that 100% of breast cancers screened showed an increase in cellular
phosphorylation levels and 70% of these being the result of SFK activity (180).
Similarly, Rosen et al. found that cSrc activity was higher in breast tumors as
compared to adjacent normal tissue, while Verbeek et al. observed a 4-30 fold
increase in Src kinase activity accompanied by an elevation in protein levels
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(209; 249).
As mentioned earlier, abnormal cSrc activity has been shown to occur in
ovarian cancer. The knockdown of cSrc by siRNA in human ovarian cells
resulted in a reduction of anchorage-independent growth, decrease in tumor
growth and tumor vascularity. Similarly, this reduction in cSrc tyrosine kinase
levels in ovarian cancer xenographs reduced tumor growth and angiogenesis as
a result of concomitant reduction of VEGF mRNA levels as compared to ovarian
cancer cells that expressed normal levels of cSrc (259). The role of cSrc in tumor
progression has been extensively studied, but the contribution of cSrc in tumor
resistance to chemotherapeutic compounds is currently gaining attention
especially in ovarian and breast cancers. Work by Pengetnze et al. documented
that ovarian cancer cells that express a constitutively active form of Src resulted
in an elevation in PI3-kinase activation and FAK phosphorylation. This
phosphorylation of FAK resulted in the activation of downstream Ras, which in
turn can further promote the activation of PI3-kinase (186). Pengetnze et al.
examined the role of cSrc in chemoresistance on ovarian cancer cells and
indicated that cSrc activation resulted in an increase in PI3-kinase activation and
subsequent phosphorylation of Akt and forkhead transcription factor (186).
Further, inhibition of cSrc activity by PP2 abrogated the ability of these cells to
resist apoptosis initiated by both Paclitaxel and Cisplatin treatment. In
agreement, Planas-Silva et al. demonstrated, that the activation of cSrc and FAK
in estrogen receptor positive (ER+) breast cancer cells promotes cancer
progression and resistance to killing by taxol treatment (190). These studies
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indicate that elevated Src kinase activity can be linked to PI3-kinase activity and
that cSrc can play a key role in tumor development and progression to a more
aggressive phenotype.

The Structure And Function Of PI3-Kinase.
PI3-kinase has been shown to play a role in multiple functions including
apoptosis, cell survival, vesicle trafficking, cytoskeleton reorganization and cell
growth and angiogenesis (29; 35; 63; 116). The majority of these functions are
dependent on the lipid product acting as a second messenger.
Phosphatidylinositol kinases are a family of lipid and protein kinases divided into
three sub-families, including phosphatidylinositol-3-kinase (PI3-kinase),
phosphatidylinositol-4-kinase (PI4-kinase) and phosphatidylinositol-5-kinase
(PI5-kinase), based on the inositol ring position phosphorylated (85). The latter
two kinases will not be discussed in this literature review. Several studies have
indicated that the p110 catalytic subunits have a non-redundant function in the
regulation of many of these cellular processes. Phosphatidylinositol-3-kinase was
first identified as a lipid kinase and binding partner for oncoproteins, such as vSrc
and polyoma middle-T antigen (polymT).
The typical PI3-kinase is a heterodimer consisting of a 110 kDa catalytic
subunit and a 85 kDa regulatory subunit (35; 127). PI3-kinase is a lipid kinase
that phosphorylates phosphoinositides at the D-3 position of the inositol sugar
ring, generating PtdIns-3-phosphate (PtdIns-3-P), PtdIns-3,4-bisphosphate
(PtdIns-3,4-P2) and PtdIns-3,4,5-trisphosphate (PtdIns-3,4,5-P3). PtdIns-3,4,5-P3
is not normally detected in quiescent cells (35). In mammals, PI3-kinases are
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divided into three classes: Class I (IA and IB), Class II and Class III, based on
their structure and substrate specificity. Some authors indicate that existence of a
fourth class (Class IV), which are considered PI3-kinase-related based on
conserved sequence homology present within their catalytic domain; however,
this family does lack the PIK domain found in the other classes. These classes of
PI3-kinase-related enzymes exhibit only protein kinase function and include the
target of rapamycine (mTor) and members of the ataxia telangiectasia mutated
(ATM)/ataxia telangiectasia related (ATR)/ DNA-dependent protein kinase (DNAPK) family of enzymes (26; 138; 218). However, true PI3-kinases have both lipid
kinase activity and minimal protein kinase activity with the latter function
remaining controversial.
The eight members of Class I form heterodimers that consists of a 110-120kDa
catalytic subunit and a regulatory subunit. Class I is further subdivided into Class
IA and IB determined by which regulatory and catalytic subunits associate to
form the heterodimer, with Class IA being the major source of PtdIns-3,4,5-P3 .
The preferred substrate for Class I PI3-kinase appears to be PtdIns-4,5-P2 (86;
112). In mammals, three Class IA catalytic subunits encoded by three different
genes have been identified and include p110α (PIK3CA), p110β (PIK3CB) and
p110δ (PIK3CD); these subunits share approximately 42-58% sequence
homology. The p110α and p110β subunits are expressed in all tissues but p110δ
was mainly found in leukocytes (127; 207; 247). The domain structure of the
catalytic subunits are identical and contain a carboxy terminal catalytic domain,
an amino terminal regulatory subunit binding-site, a Ras homology binding
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domain, one C2 domain and a PIK domain (Figure 2) (127). The PIK domain is
present in all PI3-kinases and functions to regulate substrate binding and
presentation for phosphorylation (79). The catalytic domain contains the required
ATP binding-site and an adjacent lipid-binding site, which is responsible for the
phosphorylation of the inositol ring. The binding affinity for regulating the catalytic
subunit for ATP is highest in the presence of PtdIns-4,5-P2 followed by PtdIns
and PtdIns-4-P (36). The Ras-binding site regulates lipid kinase activity by
binding Ras-GTP (207). An increase in PI3-kinase

activity can result following the association of GTP-bound Ras or an activating
point mutation of the Ras binding site. However an inactivating mutation of this
binding site failed to abrogate oncogenic transformation associated with activated
forms of p110α and p110δ isoforms (135; 206; 207). Signals from receptor
tyrosine kinases (RTK) promote the activation of both the α and δ isoforms while
both RTK and G-protein-coupled receptors (GPCR) promote activation of p110β
(158; 167). The p110β catalytic subunit exhibits the weakest oncogenic ability as
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compared to p110δ, which was the strongest of these lesser tumorigenic catalytic
isoforms. Knockout of either the p110α or p110β isoforms results in early
embryonic death in mice (81). The C2 domain consists of approximately 80-160
amino acids and functions in calcium-dependent binding of phospholipids and
lipid kinase activity (251).
Class IB contains a single catalytic subunit, p110γ, which binds with the
largest identified regulatory subunit, p101. Structurally the p110γ catalytic
subunit is similar to the other classes of PI3-kinase except the amino-terminal
p85-binding site is replaced with a pleckstrin homology (PH) domain, however
significance of this domain is unknown (233). Currently, the p110γ has only been
identified in mammals and was mainly found in leukocytes (247). Knockout of
p110γ in mice are viable and fertile but exhibit defects in immune cells (81). In
contrast to other classes of PI3-kinase, this class was not activated by binding of
tyrosine-phosphorylated proteins. This catalytic subunit isoform was activated by
GPCRs and mutation of the Ras-binding site markedly reduced oncogenic
transformation of cells (251). To date, the p101 regulatory subunit is unique
because no known binding modules have been identified in its’ structure.
However, it was required for heterdimeric GTPaseβγ induced activation of p110γ
and subsequent lipid kinase activity (230). Overexpression of p110γ fails to
increase Akt phosphorylation but the expression of myristylated p110γ promotes
oncogenic transformation of CEF (251).
Three genes have been isolated that encode five regulatory subunits found in
Class IA PIK3r1, PIK3r2 (encodes p85β) and PIKr3 (encodes p55γ also known as
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p55PIK). However, the PIK3r1 gene undergoes alternative spicing to produce
three subunits the well-studied p85α, and the lesser characterized p55α and
p50α. The subunits bind to and regulate kinase activity of class I catalytic
subunits. The domain structure of p85α and p85β isoforms are identical and
contain an amino-terminal SH3 domain, a breakpoint cluster (BCR) domain
flanked by two proline-rich regions (PR1 and PR2), two SH2 domains (C-SH2
and N-SH2) and the p110 catalytic bind region (inter-SH2= iSH2) (Figure 3). Both
p85 isoforms serve as a binding

partner for the catalytic subunit and substrates for receptor or non-receptor
tyrosine kinases. In regards to their function, Otsu et al. demonstrated that the
deletion of one subunit, the others may compensate to allow PI3-kinase
activation in response to upstream signals (179). However, work by
Baltensperger et al. showed that p85β induced PI3-kinase activity was markedly
weaker than that observed with p85α following insulin receptor stimulation,
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indicating some variation in signaling between these regulatory subunits (16). In
contrast to the p85 regulatory subunits, the p55α and p50α splice variants do not
have the SH3, BCR and amino terminal PR1 domains. Instead these domains
are replaced by either 34 or 6 amino acids addition to the amino terminus of the
p55α and p50α, respectively. These additional amino acids residues found in
p50α are not encoded in the p85α sequence (109). However, PI3-kinase activity
was higher when the catalytic subunit was associated with p50α in response to
insulin signaling as compared to p85α (177). The addition of these amino acid
residues were hypothesized to promote an increase in PI3-kinase when they are
in complex with the catalytic subunit. In contrast, these splice variants may result
in a reduction of kinase activity in some cell types in response to insulin. For
example, in the brain and skeletal muscle p85 was not detected therefore p55α
functions to regulate PI3-kinase activity (109). However, in other tissues were
p85 was expressed, the p85 regulatory subunit complexes with the p110α
catalytic subunit resulting in kinase activity in response to insulin receptor
substrate (IRS) signaling (244). To the contrary, these authors and others
showed that PI3-kinase activity in response to insulin receptor signaling was
higher when the catalytic subunit, p110α, was associated with the p50α
regulatory subunit (110; 225; 243). These studies indicate that each of these
regulatory subunits regulate PI3-kinase lipid kinase activity differently and was
based on the structure of the amino terminal region, cell type and upstream
signaling.
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The requirement and functions of the regulatory subunits in development
has shown that deletion of all subunits results in early embryonic death (E12.5d).
Furthermore, deletion of both p85α and p85β isoforms or the catalytic subunit,
p110α also results in death (20; 84). These data indicate that both p85α and
p85β regulatory subunits and p110α play a role in development that cannot be
compensated by p55α/p50α or p110β, probably because this subunit was
responsible for targeting the PI3-kinase catalytic subunit to substrates, such as
the insulin receptor (101).
Src homolog-3 (SH3) domains are 50-70 amino acid residues in length
and have been identified in a number of proteins, including Src. In general, SH3
domains recognize proline-rich regions with a core conserved consensus
sequence, -PxxP-. The selectivity and affinity of SH3 domains for their substrates
are relatively low and these associations are weak (160). The target proline-rich
region forms hydrophobic and hydrogen bonds with a hydrophobic cleft
containing tyrosine and tryptophan residues of the SH3 domain (176). Several
SH3 binding partners have been identified for p85, including SOS and Cbl, both
of which contain the consensus sequence -RKLPPRPRR- (177). This domain
functions to localize the PI3-kinase complex resulting in kinase activation.
However, the association of p85 with Cbl results in downregulation of PI3-kinase
activity in a manner independent of receptor signaling (75; 96). The BCR is a
200 amino acid residue region found in a number of proteins, including members
of the Rho subfamily of GTPases. The greatest sequence divergence between
the p85α and p85β regulatory subunits fall within this domain and may contribute

16

to their differences in function (179). The BCR region of p85 consists of 7 helices
with the middle 4 helices that contain the residues needed for G-protein binding
(168). The BCR region has been shown to bind to Cdc42Hs and Rac but not Rho
and this association does not result in GTP hydrolysis or GTPase activation (168;
241; 273). The exact function of this association was hypothesized to function in
localization and sequestration of both PI3-kinase and Cdc42Hs, but this function
is not well understood. The p85 regulatory subunit contains two SH2 domains,
one amino terminal (N-SH2) and one carboxy terminal (C-SH2), which recognize
phosphorylated tyrosine residues. In general, SH2 domains are approximately
100 amino acids in length and have been identified in over 100 proteins, to date.
Specifically, the p85 N-SH2 domain prefers closely spaced tyrosine
phosphorylation sites, such as those found in PDGFR (Y740 and Y751) and
polyoma mT antigen (Y315 and Y322). Phosphorylation of the tyrosine residue
within the –pYMxM- conserved sequence binds to the p85 SH2 domain and
promotes recruitment of PI3-kinase to cell membranes (34; 207; 216; 255). In
addition to binding tyrosine-phosphorylated proteins the C-SH2 domain has the
ability to bind phosphoinositides, mainly PtdIns-4,5-P2. Ching et al. showed that
the carboxy terminal SH2 domain contains the PtdIns-4,5-P2 binding consensus
sequence which also binds PtdIns-3,4,5-P3 with high affinity. Further, mutation of
the Arg residues at positions 18 and 29 promote the association with PIP2 and
PIP3, respectively. Thus it was hypothesized that the binding of PtdIns-4,5-P2
displaces the bound tyrosine phosphorylated proteins resulting in localization of
PI3-kinase to the cell membrane (50; 260).
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Class II members are similar amino acid sequence as Class IA members
but are larger in size with an average greater than 170kDa. These enzymes
contain two C2 domains (C2A and C2B), the carboxy terminal C2B domain which
regulates the kinase through binding of phospholipids or calcium (see Figure 2)
(120; 230). To date, three PI3K-C2 isoforms (α,β and γ) have been identified in
mammals and they are encoded by three separate genes (247). The PI3K-C2α
and PI3K-C2β isoforms have been detected in all tissues but the PI3K-C2γ has
only been isolated from the liver. Other members of this family consist of those
isolated from Drosophila, 68_D and cpk, and murine m-cpk and p170 (156; 165;
250). The C2 domain was first identified in mammalian calcium-dependent PKC
isoforms (120). PI3K-C2 mRNA levels are the highest in the heart and ovary as
compared to other tissues. PI3-kinase-C2α utilizes PtdIns and PtdIns-4-P as
substrates, however PtdIns-4,5-P2 serves as a substrate in the presence of
phosphatidylserine (PtdSer), with the latter remaining controversial (67; 230).
Interestingly, PI3-kinase-C2α and p170 differ from other PI3-kinases because
they are not susceptible to PI3-kinase inhibitors, LY294002 and wortmannin (67).
Further, PI3-kinase-C2 lacks both the p85-binding motif and the type II
polyproline motif (-PPLPPR-) found in other in other classes. Further, in resting
cells Class II kinases are localized to the cell membranes, including the plasma
membrane and some low-density microsomes, specifically, PI-3K-C2α
concentrates in both the TGN and clathrin-coated vesicles (8; 66). However, the
mechanism of activation remains unclear and is currently under investigation.
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Class III PI3-kinase family members are classified as being solely protein
kinases and are related to Saccharomyces cerevisiae gene vesicular-proteinsorting protein (Vps34). Vps34p and its homologues recognize PtdIns
specifically and are believed to produce the majority of the cellular PtdIns-3-P
(230). However, it is widely believed that this kinase is constitutively active
because of the constant levels of PtdIns-3-P in the absence of cellular stimulation
(230; 247). Previously, these kinases were demonstrated to play a role in vesiclemediated trafficking and vesicular sorting, however this remains a controversial
function in humans (217).

The Regulation Of Lipid Kinase Activity Of Class I Family Of PI3Kinase.
PI3-kinase activation results in the formation of the secondary messenger
phosphoinositides-3,4,5-trisphosphate (PtdIns-3,4,5-P3), which functions in
recruiting of PIP3 binding proteins to cellular membranes (251). The individual
PtdIns produced depends on the upstream signals and the activated lipid kinase.
For example, certain mitogenic signals promote the production of PtdIns-3,4,5-P3
followed by a delayed increase in PtdIns-3,4-P2 with no change in PtdIns-3-P
levels (9; 114). The levels of these phospholipids were dependent on a balance
between the activity of the generating lipid kinase and the reducing lipid
phosphatase.
Several lipid phosphatases have been identified to regulate the levels of
D3 phosphorylated PtdIns present in the cell at any given time. The 3- and 4phosphatases fall into several classes and include Cx5R-PI and type II 5-
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phosphatases. Cx5R-PI does show homology to the tyrosine phosphatases but
uses PtdIns phosphorylated at D3 or D4 position as substrates. The Cx5R-PI D3
phosphatase members include the tumor suppressor, PTEN. Phosphatase and
tensin homolog on chromosome 10 (PTEN) dephosphorylates that D-3 position
of PtdIns and the PtdIns-3,4,5-P3 mimic, Ins-1,3,4,5-P4 in vitro (31; 157; 245).
PTEN is conserved in all species and its activity antagonizes growth factor
induced PI3-kinase. PTEN is a 403 amino acid protein and contains a tandem
phosphatase, PDZ binding motif and C2 domain. In addition, PTEN exhibits a
wide catalytic domain which allows for the bulky PtdIns and conserved lysine
residues facilitate binding to PtdIns-3,4,5-P3. In vitro, the C2 domain associated
with lipid vesicles and was believed to localize PTEN to membranes adjacent to
its lipid substrates. The carboxy terminal PDZ binding motif promotes the
association with PDZ containing proteins, such as MAGI-2/3, promoting
translocation to tight junctions in epithelial cells and was required for PTEN
function (245). Tumor associated mutations have been identified to occur in the
carboxy terminus of PTEN and alters both kinase activity and protein stability (91;
248; 262). SH2 domain-containing inositol-5-phosphatases (SHIP) are members
of the type II 5-phosphatases. Two SHIP enzymes have been identified, SHIP-1
and SHIP-2, with SHIP-1 being spliced into α and δ variants. SHIP-1 is mainly
found in hematopoietic cells whereas SHIP-2 was detected in most tissues (149;
187; 245). The preferred substrates for SHIP are PtdIns-3,4,5-P3 and Ins-1,3,4,5P4 and, under some circumstances, PtdIns-4,5-P2 (132). SHIP activity has been
shown to negatively regulate PI3-kinase mediated Akt activation as well as Btk
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and GLUT4 membrane localization (245). These are the most well-known
examples of lipid phosphatases and have been shown to play key roles in
regulating the level of PtdIns-3,4,5-P3 within a cell.
In addition to the regulation of it’s’ lipid products, PI3-kinase activity itself
can be controlled. One such method is through that the sequestered of the p85
regulatory subunit which prevents it from forming a complex with the catalytic
subunit. Both the p85α and p85β regulatory subunits can form homodimers
through the associations between the SH3 domains and the first proline-rich
region as well as intermolecular binding between the BCR domains (99).
However, the consequence of this association is unclear, but it was hypothesized
to block the binding of ligands to the SH3 and proline-rich motif to target
substrates. Similar regulation has been identified in Tec family member, Itk, with
SH3 binding to the intramolecular proline-rich region resulting in abrogation Grb2
SH3 binding (6). Further, dimerization may indicate a non-lipid kinase function of
the regulatory subunit. Under normal physiological conditions, the p85α subunit
was required for insulin receptor signaling to a mitosis regulatory adaptor protein,
p68-Sam (214). Several studies have demonstrated possible adaptor functions of
the p85 regulatory subunits, such as those observed with the truncated form of
p85α, p65, found in some cancers (117).
As SH2 binding partners for p85α are known to activate PI3-kinase
activity, it was proposed that the p110α/p85α complex represents an inactive
kinase complex and competitive binding to p85α may alter this interaction and
serve to activate lipid kinase activity (177). In quiescent cells, it was hypothesized

21

that the p85 regulatory subunits are constitutively associated with the catalytic
subunit. Upon stimulation, the heterodimer translocate from the cytosol to the cell
membrane where it associates with potential substrates. The catalytic subunit
binds to the iSH2 domain, which has been shown by molecular modeling studies
to form a coiled-coil (263). Specifically, the catalytic subunit binds to a highly
conserved TIF motif (threonine, isoleucine and phenylalanine) and this sequence
is present in most species (65). Many early studies indicate that the binding of
the p85α to the p110α subunit was required for maximal activation of lipid kinase
activity by increasing the affinity of the kinase domain for ATP compared to
catalytic subunit alone (261). However, Backer and colleagues reported that the
p85α subunit serves to both stabilize the p110α subunit and repress its kinase
activity (267). The regulatory subunit plays a role in localizing the catalytic
subunit adjacent to lipid substrates, binds to, and recruits tyrosine
phosphorylated proteins. The p110α and p110β catalytic subunit can regulates it
own activity by phosphorylating serine 608 on the p85α and p85β and not the
spliced isoforms (81; 230; 261). While the p110δ catalytic subunit regulates its
function through autophosphorylate of the carboxy terminal region resulting in
down regulation of kinase activity (230). Therefore, substantial evidence exist to
show that the regulatory subunit of PI3-kinase function to regulate activity and
stability of the catalytic subunit. PI3-kinase activity can also be regulated by the
catalytic subunit through phosphorylation.
It is well established that the PI3-kinase/Akt pathway has many other
targets including NF-κB (208), BAD (61), p70S6kinases (166), glycogen
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synthase kinase-3 (57), and c-Jun N-terminal kinase (JNK) (133). The bestknown downstream target of PI3-kinase is the serine-threonine kinase Akt, which
transmits survival signals from several growth factors (178). Akt is
phosphorylated by phosphoinositides-dependent kinase-1 (PDK1) and maybe
PDK-2, with the later remaining controversial, resulting in membrane
translocation and activation (4; 14). PDK-1 is a 63kDa serine/threonine kinase
found in all tissues and mainly functions in phosphorylating (Thr 308) and
activating Akt. PDK-1 binds PtdIns-3,4,5-P3 and PtdIns-3,4-P2 with high affinity
via its two PH domains, resulting in translocation to the plasma membrane.
Interestingly, activation of PDK-1 was not dependent on lipid binding because of
the high basal activity of cytosolic PDK-1 (245). PDK-1 has also been shown to
prime other AGC kinases, such as PKC, resulting in their activation (230). Akt
may also be phosphorylated by PDK-2, which remains controversial, resulting in
activation. Possible candidates for PDK-2 include integrin-linked kinase (ILK),
PKC, DNA-dependent protein kinase and TOR/Rictor complex (251).
Collectively, these studies indicate that PI3-kinase/Akt pathway function in a
number of normal cellular processes and abnormal signaling may result in and
correlate with cellular transformation and tumor formation.

The Role Of PI3-Kinase In Tumor Formation And Progression.
The role of cellular homologues of PI3-kinase in tumor progression has
been extensively studied (reviewed in (11)). To fully understand its’ role in
cancer, the function of PI3-kinase in normal physiological processes must first be
discussed. Further, PI3-kinase functions in various physiological process,
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including cell survival, cell migration and cell proliferation. PI3-kinase generated
lipid products function as secondary messenger and regulation of these functions
are mainly via activation of downstream targets, indicating that under
pathological conditions, an increase in PI3-kinase activity may promote tumor
formation and tumor cell invasion.
The role of PI3-kinase in tumor formation was initially identified to be
associated with its’ retroviral form. The oncogenic retrovirus, Avian sarcoma virus
16 (ASV16) was first identified in the late 1980s as a cause of spontaneous
hemangiosarcomas in young chickens and the ability to transform chicken
embryo fibroblast (CEF) in culture. Further examination and characterization of
ASV16 revealed a single truncated viral Gag sequence fused with the avian
cellular p110α catalytic subunit, named as v-p3k (7; 43). Several key differences
have been identified between the oncoprotein, v-p3k and its’ non-transforming
cellular homolog, c-p3k. However, that main variation was the viral Gag
sequence (p19, p10 and p27) replaced the first 13 amino acid residues of c-p3k,
which was not required for transformation. The addition of the Gag sequence
drives localization of the protein to the membrane and promotes in activation,
similar to myristylation or farnesylation. This was confirmed by Aoki et al. who
demonstrated that transformation of chicken embryo fibroblast cells with c-p3k
requires either myristylation, which mimic that of Gag fused v-p3k or c-p3k.
Further, it has been hypothesized that the deletion of the amino terminal residues
and the mutations in the p85 regulatory binding site in conjunction with Gag
sequence, are required for the oncogenic activity of v-p3k (7; 43; 133).
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The PI3-kinase/Akt pathway has been implicated in cell cycle progression
and evasion of apoptosis. The ability of PI3-kinase to regulate cell cycle
progression is mediated by PDK-1 activation of Akt and p70S6K results in
activation of downstream targets including E2F and eukaryotic translation
initiation factor-4E (eIF4E)(92);(41). The promotion of survival appears to be
contributed to the downstream targets of Akt, which include BAD (70); caspase-9
(32);(274). Specifically, in ovarian cancer cells activation of the PI3kinase/Akt/mTor pathway regulates the G1 phase cyclins and promotes cell cycle
progression (88). Collectively, these studies indicate that the PI3-kinase/Akt
pathway can promote cell cycle progression that can in turn contribute to cancer
cell growth and progression.
Substantial evidence exists to demonstrate a link between tyrosine
kinases and Ras pathways that are up-regulated or mutated in a number of
cancers and the PI3-kinase. For example, oncogenic Ras was usually the result
of a point mutation and was hypothesized to be an initiation event in cancer
formation (145; 146). The active form of Ras-GTP was able to bind directly to the
p110 catalytic subunit and in some cases the p85 regulatory subunit resulting in
activation of PI3-kinase. These associations may act synergistically with the
binding of the regulatory subunit to phosphotyrosine containing proteins (93;
207). Similar phenotype was observed in cells that expressed the Ras binding
site (K227E) mutant which is considered constitutively active form of PI3-kinase.
Several cancers have been reported to display an increase expression of
the p110α catalytic subunit as a result of gene amplification in ovarian and some

25

head and neck cancers. The majority of human cancers where an activation of
PI3-kinase is involved was mainly associated with the α isoform of the catalytic
subunit, however other catalytic subunit isoforms have been implicated to a
lesser extent. However, an increase in expression of p110β and p110δ isoforms
have been associated with colon cancers, bladder cancers and glioblastomas
(19; 163). The ability of these minor catalytic subunits to induce tumor formation
can occur but at a lesser extent. Work by Kang et al. indicated that the other
class I isoforms can promote tumor formation but each differs in the upstream
signaling requirement and ability to activate downstream effectors (122). Gain of
function mutation most frequently occur within the p110α (PIK3CA) gene with the
majority (47%) of these mutations occur in the helical region, similar to activating
mutations found in Ras (213). Samuels et al. indicated that 74/234 (32%) of
colon cancer expressed a mutated PIK3CA gene, however these mutations were
not observed in pre-malignant colorectal tumors. Furthermore, mutations were
isolated in 4/15 (27%) glioblastomas, 3/12 (25%) gastric cancers and a lesser
extent (≤8%) in lung (1/24) and breast (1/12) cancers tested. Greater than 75%
of somatic mutations (E542K, E545K and H1047R) have been identified to map
within the helical region (exon 9) or the kinase domain (exon 20) of human p110α
(155; 223) (254). Introduction of these mutations in to avian p110α resulted to an
increase in transformation of chicken embryo fibroblast similar to those observed
with myristylated controls. In addition, these mutations also display a gain of
function in kinase activity, in vitro as well as an increase in angiogenesis (10;
107; 122; 213; 251). Zhao et al. demonstrated that expression of the H1047R
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and E545K mutants in breast cancer cell lines resulted in an increase in
tumorigensis and that these mutation are not oncogenic in the p110β catalytic
subunit (272). Further, amplification of PIK3CA has been identified in 40% of
ovarian carcinomas, as well as some cervical cancers, which results in an
increase in protein expression and function (155; 223). Mutations within PIK3CA
most frequently occurring in ovarian cancer is E454A. Recent studies indicate
that mRNA levels of PIK3CA correlated with ovarian cancer formation as
compared to benign tumors (271). In addition, a gain of function has been
documented through amplification and elevation in phosphorylation in the Akt
portion of this pathway, was most likely the result of activation of PI3-kinase.
These studies indicate that gain of function mutation within the catalytic subunit
promotes cancer progression.
The amplification in PI3-kinase activity has been documented to mainly be
the result of the catalytic subunit but may be influenced by the regulatory subunit.
Work by several groups has demonstrated a potential role of the regulatory
subunit in tumor progression in the presence of a normal catalytic subunit. Gain
of function mutations in p85α have been identified in ovarian and colon
carcinomas. Some mutations result in the expression of a truncated form of the
p85α (p65) regulatory subunit which has been identified in both ovarian and
colon cancers. This truncation was the result of a deletion of the carboxy terminal
SH2 domain and 52 amino acid residues in the adjacent iSH2 domain and results
in an increase in PI3-kinase activity (117; 189; 224). In agreement, several
groups have shown the importance of the regulatory subunit in the progression of
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ovarian cancer. Kobayashi et al demonstrated that treatment of ovarian cancer
cells transfected with antisense p85 (AS-ODN) with TGF-β1 displayed a
reduction in invasiveness and metastasis similar to that observed following
treatment with PI3-kinase inhibitors. In addition, when AS-ODN ovarian cancer
cells were injected into the peritoneal cavity of nude mice these cells produced
smaller tumor size and an increase in survival of the mice (134).
Amplification of PI3-kinase activity in some human cancers can also be
contributed to either the activities of downstream target Akt, or the result of a loss
of function mutations or gene downregulation in the PTEN phosphatase. Work by
Lee et al. examined the role of PIK3CA and PTEN in chemoresistance of ovarian
cancer cells. This group indicated that an elevation in PIK3CA expression and
reduction of PTEN levels correlated with resistance to cisplatin treatment in
OVCAR-3 ovarian cancer cell lines (142). In agreement, Work by Yan et al.
demonstrated that overexpression of PTEN promoted sensitivity to cisplatin
resulting in p53-mediated apoptosis (265).

The Structure And Function Of Pkc.
Protein kinases C (PKC) is a large family of serine/threonine kinases and
belongs to the ACG superfamily, which also includes Akt. PKC is a multigene
family that consists of twelve isoforms divided into 4 subfamilies, based upon
their structure and activation requirements (105; 174; 175; 242). All PKC
isoforms include conserved domains (C1-C4) and intermingled variable regions
(V1-V5) (Figure 4).The 50 amino acid C1 domain contains a consensus
sequence identified in the phosphorylation sites of known PKC substrates,
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however these domains are not unique to PKC isoforms (102; 162). This
sequence functions as a pseudo-substrate (PS) that binds the carboxy

terminal catalytic domain, acting as an autoinhibitory mechanism and blocks
substrate binding (229). This domain also contains two cysteine-rich regions that
are required for diacylglycerol (DAG) and phorbol ester binding. The C2 domain
was the site of calcium and membrane binding, and PKC isoforms that lack this
domain do not require calcium for activation. This region also serves as the
binding site of the receptor for activated C kinase, RACK-1, and in some cases
phospholipids (17; 149; 162). Research shows that binding of calcium to this
domain increases its affinity for anionic membranes. The C3-V5 regions make up
the catalytic domain containing the ATP binding site, while the substrate binding
site and phosphate-transfer region occurs in the C4 (150). The carboxy terminal
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region contains a conserved phosphorylation site that functions to regulate
kinase activity and cellular localization.
PKC isoforms are divided into four subfamilies, including classical
(conventional), novel, atypical and PKD/PKCµ (PKC-like). The classical PKC
(cPKC) isoforms (α, βI, βII, and γ) are activated by phosphatidylserine (PtdSer),
calcium and diacylglycerol (DAG) or phorbol esters (130). These isoforms are
ubiquitously expressed, except for PKCγ, which was mainly restricted to the
central nervous system and the spinal cord (150). The novel PKC (nPKC)
isoforms (δ, ε, η, and θ) lack the conserved cPKC homology C2 domain, allowing
these isoforms to function independent of calcium binding (130). Different
isoforms of this family are activated by various combinations of lipids. PKCη was
strongly expressed in the skin and the lung, while PKCθ was expressed in
skeletal muscle, and to a lesser extent in the lungs, spleen, skin, and brain, while
PKCε and δ are expressed ubiquitously (129; 212). The atypical PKC (aPKC)
isoforms (ζ, and ι/λ) possess only one cysteine-rich zinc finger motif, and these
isoforms are not dependent on DAG or calcium although they still require the
presence of PS for activation (150). Similar to the classical isoforms, tissue
expression pattern of the atypical family varies. Structurally, both classical and
novel PKC isoforms contain tandemly repeated C1 domains, C1A and C1B,
however only one copy is present in the atypical isoforms. The C1B domain
regulates protein stability and binding promotes the localization to cell
membranes. The zinc binding motifs are not interchangeable, as mutation
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studies indicate that the second zinc motif functions in PMA-induced activation
and binding (162).

The Regulation Of Serine/Threonine Kinase Activity Of Protein
Kinase C.
In general, activation of PKC requires the fulfillment of three key
sequential serine/threonine phosphorylations events within the activation loop,
the turn motif and the hydrophobic motif. First, PKC binding and phosphorylation
of threonine 497 (T500 PKCβII) in the activation loop by PDK-1 is considered the
rate-limiting step. Second, autophosphorylation at threonine 638 (T641 PKCβII)
within the turn motif promotes a conformational change, locking PKC into the
active position, increases resistance to phosphatases and thermal degradation.
Further, phosphorylation at this position serves as a docking site for other
proteins, such as 14-3-3. Finally, autophosphorylation at serine 657 (S660
PKCβII) within the hydrophobic motif further promoting an increase in thermal
stabilization and a reduction to phosphates (171; 173). In resting cells, inactive
PKC is located in the cytoplasm, with the PS domain contacting the substratebinding domain in the catalytic domain. Upon cell stimulation, PKC is rapidly
translocated to the membrane, where it becomes activated by specific lipid cofactors. Further, this membrane association promotes a conformational change
exposing the active site, which was required for PDK-1 phosphorylation. Specific
membrane localization was determined by the individual isoform and is regulated
by the C1 and C2 domains. After phosphorylation, the kinase is released back
into the cytosol in its fully activated form. However, prolonged stimulation with
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activators such as PMA (TPA) results in the proteolytic cleavage by trypsin or
calpain to promote protein degradation and subsequent downregulation (172).
Under normal conditions, novel and classical PKC isoforms are activated by
growth factor induced phospholipase C signaling. PLC activation results in the
formation of DAG and IP3, in which DAG and Ca2+ released bind to and activate
classical PKC isoforms.

The Role Of Pkc Family In Tumor Formation And Progression.
The role of PKC in cancer progression was dependent on cell type and
upstream stimulation. PKC isoforms α, β and δ are most commonly associated
with cancer formation and progression. However, other PKC isoforms ι, ε and λ
have been identified in a small number of cancers (136; 257). Several
extracellular signals can trigger the activation of PKCα, including PMA and
growth factors (275). The activation of PKCα results in the stimulation of several
downstream effector proteins involved in gene transcription regulation, cell cycle
progression, and maintenance of the actin cytoskeleton (136).
Amplification of classical PKC isoforms, PKCα and PKCβ, has been
shown to promote cancer progression and promote that development of
chemotherapeutic resistance in ovarian cancer. Work by Chen et al.
demonstrated that overexpression of these PKC isoforms, mainly PKCα in
ovarian cancer cells resulted in an increase in resistance to Paclitaxel and Taxol.
In addition, examination of several ovarian cancer cell lines with known
resistance to these compounds expressed elevated levels of PKCα mRNA (48).
The ability of PKCα to promote chemoresistance may be associated with an
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increase in expression and stability of P-170 glycoprotein as well as downstream
targets, including glutathione-S-transferase. Downregulation of PKCα, following
prolonged exposure to TPA or use of siRNA promoted platinum compoundinduced apoptosis of ovarian and breast cancer cells (3; 136). Laboratory and
clinical studies indicate a major role for PKCα in tumor progression promoted the
development of a PKCα inhibitor, Affinitak™, for the treatment of breast and
ovarian cancers. In addition to PKCα, other PKC family members have been
implicated in tumor progression but to a lesser extent. These studies
demonstrate a major role for PKCα in the formation and progression of cancer,
as well as the development of chemoresistance.

The Cross-Talk Between PKCα AND cSrc Pathways.
The linkage of PKC and cSrc signaling pathways are well studied and
indicate that signal may flow in both directions, where Src activation results in
PKC activation and visa versa. For example, treatment of cells with bradykinin,
vasopressin, or PMA results in an increase in kinase activity of both cSrc and
PKC (89; 210). Likewise, treatment of neuroblastoma cells with PMA resulted in
the elevation of both FAK and cSrc activity, indicating that PKC can induce
activation of tyrosine kinases (28). Therefore, the activation of PKC appears to
direct the upregulation of cellular tyrosine phosphorylation levels and activation of
several tyrosine kinases, and these events correlate with a reorganization of
actin filaments into motility structures. Further, PKC was found to synergize with
authentic oncoproteins, like Ras and Src, to promote cellular transformation and
increase metastatic potential (18; 102). Several studies have shown that PKC
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activity was elevated and was hypothesized to be required for Src transformation
cells (62; 270).
Activation of either PKCα or cSrc results in similar effects on cell
morphology, including a loss in actin filament integrity, changes in cell shape and
stimulation of signals associated with increased motility and invasion (100; 108;
115; 234). Several studies support the existence of cross-talk between cSrc and
PKCα-mediated signaling pathways. Constitutive activation of cSrc or stable
expression of vSrc will concomitantly stimulate an increase in PKCα signaling,
suggesting that PKCα could function downstream of cSrc (62; 198; 270). In
addition, PKC phosphorylation induces the formation of lamellipodia and
filopodia, and these structures are observed in Src-transformed cells (73). Others
have shown that PKCα may function upstream as an activator of cSrc. Brandt et
al. demonstrated that PKCα can directly stimulate cSrc activity in rat aortic
smooth muscle cells, and the induction of Src kinase activity was necessary for
PKC-mediated actin reorganization (23).
Several studies have demonstrated that activation of PKCα results in the
subsequent activation of cSrc (23; 24; 28). The ability of PKCα to activate cSrc
was not due to direct interactions between these two kinases. Although PKCα
can phosphorylate cSrc in vitro studies using purified cSrc and PKCα
demonstrated that PKCα was unable to directly activate cSrc (24). Thus, the
ability of PKCα to activate cSrc was likely due to the activity of other proteins that
relayed signals from PKCα, which in turn directed activation of cSrc. Data
produced by our laboratory suggest that PKC serine/threonine kinases signal
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upstream of AFAP-110 subsequently results in cSrc activation. In addition,
AFAP-110 was strongly phosphorylated on serine and threonine residues in
Src527F transformed cells (123), contains several consensus sequences specific
for PKC phosphorylation (80), and contains two PH domains that have the ability
to mediate interactions with serine/threonine kinases like PKC (205). Recently, it
was demonstrated that AFAP-110 undergoes a conformational change in
response to serine/threonine phosphorylation that was concomitant with a
decrease in self-association and the formation of protein dimers (193). Extensive
studies by us have shown that AFAP-110 was able to bind the PKCα, β, γ and λ
isoforms of PKC via the amino terminal PH1 domain and deletion of this domain
abrogated the autoinhibitory interaction between the PH1 domain and the leucine
zipper motif (13; 196). Furthermore, AFAP-110 was demonstrated to be a
substrate for PKCα both in vitro and in vivo. Further analysis indicated that the
interaction of PKCα with AFAP-110 directed a conformational change that
destabilizes the ability of AFAP-110 to form multimers and promote actin filament
cross-linking (194; 196; 197). Collectively, these studies indicate that PKCα can
promote the activation of cSrc and disruption of actin filaments in a pathway that
requires AFAP-110.

The cross-talk between PI3-kinase and cSrc signaling pathways.
The ability of cSrc to regulate PI3-kinase activation and its effectors has
been well studied. It has been well documented in the literature that cSrc
activation will promote PI3-kinase activity following growth factor stimulation
(126; 137; 231). Extensive studies demonstrated a link between PI3-kinase
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signaling and vSrc transformation. Fincham et al. documented that association of
vSrc with FAK-mediated focal adhesions requires binding to the p85 subunit and
PI3-kinase activity. In addition, the SH3 domain of vSrc was required for
translocation from the perinuclear region to focal adhesions via the actin
cytoskeleton (77).
The ability of SFK to associate and activate PI3-kinase was first identified
in hematopoetic cells. Several studies have shown that these non-receptor
tyrosine kinases can physically associate with the p85 regulatory subunit of PI3kinase. The activation of PI3-kinase by Src family members, including cSrc, Fyn
and Lyn bind to the second proline-rich region of p85 via their SH3 domain, result
in the subsequent tyrosine phosphorylation in response to BCR/TCR receptor
engagement was associated with the binding of Lyn to the regulatory subunit of
PI3-kinase. The SH3 domains of SFK members, vSrc, Lyn and Fyn bind to the
proline-rich region (residues 84-99) of p85 resulting in PI3-kinase activity by
greater than 5 times over controls (125; 151; 191; 192; 211).
In addition to SH3 interactions these complexes, SFK can bind the SH2
domain of p85 resulting in subsequent tyrosine phosphorylation at position 688 of
p85. Interestingly, this phenomenon can occur following binding with Abl or vSrc
(59; 252). This phosphorylation within the C-SH2 was hypothesized to function in
both targeting PI3-kinase to specific locations and regulating lipid kinase activity.
Work by Chan et al. hypothesized that the regulatory subunit acts as a molecular
switch to regulate the activity of PI3-kinase in response to activate tyrosine
kinases, such as cSrc. This group showed that inhibitory function of the p85
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regulatory subunit was abrogated by association with active tyrosine kinases,
such as Src and EGF receptor, and this effect was synergistic with the activation
of Ras, Rac1 and Cdc42 (42; 59). According to this group, the cSH2 domain of
p85 binds tyrosine phosphorylated proteins and was subsequently
phosphorylated on Y688 by tyrosine kinases (i.e. Src) resulting in a
conformational change which allows the binding of small GTPases resulting in
PI3-kinase activation. These studies demonstrate that SFK can regulate PI3kinase activity directly via binding and phosphorylation of the regulatory subunit.
In addition to regulating the regulatory subunit of PI3-kinase, SFK may
regulate cellular levels of PtdIns-3,4,5-P3 and PI3-kinase activity indirectly.
Activation of PI3-kinase was also achieved by the tyrosine phosphatase, SHP-1.
Work by Cuevas et al. documented that T-cell receptor (TCR) activation of Lck
results in the phosphorylation of tyrosine 564 of SHP-1 allowing it to associate
with the p85 subunit promoting subsequent PI3-kinase activity. In addition, Src
and Lck promote an increase in cellular PtdIns-3,4,5-P3 by phosphorylating the
lipid phosphatase, PTEN, resulting in its inactivation and subsequent increase in
PI3-kinase activity. Lu et al. demonstrated that expression of dominant-positive
cSrc and Lck phosphorylate PTEN on tyrosine residues (i.e. Y336) results in the
reduction of PTEN stability (58; 153).
As mentioned previously, in quiescent cells cSrc was localized on
perinuclear vesicles. Several studies have indicated a possible role of PI3-kinase
was vesicular trafficking, including its requirement in the trans-Golgi network
(TGN). Research by Jones et al and others demonstrated that treatment of cells
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with PI3-kinase inhibitors abrogated the incorporation of calcium-independent
mannose-6-phosphate receptor (ciM6PR) into the TGN vesicles (87; 119).
Interestingly, cSrc has also been shown to associate with those vesicles in the
perinuclear region, further indicating that PI3-kinase can function in cSrc
signaling pathway. We hypothesize that PI3-kinase activity is required for AFAP110 to colocalize with inactive cSrc in response to PMA treatment.

The cross-talk between PKC and PI3-kinase signaling pathways.
The ability of PI3-kinase to direct activation of PKC has been well
demonstrated; however the ability of the reverse to occur has remained
controversial. The link between the PI3-kinase/Akt pathway and some PKC
isoforms has been shown to be mainly indirect via an intermediate signaling
protein, however PI3-kinase can directly interact with PKCδ, ε, ζ isoforms
following various stimuli, such as IL-2 (74; 94). It has been well established that
most PKC isoforms are activated by PI3-kinase effector PDK-1, by
phosphorylation of key regulatory serine/threonine residues within the activation
loop of PKC resulting in a confirmation change and subsequent activation (15;
140; 173). In addition to being able to activate PKC via PDK-1, studies have
indicated that PI3-kinase generated lipid products can direct the activation of
PKC. Numerous studies have indicated that PI3-kinase generated lipid products
can activate several PKC isoforms, including PKCδ, PKCε and PKCα (182; 227;
240). However, the mechanism by which this occurs remains controversial.
Several groups have shown that the addition of exogenous PI3-kinase generated
lipid products were able to activate PKC by binding the C2 domain resulting in
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the formation of motility structures, such as lamellipodia (63). Similarly, Lu et al.
demonstrated that increasing levels of PtdIns-3,4,5-P3 resulted in a proportional
increase in PKCα activation and recognition of target peptides. Further, the
authors hypothesize that recruiting of PKCα to target proteins was responsible
for this phenomenon (152). However, the requirements for this activation remain
debated. Toker et al indicated that the activation of PKC family members by PI3kinase generated lipid products, PtdIns-3,4-P2 and PtdIns-3,4,5-P3 requires the
presence of PtdSer (240). These studies indicate that PI3-kinase/Akt signaling
pathway is able to promote the activation of the PKC signaling pathway.
The ability of PKC to promote the activation of the PI3-kinase/Akt signaling
pathway has remained controversial. The majority of the data published
demonstrate an indirect link to PI3-kinase downstream effects. Huang and
colleagues were able to demonstrated that PMA treatment of JB6 epidermal cells
stimulated PI3-kinase activation and AP-1 formation, while pretreatment with
bisindolylmaleimide or LY204002 blocked AP-1 formation, indicating that PKC
could induce activation of PI3-kinase in conjunction with insulin stimulation in
epithelial cells (104). However, further studies using a dominant-negative form of
PKCα failed to abrogate PMA-directed activation of PI3-kinase in these cells,
indicating that perhaps PMA induced activation of another PKC isoform which in
turn activated PI3-kinase (103). This study was one of the few that showed a
direct link to PI3-kinase activity. One PKC isoform has been implicated in the
activation of Akt. It has also been shown that several PKC isoforms can directly
phosphorylation of Akt by acting in a similar fashion to PDK-1, and was thought
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to be PDK-2 (4; 14). In agreement, Kawakami et al. demonstrated that PKCβII
did indeed phosphorylate a serine residue at position 473 of Akt resulting in
activation, however this event varied by cell type and upstream stimulus (128). In
addition to Akt, studies have shown that PKC activation upregulated HIF-1α gene
transcription and may lead to stabilization of HIF-1α protein under normoxic
conditions (51; 181). HIF-1 is a heterodimeric transcription factor comprised of a
beta and alpha subunits. HIF-1 transcriptional activity is elevated in response to a
number of cellular signals, including and mainly hypoxia (219; 220). These data
indicate that cross-talk exists between PKC and PI3-kinase in a variety of cells in
response to a number of upstream signals. However, the mechanism by which
PKCα specifically directs PI3-kinase remains unclear.

Cell Motility And The Actin Cytoskeleton.
The cytoskeleton of a cell plays a essential role in many cellular processes
including maintaining cellular shape, organelle transport, cell polarity, cell
division, exocytosis, and the formation of motility structures (95). The
cytoskeleton is composed of three major components, which are actin filaments,
microtubules, and intermediate filaments. Actin filaments (microfilaments, or
stress fibers or F-actin) are polymers of globular actin (G-actin) proteins. A
multitude of actin-associated proteins work together with microfilaments
regulates cell shape, localize signaling complexes to specific locations within the
cell, and generates the protrusive force needed for membrane projections and
cell motility (33; 95).
Cell migration is required during development in which different cell types
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work together to regulate the formation and growth of tissues. In response to its
environment, cells respond to signals derived from ECM components, growth
factors and chemokines by extending membrane sheets (lamellipodia) or cellular
protrusions (filopodia) at the leading edge (256). These structures are composed
of highly organized actin filaments that generate a force that allows the cell to
migrate. At the same time, actin networks retract at the lagging edge of the cell,
resulting in a forward propulsion of the cell body (256). Alternatively, actin
filaments can be assembled into bundles (stress fibers) anchored to focal
contacts on the periphery of the cell (200; 256). A balance between a stress
fiber-rich and a lamellipodia-rich phenotypes is required for cell motility. The
alteration between these phenotypes was achieved through actin filament
reorganization, which was regulated by the activity several signaling proteins,
including cSrc, Rho GTPases, and PKC. During tumor progression, these
pathways function abnormally and can promote the formation of cancer and
increase in metastatic potential.

Activation Of Src Induces Podosome Formation.
The role of Src in actin filament disruption which results in the formation of
motility structures, including lamellipodia and podosomes, has been extensively
studied. Src activation regulates the actin cytoskeleton through tyrosine
phosphorylation of a number of proteins in response to growth factor receptor
activation. Parson et al. demonstrated that ligand binding to the platelet-derived
growth factor receptor (PDGFR) recruits SFKs (Src, Fyn and Yes) resulting in an
increase in tyrosine kinase activity and promote a disruption in actin filament
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integrity (184).
Podosomes are highly dynamic structures were first identified in
macrophages and osteoclasts, and are involved in adhesion and tissue invasion
(30; 147; 148; 159). In osteoclasts, podosomes are observed in zones where
they are participate in bone reabsorption and bone degradation (64; 268). In
addition to macrophages and osteoclasts, podosomes have been observed in a
variety of other cell types, including transformed fibroblasts (24; 159; 236).
Podosomes are located on the ventral cell membrane and measure about 0.2 0.5µm in diameter (147). These structures are composed of an F-actin core
which surrounded by a ring structure containing essential proteins such as
cortactin, integrins, talin, WASp, Arp2/3, cSrc, p190RhoGAP, and PI3-kinase
(147). Greater than 43 proteins have been found to associate with podosomes
and many of these proteins are also detected in focal adhesion complexes (147).
However, podosomes contain an F-actin core and instead actin bundles attached
to integrin (147). Further, podosomes contain cortactin, Wiskott-Aldrich
syndrome proteins (WASp) and gelsolin which are not present in focal contacts
(90; 188); (45). Work done by Kaksonen and colleages found that GFP-tagged
cortactin associated with endosomal vesicles in addition to localizing to motility
structures in fibroblast (121). In addition to actin and actin-associated proteins,
podosomes contain components of an actomysoin motor and dynamin, which
facilitate matrix metalloproteases (MMP) secretion, including membrane-bound
MMP-1 (MT1-MMP). Proteins found in focal adhesions include Grb2, FAK, and
Shc, which are not present in podosomes. In contrast to focal adhesions, de
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novo protein synthesis is not required for podosome formation, but instead
utilizes a rearrangement and assembly of all essential proteins (236). This
process allows podosome formation to occur in less than one hour, while focal
contacts requires as much as three hours to form (147). Finally, podosomes are
highly dynamic with a half-life of 2 to 12 minutes, with core actin turning over 2 to
3 times during the life of the podosome (49; 64).
Podosomes have a range of functions and are normally observed in cells
that cross tissue barriers. One of these functions is to promote the invasive
potential of a cell. Studies by Mizutani et al. and others demonstrate that
podosomes function in ECM degradation, and may represent precursors to
invadopodia (49; 164). Invadopodia are cylindrical membrane structures that
project out from the ventral surface of transformed cells (161). These structures
were once thought to be interchangeable with podosomes because of the similar
(0.4µm) to that observed with podosomes. Further, invadopodia are composed of
similar proteins found in podosomes, including tyrosine phosphorylated proteins
and MMP’s. Both invadopodia and podosomes contain MMP’s, such as MT1MMP and MMP-9, which associates with the actin core at the tip of their
extensions, which are significantly longer in invadopodia (161). Further, these
structures promote invasion through their ability to degrade the extracellular
matrix. The presence of podosomes on the ventral surface of cells and the
occurrence of integrins within the podosome structure indicate that the
importance of podosomes for cellular adhesion and migration as well. Movement
of podosome groups occurs by disassembly of podosomes at the rear of the cell,
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and formation of new podosomes at the leading edge in a continuous, dynamic
cycle.
Several studies have shown that cSrc plays a central role in affecting
podosome formation and the associated appearance of tyrosine phosphorylation
in podosomes. Transformation of cells with vSrc oncogene resulted in efficient
podosome formation (159; 236). Activated Src (e.g., vSrc or constitutively active
cSrc527F) will induce changes in cell morphology that are characterized by a loss
of actin filament integrity, increased podosome formation and associated
development of motility structures. Further, these changes in motility and
formation of podosome are abrogated in cells expressing a dominant-positive
RhoA (RhoAV14) (12). A variety of signaling proteins will direct activation of cSrc,
including receptor tyrosine kinases, PKCα, and integrins. Upon activation, cSrc
autophosphorylates at Tyr416 enabling it to affect activation of cellular signals
sufficient to direct transformation. Proteins that interact with cSrc can also
promote the disruption of actin filaments and podosome formation. For example,
activation of the αvβ3 integrin results in the activation of cSrc and subsequent
tyrosine phosphorylation and podosomes ring colocalization of known Src
substrates, such as p130Cas (47; 90; 139; 188). These structures are one of the
hallmarks of transformation by vSrc. Thus, cSrc plays a central and important
role in the formation and maintenance of podosomes.

Activation Of PI3-Kinase Induces Podosome Formation.
The role of PI3-kinase activity in the alteration of the actin cytoskeleton
has been linked to those changes elicited by EGF and other growth factors. Work

44

by Brachmann et al. observed that deletion of all isoforms displayed impaired
membrane ruffling in response to PDGF activation. These data indicate that PI3kinase activity was required for PDGF-induced change in the actin cytoskeleton
(22). Further, mutants of PDGF receptor in the p85 binding site that fail to bind
the regulatory subunit abrogated the ability of PDGF to disrupt actin filaments.
However, when cells expressing wild-type PDGF were treated with wortmannin,
breakdown of stress filaments was not prevented indicating that the p85
regulatory subunit may be playing a role independent of PI3-kinase activity (118).
The expression of full-length p85α, but not p50α and p55α, abrogate actin
filament disruption and indicate that the proline-rich region-1 (PR1) and the BCR
domain are responsible for this function. The ability of these domains to regulate
the actin cytoskeleton may be associated with Cdc42 activation since it was
known that the activation of Cdc42 results in disruption of stress fibers. However,
the exact mechanism by which p85 activates Cdc42 was not currently known but
it appears to depend on their direct interaction and not PI3-kinase activity (117).
Until recently, the role of PI3-kinase on the actin cytoskeleton was thought to be
associated with its function on GEF and GAP in small GTPase activity. The
domain structure of these exchange factors and activation proteins contain a PH
domain, indicating that PI3-kinase may function upstream of these proteins.
These proteins in turn activate PI3-kinase resulting in a positive feedback loop
(203; 241; 273). The ability of PI3-kinase to alter Rac1 activity was hypothesized
to be via its role on Rac-GEFs (Vav1, Sos1 and Tiam-1), however the exact
mechanism is unclear. PI3-kinase may regulate these proteins either through
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phosphorylation by downstream effectors or via lipid binding because each
contain a PH domain that may bind PI3-kinase lipid products (199; 201).
In addition to PDGF signaling, PI3-kinase regulates actin filament
disruption and cell migration in macrophages in response to colony-stimulating
factor-1 (CSF-1). However, this event was mediated by p110β and p110δ, with
the p110α catalytic subunit controls the mitogenic effects of CSF-1 (246). PI3kinase function in conjunction with RhoA and cSrc plays a role in osteoclasts
attachment and spreading on plastic or bone. This event was associated with
translocation of these signaling proteins to the actin cytoskeleton and this was
dependent on αVβ3 integrins (139).
As mentioned previously podosome are made up of at least 43 known
components, including dynamin 2, Src, PI3-kinase and FISH (1; 147). The
formation of podosomes occurs rapidly (in less than 15 minutes) and in the
absence of de novo protein synthesis, unlike focal adhesion plaques (269). Work
by others indicated that PI3-kinase activation could result in podosome formation
in osteoclasts in response to osteopontin binding to αvβ3 integrins subsequently
promoting the activation of cSrc and gelsolin. Further, treatment of osteoclasts
with PI3-kinase inhibitor, wortmannin, blocked podosome formation mediated by
αvβ3 integrins (46; 139). These studies indicate that several signals that activate
PI3-kinase do promote the formation of podosomes in various cell types.

Activation Of PKCα Induces Podosome Formation.
Numerous extracellular signals can promote the activation of PKCα. PKC
appears to affect these changes through the phosphorylation of several actin
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binding proteins, including VASP, Facin, MARCKS, and AFAP-110 (89). PKCmediated phosphorylation of these proteins correlates with their decreased ability
to cross-link actin filaments. Similarly, Src-mediated tyrosine phosphorylation of
cortactin causes a decrease in the ability of this protein to cross-link actin
filaments.
Treatment of SH-SY5Y neuroblastoma cells with PMA resulted in the
elevation of both FAK and cSrc activity, indicating that these tyrosine kinases
may play a role in neurite extension (28). Therefore, the activation of PKC
appears to direct the upregulation of cellular tyrosine kinase and the events that
promote the disruption of actin filaments into podosomes. Work by Lee et al.
demonstrated that treatment of gastric carcinoma cell lines with PMA or TGF-β1
resulted in the phosphorylation of focal adhesion proteins, including cSrc, FAK,
and paxillin. Further, TGF-β1 or PMA treatment promoted cell spreading and
actin disruption via the activation of integrins through PKC (141). In agreement,
Sloan et al. documented that PKCα activation regulates tumor cell adhesion by
β3 integrin in addition to promoting tumor cell migration in breast cancer patient
samples (228). The ability of PMA (PKC activation) to promote podosome
formation was demonstrated by Tatin et al., who showed that PMA-treatment of
HUVEC endothelial cells promoted the formation of podosomes, and disruption
of PKC isoforms α and δ abrogated podosome formation in response to PMA.
However, only expression of active PKCα could produce podosomes similar to
those observed with PMA treatment. In agreement with previous studies, PMAinduced podosome formation required activation of cSrc, and inhibition of cSrc
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blocked podosome formation and the association of metalloproteases (MT1MMP and MMP-2). Further, the expression of vSrc promoted the activation of
MMP-2 associated with cleavage by MT1-MMP (237). These studies indicate that
PKCα activation can promote the formation of podosome in various cell types
and this pathway requires cSrc activity.

AFAP-110 Is A Binding Partner And Substrate For Src Family
Members.
Previous work by us demonstrated that AFAP-110 has an intrinsic ability to
cross-link actin filaments and activate cSrc. The actin-filament associated
protein, AFAP-110, consists of several domains and binding motifs including an
actin-binding domain (Figure 5). AFAP-110 was originally defined as an Src
SH2/SH3 binding partner and substrate for activated forms of Src, such as vSrc
and Src527F (80; 123). AFAP-110 contains several protein binding motifs that are
important for mediating protein interactions, including two SH3-binding motifs,
two SH2-binding motifs, two pleckstrin homology (PH) domains, a target site for
multiple serine/threonine phosphorylations (STK), and a carboxy-terminal
leucine zipper domain that directs protein self-association. Amino terminal to the
actin-binding domain are a series of protein binding modules that serve to link
signaling molecules to actin filaments. These domains include a proline-rich SH3
binding motif (SH3bm) that is able to contact the opposing SH3 domains of SFK
(cSrc, Fyn and Lyn) (80; 97; 234). AFAP-110 is also an SH2 binding partner for
cSrc, Fyn and Lyn. The SH3 binding motif serves to present AFAP-110 for
tyrosine phosphorylation by constitutively activated Src527F and also plays a
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central role in stable complex formation with Src527F (97). Subsequent to SH3
binding, Src527F directs phosphorylation of three tyrosine residues on AFAP-110
(Y94, Y451, Y453), which effectively creates two separate and functional SH2
binding motifs (SH2bm) (98). Studies by our laboratory have found that AFAP110 links Src signaling molecules to actin filaments. Qian et al. found that the
carboxy terminal region was also the site of interaction between AFAP-110 and
F-actin (194). Early work indicated that SH2 and SH3 domain mutants of Src that
failed to bind to AFAP-110 also failed to transform cells and induce changes in
the actin cytoskeleton (123). Guappone and Flynn determined that the SH3
domain was important for presentation of AFAP-110 for tyrosine phosphorylation,
but both SH2 and SH3 interactions were essential for stable complex formation
with Src and subsequent alterations in actin filament integrity (97). Therefore,
AFAP-110 can modulate activation of cSrc and subsequent changes in actin
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cytoskeleton which are hallmarks of cSrc activation. Deletion of both the leucine
zipper motif or co-expression of Src527F resulted in a similar change in cell
morphology, therefore Src527F transformed cells provides a model system for
studying upstream signals that are capable of inducing changes in the
conformation of AFAP-110. Likewise, independent activation of this signal alone
resulted in a conformational change in AFAP-110, the activation of cellular
tyrosine kinases, and alterations in the actin cytoskeleton. Thus, AFAP-110
affects actin filaments in a direct manner, serving as a protein linker between
activated Src and actin filaments.

AFAP-110 Is An Actin Filament Binding And Cross-Linking
Protein.
Previous work done by our laboratory has shown that AFAP-110 both
multimerize and directly binds to and cross-links actin filaments (193). Further,
Qian et al. demonstrated that AFAP-110 binds directly to actin filaments via a
carboxy terminal actin binding domain (195). Deletion of the carboxy terminal
amino acid residues 553-730 in AFAP-110 (AFAP-110∆cterm) prevented
colocalization with actin filaments, indicating that these amino acids of AFAP110 (553-730) are both necessary and sufficient for F-actin association; however,
further analysis showed that amino acids 600-620 serve as the actin filament
binding domain (ABD). The actin binding domain is both necessary and
sufficient for AFAP-110 to bind the actin cytoskeleton. Interestingly, deletion of
the leucine zipper motif (Lzip) increased the ability of AFAP-110 to cross-link
actin filaments. Previous work by others demonstrated that multimeric actin
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filament binding proteins are able to cross-link actin filaments, however smaller
multimers cross-link actin filaments more efficiently because they form more
ordered arrays. In agreement with this, AFAP-110∆Lzip was able to direct more
efficient cross-link F-actin. The smaller size of AFAP-110∆Lzip exists as both
nonamers (≈750 kDa) and trimers (≈250 kDa) whereas the wild-type AFAP-110
were found only as nonamers (MW-82 kDa/monomer). The data indicated that
loss of the Lzip motif destabilizes AFAP-110 multimers and upon contact with Factin, enabled the smaller protein to cross-link actin filaments more efficiently.
In quiescent cells, AFAP-110 was found in self-associated complexes of
trimers, tetramers, and larger multimers (194). Transient transfection of AFAP110∆Lzip into cells resulted in a cellular phenotype similar to Src transformed cells.
Actin stress fibers were lost, and instead actin filaments were repositioned into
podosomes and motility structures (194). In Src transformed cells, AFAP-110
was hyperphosphorylated on tyrosine, serine, and threonine residues. In
response to the serine/threonine phosphorylation, AFAP-110 undergoes a
conformational change resulting in a loss in protein multimerization and the
formation of protein dimers (194). Similarly, the deletion of the leucine zipper
motif of AFAP-110 was hyperphosphorylated on these residues and an increase
in tyrosine phosphorylation (13). Therefore, AFAP-110 becomes a more
favorable SH3 binding partner for cSrc, displacing the inhibitory intramolecular
interactions and facilitating kinase autophosphorylation. Site-directed
mutagenesis studies determined that mutation of an essential proline residue at
position 71 to an alanine blocked the ability of AFAP-110 to interact with the Src
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SH3 domain (97). Expression of AFAP-11071A/∆Lzip in cells blocked the ability of
AFAP-110∆Lzip to activate cSrc and mediate changes in actin filament integrity
(13). Interestingly, dominant-positive Rho was able to block the effects of AFAP110∆Lzip upon the actin cytoskeleton, suggesting that AFAP-110∆Lzip-activation of
Src mediates changes in the cytoskeleton through a signaling pathway involving
Rho (13). Thus, AFAP-110 is a binding partner and activator of cSrc and this
activation is dependent on the integrity of the amino terminal SH3 binding motif.

AFAP-110 Is Both A Binding Partner And Substrate For PKC.
Studies have shown that expression of activated PKCα, or activation by
treatment with PMA, results in significant changes in actin filament integrity,
including a loss of actin filament organization, changes in cell morphology and
generation of cell motility structures, such as lamellipodia (83; 131). Although
PKCα can direct a reduction in general actin filament organization, it also directs
the formation of motility structures which are rich in cross-linked F-actin and
promote an increase in cell motility and invasion (52; 53; 73). Studies have
shown that some PKC isoforms are able to directly interact with small GTPases,
such as Rho and Cdc42. For example, PKCα was able to bind RhoA in a GTPdependent manner to act downstream of Rho (44). These studies indicate that
PKC isoforms are able to direct both loss of actin filament integrity and the
formation of motility structures, as well as generalized loss of actin filament
organization.
Several lines of evidence show that PKC may signal upstream of AFAP110. First, PKC activity was elevated in Src transformed cells (62; 270). In
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addition, AFAP-110 was strongly phosphorylated on serine/threonine residues in
Src527F transformed cells, contain several consensus sequences specific for PKC
phosphorylation, and contains two PH domains that have the ability to mediate
interactions with serine/threonine kinases like PKC (80; 123; 205). Qian et al.
demonstrated that AFAP-110 undergoes a conformational change in response to
serine/threonine phosphorylation that was concomitant with a decrease in selfassociation and the formation of protein dimers (193). Data published by our
laboratory has demonstrated that AFAP-110 moves into motility structures
concomitant with PKC activation, and mutants of AFAP-110 that fail to bind to
PKCα block activated PKCα (myrPKCα) from directing changes in actin filament
integrity and the formation of motility structures (193). AFAP-110 was
demonstrated to be both a binding partner and substrate for PKCα. We have
shown that (a) PKCα can activate cSrc, (b) AFAP-110 has an intrinsic ability to
activate cSrc, and (c) PKCα can affect conformational changes upon AFAP-110.
Collectively, these studies indicate that PKC can phosphorylate serine/threonine
residues within the PH1 domain of AFAP-110 resulting in a conformational
change resulting in more efficient cross-linking of actin and subsequent formation
of motility structures. Thus, AFAP-110 is a binding partner and substrate for PKC
isoforms α, β, γ and λ. Further, AFAP-110 serves to link PKC signal pathway to
cSrc.

Phospholipids And Phospholipid Binding Domains.
Phosphatidylinositol (collectively known as phosphatidylinosites, PtdIns)
consist of D-myo-inositol-1-phosphate (Ins1P) linked with a diacylglycerol and
53

are the building blocks for eukaryotic intracellular lipids (247). The PtdIns head
group has five hydroxyl groups that are phosphorylated in various combinations
in cells, except positions 2 and 6. Phosphatidylinosites are found associated with
all cellular membranes, including the plasma membrane. Further, these lipids are
regulated and serve as substrates for lipase, phosphatases and lipid kinases. In
quiescent cells, PtdIns is the predominant inositol lipid with levels 10-20 times
higher than PtdIns-4-P and PtdIns-4,5-P2 (247). Generation of PtdIns-3,4-P2 is
most likely to result for hydrolysis of PtdIns-3,4,5-P3 by lipid phosphatases;
however, PtdIns-3,4,5-P3 is formed as the result of phosphorylation of PtdIns-4,5P2 by class I PI3-kinase.
Several protein modules have been identified for their ability to bind
various cellular lipid products. In this review only three modules that bind D3
phosphorylated lipids, FYVE, Phox and PH domains, will be discussed. FYVE
domains were named after first proteins in which it this domain was identified
(Fab1p, YOTB, Vac1p, and Early endosome antigen-1 (EEA-1)); these domains
are approximately 70kDa in size. FYVE domains contain eight (8) conserved
cysteine residues that form two zinc binding sites and the third cysteine residue
associates with the inositol head group of the lipid (247). These domains contain
two β-sheets, amino terminal loop, carboxy terminal α-helix, two zinc-binding
clusters and a hydrophobic core. Molecular modeling shows that the surfaces of
these domains contain a basic residue conserved consensus sequence [-R/KR/K-HHCRxCG-] which facilitates lipid binding (56; 71; 72). FYVE domains
selectively bind PtdIns-3-P and are less common than PH domains. More than
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25 FYVE domain containing proteins (i.e. CKIP-1) have been identified in
mammals and these proteins are implicated in membrane trafficking, receptor
recycling and cytoskeleton rearrangement (56; 71; 72) (54; 56).
Phox domains (PX) were originally identified in the cytosolic portions of
NADPH oxidase, p40phox and p47phox, and are present in both mammals and
yeast. PX domains are 120 amino acids in length and function in protein
trafficking to membranes and only a small number of these proteins associate
with PI3-kinase generated lipids. Similar to FYVE domains, PX domains
preferably bind PtdIns-3-P lipids but can associate with PtdIns-3,4-P2 and PtdIns4,5-P2 phospholipids (55; 264). The general lipid binding consensus sequence
motif is [-(R/K)(R/K)(Y/F)xxFxxLxxxL-] AND [-R(R/K)xxLxx(Y/F)-]. In addition to
binding lipids, these domains can function in protein-protein interactions, similar
to PH domains. PI3-kinase-C2γ contains a PX domain that allows this lipid kinase
to bind its substrate, PtdIns-4,5-P2, however this domain was not absolutely
required for function (215). Interestingly, phospholipase D contains both a PX
domain and a PH domain, which are believed to play distinct roles in substrate
recognition and protein localization (106; 215).
Pleckstrin homology (PH) domains are protein modules indicated in
regulating protein function and cellular localization. Initially, it was hypothesized
that PH domains function only in protein-protein interactions, but the idea that
these domains could bind lipid was not well received. Several proteins with PH
domains that specifically bind PtdIns-3,4,5-P3 have been shown to also regulate
PI3-kinase activity. These domains are highly conserved and were first identified
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in early 1990s as 100-120 amino acids protein modules present in the internal
repeats of the pleckstrin protein. Pleckstrin is a 47kDa protein with two PH
domains and has been shown to be the major PKC substrate in platelets (76;
143). These domains have been identified in over 100 proteins that are involved
in various cell signaling processes within the cell and found in many vertebrates
and only 10% of these proteins recognize phospholipids with high affinity. The
amino acid consensus sequence of known PH domains varies and shows less
than 10-20% homology. A highly conserved carboxy terminal tryptophan
residue, usually downstream of 1-3 negatively charged amino acids and was
found to be required for PH domains to bind phosphatidylinositols. Interestingly,
proteins that have one or more PH domains also contain one or more Src
homology domains (SH2 and/or SH3) (221; 222). All known PH domains have a
similar structure consisting of 7 anti-parallel β-strands, 7 linker regions and a
carboxy terminal α-helix which contains the conserved Trp residue. However, the
loop 3 region of β-spectrin also contains an additional α-helix. Beta strands (β1β4) and β-strands (β5-β7) make up small β-sheets that are 60° to each other. The
positively charged loops (L1, L3 and L5) and a portion of the negatively charged
carboxy terminal α-helix form the binding pocket (222; 245). However, this core
structure has been identified in other protein modules including the
phosphotyrosine binding domain and Ran-binding domain (76; 144). Further, in
vitro binding studies indicate that the PH domains of Akt and DAPP-1 selectively
bind PtdIns-3,4-P2 as well as PtdIns-3,4,5-P3 (69; 245).
The recognition and substrate specificity of PH domains for lipid products

56

has remained elusive. The ability of PH domains to specifically bind PI3-kinase
generated phospholipids, mainly PtdIns-3,4,5-P3 has been shown to be
dependent on several conserved amino acid residues. Work done by Isakoff et
al. and others indicate that six highly conserved amino acids in the amino
terminal portion of PH domains, however the presence of this sequence does not
guarantee binding to these lipid products. The hydrophobic residues found in the
β1/β2 function in binding to the head-group of PtdIns-3,4,5-P3 (68; 113). These
authors and others hypothesize that amino acid residues outside of this motif,
such as those in the loop between β1 and β2 strands, also play a role in lipid
recognition. These data indicate that prediction of lipid binding capabilities can
not be determined solely on the presence of this motif. However, the PH1 domain
of AFAP-110 does contain this conserved sequence. The role of these domains
in the regulation of various kinases has been indicated to play a role in
oncogenesis (222). Thus, several protein modules function in binding to
phospholipids and target proteins to subcellular membranes.

AFAP-110 Has The Ability To Bind Phospholipids.
As stated earlier, AFAP-110 consists of two PH domains with the amino
terminus PH1 domain being required for its’ association with PKC isoforms. The
deletion of this domain abrogated the ability of AFAP-110 to colocalize with or
activate cSrc. Therefore, we predicted that the requirement of the PH domain of
AFAP-110 for cSrc colocalization and subsequent activation might be dependent
of a lipid signal. Furthermore, molecular modeling studies indicate that the amino
terminal PH1 domain contains conserved residues predicted to bind to
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phospholipids or membranes, a feature common to many PH domains (13; 143).
Deletion of the PH1 domain of AFAP-110 blocked the ability of AFAP-110 to
colocalize with cSrc, indicating that the integrity of this domain is required for
cellular targeting.
PH domains have been shown to be important for membrane localization
of several well-studied proteins, such as Akt. Further, these domains also
recognize lipid products including those resulting from PI3-kinase activity (76;
113). Previous work by others demonstrated that the PH domains of Bruton’s
tyrosine kinase (BTK) and pleckstrin bind to PKCα as well as to lipid products (2;
266). The PH domain of BTK associates with high affinity to PI3-kinase lipid
products, PtdIns-3,4-P2 and PtdIns-3,4,5-P3 (21). Interestingly, proteins that
contain PH domains have been shown to regulate actin filament integrity. For
example, PtdIns lipid products regulate the activation and localization of pleckstin
resulting in actin filament rearrangement in platelets. In addition, the PH domain
of Vav binds PI3-kinase generated lipid products resulting in release of the
autoinhibitory mechanism promoting disruption of the actin cytoskeleton (154).
Therefore, we hypothesized that colocalization of AFAP-110 with and
subsequent cSrc activation may require a lipid second messenger to promote
disruption of the actin cytoskeleton.
The mechanism by which PI3-kinase may enable AFAP-110 to move to
and activate cSrc was not clear. It is possible that PI3-kinase activation produces
a lipid product that would promote AFAP-110 transit to cSrc. This would not be
without precedence, as PI3-kinase generated lipid products are required for Akt
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transit to membranes and subsequent activation. Preliminary studies indicate
that AFAP-110 has the capacity to bind PI3-kinase lipid products and this
association appears to play a role in the ability of AFAP-110 to translocate with
inactive cSrc ((13) (253); Walker and Jett in preparation). However, AFAP-110
also has the capacity to bind the p85 regulatory subunit of PI3-kinase. Thus, it is
also possible that a protein chaperone could foster colocalization between AFAP110 and cSrc in response to PKC or PI3-kinase activation.

Significance And Relevance.
Many of the proteins discussed in this literature review are also implicated
in the acquisition of the invasive phenotype of cancer, including Src, PKCα, and
PI3-kinase. Furthermore, these proteins are overexpressed or activated in
several cancers, including ovarian cancer, and their activation promotes the
formation of podosomes. In particular, activation of Src and PI3-kinase/Akt
pathways strongly correlates with the acquisition of the invasive phenotype (38;
234). Similarly, activation of these signaling proteins functions in promoting
resistance of ovarian cancer cells to chemotherapeutic drugs, such as cisplatin. It
is possible that AFAP-110 can integrate signals between PKCα, PI3-kinase, and
cSrc to modulate cellular motility and promote tumor progression.
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Abstract
Activation of PKCα will induce the cSrc binding partner, AFAP-110, to colocalize
with and activate cSrc. The ability of AFAP-110 to colocalize with cSrc is
contingent upon the integrity of the amino terminal Pleckstrin Homology (PH1)
domain, while the ability to activate cSrc is dependent upon the integrity of its’
SH3 binding motif, which engages the cSrc SH3 domain. The outcome of AFAP110-directed cSrc activation is a change in actin filament integrity and the
formation of ventral membrane structures that resemble podosomes or
precursors to invadopodia. In this work, we sought to address what cellular
signals promote AFAP-110 to colocalize with and activate cSrc, in response to
PKCα activation or PMA treatment. As PH domain integrity in AFAP-110 is
required for colocalization and PH domains are known to interact with both
protein and lipid binding partners, we sought to determine whether PI3-kinase
activation played a role in PMA induced colocalization between AFAP-110 and
cSrc. We show that PMA treatment is able to direct activation of PI3K. Treatment
of mouse embryo fibroblast with PI3-kinase inhibitors blocked PMA-directed
colocalization between AFAP-110 and cSrc and subsequent cSrc activation.
PMA was also unable to induce colocalization or cSrc activation in cells that
lacked the p85α and β regulatory subunits of PI3-kinase. This signaling pathway
was required for migration in a wound healing assay. Utilizing a inducible system,
we show that a dominant-negative cSrc SH3 binding mutant (AFAP-11071A)
modulated a reduction in migration into a wound. Similarly, cells that were null for
cSrc or the p85 regulatory subunits also displayed a reduction in migration.
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These data indicate that PI3-kinase activity is required for PMA-induced
colocalization between AFAP-110 and cSrc, subsequent cSrc activation and this
signaling pathway promotes cell migration.
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Introduction
There is significant evidence to indicate the existence of cross talk between
PKCα, cSrc and phosphatidylinositol-3-kinase (PI3-kinase). Activation of each of
these kinases results in substantial changes in actin filament integrity and cell
morphology concomitant with increased cell motility and invasive potential (13;
26; 45). Extensive studies by other laboratories have shown that many cancers,
including breast, prostate and ovarian, exhibit higher than normal levels of cSrc,
PKCα, and PI3-kinase (28; 44). The ability of cSrc and PKCα to cross talk was
determined by the use of a constitutively active form of cSrc or stable expression
of viral-Src (vSrc), which will stimulate an increase in PKCα signaling, indicating
that PKCα could function downstream of cSrc (52). Alternatively, other studies
have demonstrated that PKCα can function upstream and direct activation of
cSrc (6; 7). Although PKCα can phosphorylate cSrc, in vitro studies
demonstrated that PKCα does not activate cSrc directly (6). Recently, we
demonstrated that the PKCα and cSrc-binding partner, actin filament-associated
protein (AFAP-110), is able to relay signals from PKCα that direct cSrc activation.
Expression of myristylated PKCα (myrPKCα) or treatments of cells with phorbol12-myristate-13-acetate induced AFAP-110 to colocalize with cSrc and
subsequently activate it (15). The ability of AFAP-110 to colocalize with cSrc
was dependent upon the integrity of the amino terminal pleckstrin homology
(PH1) domain, while the ability of AFAP-110 to activate cSrc was dependent
upon the integrity of the proline-rich SH3 binding motif in AFAP-110, which
contacts the SH3 domain of cSrc. Thus, AFAP-110 is able to integrate signals
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from PMA or myrPKCα that enable it to colocalize with and subsequently activate
cSrc. Previous studies by our laboratory demonstrated that the integrity of the
amino terminal pleckstrin homology domain (PH1) is essential for AFAP-110 to
colocalize with cSrc (2; 15). These self-folding modular domains are known to
bind lipids, such as those generated by PI3-kinase (9; 11; 30). In this study, we
sought to determine what cellular signals enabled AFAP-110 to colocalize with
cSrc in response to PMA. As colocalization and subsequent cSrc activation was
dependent upon the integrity of the PH1 domain, and molecular modeling
analysis indicated that AFAP-110’s PH1 domain had the capacity to bind
phosphatidylinositol lipids (2), we hypothesized that PI3-kinase activity may play
a role in facilitating colocalization between AFAP-110 and cSrc in response to
PMA. This hypothesis predicts that (a) in cells where PI3-kinase activity is
blocked or PI3-kinase regulatory subunits are deleted PMA would fail to direct
AFAP-110 to colocalize with cSrc; (b) PMA should be able to direct activation of
PI3-kinase and (c) loss of PI3-kinase protein expression or activity would prevent
PMA-induced activation of cSrc and subsequent migration potential.
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Materials and Methods
Reagents: Dulbecco’s modified Eagle’s medium (DMEM), Rhodamine (TRITC)phalloidin, beta actin (β-actin), monoclonal and polyclonal anti-FLAG antibodies,
and bovine serum albumin (BSA) were purchased from Sigma (St. Louis, MO).
Protein A/G PLUS agarose beads and polyclonal cSrc antibody were purchased
from Santa Cruz biotechnology (Santa Cruz, CA). LipofectAMINE™ reagent was
purchased from Invitrogen (Carlsbad, CA). CalPhos™ mammalian transfection
kit, Tet-Off® inducible system and MEF/3T3 cells were purchased from Clontech
Laboratories (Mountain View, Ca). Doxycycline HCl, G418, and hygromycin were
purchased from Bioworld (Dublin, OH). CO2-independent media was purchased
from Gibco (Invitrogen Carlsbad, Ca). Uncoated glass bottom plates (35mm)
were purchased from MatTek (Ashland, MA). Supermix PCR reagent was
obtained from Invitrogen, while tsLA29 primers were purchased from IDT.
Phorbol-12-myristate-13-acetate, LY294002, wortmannin and
bisindolylmaleimide [I] (Bis) were obtained from Calbiochem. Monoclonal p85α
and p110α antibodies, monoclonal PKCα antibody antibodies were obtained
from BD Transduction Laboratories (San Diego, CA). The polyclonal AFAP-110
antibodies F1 were generated and characterized as previously described (39).
Monoclonal avian cSrc antibody (EC10) and polyclonal Phospho-Src family
Tyrosine 418 were obtained from Upstate (Charlottesville, VA). Phospho-Src
family (Tyr416) antibody was purchased from Cell Signaling (Beverly, MA).
Horseradish peroxidase-conjugated anti-rabbit and anti-mouse IgG secondary
antibodies and γ32P-ATP were obtained from Amersham Biosciences
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(Piscataway, NJ). Phosphatidylinositol (PI) used in the PI3K kinase assay was
purchased from Matreya LLC (Pleasant Gap, PA). All Alexa Fluor antibodies
used in the paper were purchased from Molecular Probes (Invitrogen). Srcfamily tyrosine kinase inhibitor, PP1, was purchased from Biomol (Plymouth
Meeting, PA). Phosphoinositol-3,4,5-trisphosphate monoclonal IgM antibody
was obtained from Echelon Biosciences (Salt Lake City, UT).
Chemiluminescence reagent was purchased from Pierce Biochemical (Rockford,
IL). All chemical used throughout this manuscript, except where otherwise stated,
were purchased from J.T. Baker (VWR-West Chester, PA).

Cell Lines and Culture: Mouse embryo fibroblast, SYF/cSrc and SYF (ATCC),
cells were used throughout this study. SYF/cSrc are derived from a SYF parental
cell line that is devoid of Src family of non-receptor tyrosine kinase members fyn,
and c-yes genes but engineered to re-express c-Src (27). PI3-kinase regulatory
subunit knockout mouse embryo fibroblasts (p85-/-) derived from Pik3r1
(encodes p85α genes) and Pik3r2 (encodes p85β gene) double knockout or
Pik3r2 (p85α+/+) single knockout in 129 C57BL/6 mice were kind gift from Saskia
Brachmann (Harvard). NIH3T3 mouse embryo fibroblast containing the
regulatory Tetracycline plasmid (pTeT-Off) were transfected with AFAP-110
within the tetracycline-response plasmid (pTRE2-Hyg) as described below. The
above cell lines, except the Tet-Off cells, were grown at 37°C with 5% CO2 in
DMEM supplemented with 10% (v/v) fetal calf serum, 1% (v/v) 200 mM Lglutamine and 1% (v/v) penicillin/streptomycin. The Tet-Off cells were cultured in
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DMEM media containing 10% Tet system approved fetal bovine serum, 2% (v/v)
200mM L-glutamine, 100µg/ml of G418 and 150µg/ml hygromycin B as
described by the manufacturer.

Constructs: The pEGFP-c3 (green fluorescence protein) expression system
from Clontech (Mountain View, CA) was used to express GFP-tagged full-length
and mutant forms of AFAP-110. AFAP-110 was cloned into this vector as
previously described (37). AFAP-110 was cloned into the pTRE2-hygromycin
Tet-off vector using the BamHI and SalI restriction sites. The Tet-Off MEF was
transfected with either wild-type AFAP-110 or the cSrc SH3 binding mutant
(AFAP-11071A). Avian cSrc was subcloned from Rous Sarcoma Virus (RSV) into
pCMV-1 as previously described (17). Dominant-positive and dominant-negative
forms of Flag-tagged PKCα were expressed using the pCMV-1 vectors and were
a kind gift from Alex Toker (Harvard University). Temperature sensitive viral-Src
(tsLA29) was subcloned from Rous sarcoma virus (RSV) into the pCMV-1 vector
at the XhoI site downstream of the SV40 promotor. Subcloning tsLA29 from the
pCMV-tsLA29 vector into pCMV-AFAP-110 using the unique XbaI/ScaI sites
created the AFAP-110/tsLA29 dual expression vector.

Tet-off stable clone selection: Tet-Off MEF/3T3 cells were transfected using
CalPhos mammalian transfection kit (Clontech) per manufacturer instructions.
Briefly, cells were seeded into 60mm plates then transfected at 50% confluency
with 15µg DNA. Forty eight hours post-transfection the media was changed and
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replaced with culture media containing 1 µg/ml doxycycline and 150µg/ml
hygromycin B. Colonies were harvested and screened over a three week period.
Stable clones were screen for AFAP-110 expression at around 8-10 days
following the removal of doxycycline.

Transfection and Immunofluorescence: SYF, SYF/cSrc, p85α+/+ and p85-/cells were cultured in standard culture media. Transient transfections of SYF,
SYF/cSrc, p85α+/+ and p85-/- cells for immunofluorescence were carried out
using LipofectAMINE™ Reagent (Invitrogen) as per manufacturer’s protocol.
Briefly, approximately 5.0-8.0 x 104 cells per well were transfected at 50-70%
confluent on coverslips with 2-4 µg of plasmid DNA and incubated for 3-4 hours.
Thirty-six hours after transfection, cells were serum starved for 12 hours, treated,
and subsequently fixed and permeablized as previously described (36). For
temperature sensitive v-Src experiments, forty-eight hours after transfection, SYF
cells were serum starved for 12 hours, and either maintained at 39.5°C or shifted
to 35°C for six hours and subsequently fixed. Treatment groups and those cells
at 39.5°C were treated with a PKC-specific activator, 100nM PMA for 5 or 30
minutes or in combination with the following; a PKC inhibitor, 6µM
bisindolylmaleimide for six hours; or PI3K inhibitor, 10-20 µM LY294002 for six
hours or 50nM Wortmannin for 30 minutes; and/or a Src family inhibitor, 5µM
PP1 for six hours. For actin labeling, a 1:500 dilution of TRITC-phalloidin was
used as labeled in the figures. Primary antibody concentrations used were diluted
in 5% Bovine Serum Albumin (BSA) dissolved in 1X phosphate-buffered saline
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(PBS): EC10 mAb - 1:500; Phospho-Src Family (Y416) pAb - 1:250; Anti-PI3,4,5-P3 mAb - 1:100; Anti-AFAP-110 (F1) pAb - 1:1000; Anti-cSrc pAb - 1:500;
Anti-Flag - 1:10000. All fluorescent secondary and phalloidin antibodies were
diluted 1:200 in 5% BSA, and are labeled according to figure legends. Cells were
washed and mounted on slides with Fluoromount-G (Fisher). A Zeiss LSM 510
confocal microscope was used to scan images of about 1 µm in thickness. To
prevent cross-contamination between the different fluorochromes, each channel
was imaged sequentially using the multitrack recording module before merging
the images. For all figures, representative cells are shown (>100 cells examined
per image shown).

Immunoblot Assay: All cells were cultured to 70-80% confluence, serumstarved for 16 hours, and treated as described above. The cells were lysed and
western analysis performed as previously described (16). Membranes were
probed using the following antibodies diluted in 1X Tris-buffered saline plus 0.1%
Tween-20 (TBS-T) containing 5% nonfat milk, except were indicated: 1:10000
AFAP-110 pAb (F1), 1:1000 Phospho-Src family Tyrosine 416 (Cell Signal) in 5%
BSA, 1:1000 Phospho-Src family Tyrosine 418 (Upstate) in 5% BSA,1:500 cSrc
(clone N-16), 1:1000 p85α, 1:1000 p110α, 1:1000 PKCα and 1:5000 β-actin in
1% BSA.

PI3-Kinase Assay: PI3-kinase activity was determined using the In vitro PI3K
kinase assay as previously described (23). Cells were serum-starved 24 hours.
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The media was changed and cells were then treated with either 10% fetal calf
serum or 100 nM PMA for 5 or 15 minutes. Upon completion of the incubation,
the cells were lysed in cold kinase lysis buffer [150 mM NaCl, 100 mM Tris pH
8.0, 1% Triton X-100, 5 mM EDTA, 10 mM NaF, plus inhibitors (1 mg/ml leuptin,
1 mg/ml peptatin, 0.5 M sodium vanadate, 1 mg/ml aprotinin, and 1M DTT)]. Five
hundred micrograms (500 µg) of protein was incubated with monoclonal p110α
antibody (2µg/µl) overnight at 4°C. Forty microliters (40 µl) of protein A/G PLUS
agarose beads (50% slurry) was added and incubated for an additional two
hours. The beads were pelleted and washed two times with cold lysis buffer and
one time each with fresh cold TNE buffer [20 mM Tris pH 7.5, 100 mM NaCl, and
1 mM EDTA] and 20 mM HEPES pH 7.5. The pellets were re-suspended in γ32PATP kinase reaction buffer [20 mM HEPES pH 7.5, 10 mM MgCl2, 0.2 mg/ml
phosphatidylinositol (in 10 mM HEPES pH 7.5) in 10 mM HEPES pH 7.5, 60 µM
ATP, 0.2 µCi/µl γ32P-ATP]. The samples were incubated 15 minutes on ice and
the reactions were stopped by adding 1M HCl. Followed by the addition of
chloroform/methanol (1:1) the samples were vortexed and the beads pelleted.
The lower phase was collected, the samples dried, re-hydrated in chloroform and
spotted on a prepared thin layer chromatography (TLC) plate. The finished plates
were then exposed to radiography film up to 48 hours at –70°C.

Scratch Motility Assay: SYF, SYF/cSrc, p85-/- , induced and uninduced AFAP110 Tet-Off cells were culture in glass bottom 35mm MatTek plates under and a
scratch assay performed as previously described (20). A scratch was made using
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a 200µl pipette tip in the confluent monolayer and a gentle wash with 1XPBS to
remove dislodged cells. Serum-free CO2 retaining culture media was added and
wound closure was imaged over 6 hours. Images were gathered every 5 minutes
for the 6 hours. Wound widths at time 0 and at the end were measured using the
Zeiss software. Post-wounding cells were treated with 100nM PMA, 20µM
LY294002 or 100nM PMA in conjunction with 20µM LY294002 or 6µM
bisindolylmaleimide I. Images were generated and analyzed using the AxioVision
4.4 software with the Axiovert Zoom microscope (Zeiss)
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Results
PI3-Kinase activity is required for PMA-induced translocation of AFAP-110 to
cSrc and subsequent cSrc activation. The ability of AFAP-110 to colocalize with
cSrc in response to PMA-directed signals is dependent upon the integrity its’ PH1
domain. Deletions in the PH1 domain will prevent PMA or PKCα from inducing
AFAP-110 to colocalize with cSrc and will also block PMA or PKCα-directed
subsequent activation of cSrc (15). There is significant evidence for cross talk
between PKCα, cSrc and PI3-kinase. Further, many PH domains can bind to
PI3-kinase generated lipid products and the AFAP-110 PH1 domain is predicted
to bind, as well (2). Thus, we sought to determine whether PI3-kinase activity
was required for PMA-induced colocalization of AFAP-110 with cSrc and
subsequent cSrc activation. We utilized SYF cell lines as a model system,
mouse embryo fibroblasts engineered to contain null mutations in the c-src, fyn,
and c-yes genes (27). The cells were transiently co-transfected with constructs
that encode cSrc and GFP-tagged AFAP-110, as previously described (15). It
has been well documented that over-expression of these proteins do not alter
their cellular location (37; 41). Co-expression of GFP-AFAP-110 and cSrc in
unstimulated SYF cells confirm that wild-type AFAP-110 neither colocalizes with
nor activates cSrc (Figure 1, panels a-d). PMA treatment caused GFP-AFAP-110
to colocalize with cSrc and there was evidence for activation of cSrc, based on
increased immunoreactivity with the anti-phospho-cSrc (Y416) antibody, which
recognizes cSrc in its activated state (Figure 1, panels e-h). Further, activation of
cSrc corresponded with morphological changes associated with the formation of
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dot-like structures on the ventral membrane, which are consistent with
podosomes or invadopodia. Pre-treatment of cells with the PKC inhibitor,
bisindolylmaleimide [I] (Figure 1, panels i-l) or the PI3-kinase inhibitor, LY294002
(Figure 1, panels m-p) blocked PMA-induced colocalization of AFAP-110 with
cSrc, cSrc activation and associated morphological changes. To confirm the
specificity of LY294002, cells were pre-treated with the PI3-kinase inhibitor,
wortmannin, which also blocked colocalization and cSrc activation (Figure 1,
panels q-t). These data indicate a potential role for PI3-kinase activation in
modulating colocalization between AFAP-110 and cSrc in response to PMA
treatment.
To verify the requirement of PI3-kinase, we used a p85 α/β knockout (p85/-) mouse embryo fibroblast cells (4). Work by Yu et al. indicated the regulatory
subunit of PI3-kinase is required to stabilize the p110 catalytic subunit of PI3kinase (51). Thus, loss of p85α/β would lead to a loss of PI3-kinase activity in the
cell. We sought to determine the steady state levels of expression of
endogenous PKCα or the p110 catalytic subunit of PI3-kinase in our MEF model
system. Western blot analysis indicates that p85-/- cells contain equivalent
endogenous levels of PKCα, AFAP-110 and actin relative to SYF or SYF/cSrc
cells (Figure 2A). Western blot analysis confirmed that the p85-/- cells do not
express detectable levels of p85α, which is present in the p85α+/+ and SYF/cSrc
control cells (Figure 2B). Our results also indicate that p85 -/- cells lack
detectable levels of p110α, while the p110α catalytic subunit is stably expressed
when the p85α regulatory subunit of PI3-kinase is present (p85α+/+) in these
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cells (Figure 2C). These MEF-derived cells were used as a model system to
determine if PMA could direct activation of cSrc under endogenous protein
expression levels. Western blot analysis was performed, which verified the
ability of PMA treatment to activate cSrc. As predicted, PMA induced tyrosine416
phosphorylation of endogenous cSrc in SYF/cSrc and not cells lacking cSrc
(SYF) (Figure 3A). Furthermore, PMA failed to induce endogenous cSrc
activation in the mouse embryo fibroblast that lacks the p85 regulatory subunit.
The role of the p85 regulatory subunit in PMA-induced cSrc activation was further
examined by utilizing the p85α+/+ MEF’s, which express only the p85α
regulatory subunit of PI3-kinase (Figure 3B). Both p85-/- and p85α+/+ cells were
transiently co-transfected with GFP-tagged AFAP-110 and cSrc. Cells were
treated with PMA and evaluated for the ability of AFAP-110 to colocalize with and
activate cSrc. PMA induced colocalization of AFAP-110 and cSrc, cSrc activation
and podosome formation in p85+/+ cells (Figure 3B, panels e-h). However, PMA
failed to induce significant colocalization of AFAP-110 with cSrc and there was
no evidence for cSrc activation or podosome formation in PMA treated p85-/cells (Figure 3B, panels m-p). These results further support a role for PI3-kinase
in PMA-induced cSrc activation.
In order to verify that the effects observed with PMA treatment were
associated with PKCα signaling, SYF/cSrc cells were transiently transfected with
GFP-AFAP-110 with or without a constitutively active form of PKCα (myrPKCα)
and examined for cSrc activation. Expression of GFP-tagged AFAP-110 in the
absence of myrPKCα did not direct an increase in cSrc activation (Figure 4A,
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panel a-d). Co-expression of AFAP-110 with myrPKCα resulted in an increase in
cSrc activation concomitant with significant changes in the localization of AFAP110 and stress filaments (Figure 4A, panels e and h). LY294002 treatment had
little effect on AFAP-110 localization in the absence of myrPKCα (Figure 4A,
panels i-l). Inhibition of PI3-kinase activity by LY294002 blocked the ability of
myrPKCα to induce cSrc activation or the formation of ventral membrane
structures predicted to be podosomes (Figure 4A, panels m-p). To further
evaluate the role of PI3-kinase in PKCα-directed cSrc activation and actin
filament disruption, p85-/- cells were transfected with myrPKCα. Expression of
myrPKCα failed to direct an increase in cSrc activation or promote disruption of
actin filaments (Figure 4B, panels e-h) relative to untransfected controls (Figure
4B, panels a-d). Collectively these data indicate that PMA or myrPKCα are
unable to direct AFAP-110 to colocalize with or activate cSrc in the absence of
the PI3-kinase activity. One consequence associated with this is a failure to form
ventral membrane structures that may be podosomes or precursors to
invadopodia.

PI3-Kinase is required for PMA-induced translocation of active cSrc to the cell
membrane in mouse embryo fibroblasts. In the quiescent state, approximately
90% of cSrc is found associated with in the perinuclear region of the cell and this
location was shown to correlate with an association with perinuclear vesicles
both in endogenous and over-expression systems (24; 40; 42). Upon activation,
cSrc moves to the cell membrane and stimulates phosphorylation of proteins and
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downstream signaling cascades that regulate mitogenesis, motility and invasive
potential (42; 44). SYF cells, which are null for endogenous cSrc, were
transiently transfected to express avian cSrc. This system allows for efficient
detection of avian cSrc with the highly specific avian cSrc antibody (EC10). Cells
were treated with PMA for 10 minutes. The shorter incubation time allowed for
evaluation of cSrc translocation to the peripheral membrane and activation prior
to podosome formation (Walker and Flynn, unpublished observation). Our
analysis in quiescent cells confirmed that the vast majority of cSrc is associated
with the perinuclear region of the cell; while far less is associated with the cell
periphery (Figure 5, panel a). Activation of PKCα by PMA directed cSrc to
translocate from the perinuclear region to the cell periphery (Figure 5, panel b).
This translocation was blocked by pre-treatment of cells with either
bisindolylmaleimide [I] (Figure 5, panel c) or LY294002 (Figure 5, panel d), where
cSrc remained perinuclear. Interestingly, in the absence of PI3-kinase activity
cSrc remained in the perinuclear region in p85-/- cells irrespective of PMA
treatment and these cells were comparable to untreated controls (Figure 5,
panels e and f).
As cSrc activation is rapid in response to PMA (less than 15 minutes), we
sought to design a strategy that would enable us to determine where cSrc and
AFAP-110 first colocalize, without inducing cSrc activation and subsequent
transit to the membrane. To accomplish this, we utilized the temperaturesensitive form of viral-Src, LA29 (43; 47). LA29 exists in perinuclear regions of
the cell at non-permissive temperatures (39.5°C) and moves to the cell periphery
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at permissive temperature (35°C) where it induces the characteristic cell shape
changes associated with transformation, including the formation of motility
structures and podosomes (32; 48). We transiently transfected SYF cells with a
dual expression vector encoding both AFAP-110 and LA29 at the non-permissive
temperature of 39.5°C. After 48 hours, the cells were left at 39.5°C or transferred
to the permissive temperature, 35°C. Western blot analysis demonstrated that
LA29 is active at 35°C and not at 39.5°C, based on immunoreactivity with antiphospho-Src family (Y418) (Figure 6A). At the non-permissive temperature,
LA29 is predominantly observed in the perinuclear region of the cell and does not
colocalize with AFAP-110 (Figure 6B, panels a-d). In cells treated with PMA at
39.5°C, AFAP-110 colocalized strongly with LA29 in the perinuclear region of the
cell (Figure 6B, panels e-h). Pretreatment of cells with either bisindolylmaleimide
(Figure 6B, panels i-l) or LY294002 (Figure 6B, panels m-p) blocked PMA
induced colocalization between LA29 and AFAP-110. When untreated control
cells were shifted to the permissive temperature (35°C) for 6 hours, LA29
becomes activated and moves to the cell periphery (Figure 6B, panels q-t). In
these cells, there was evidence for numerous actin-rich, punctate structures
found on the ventral membrane (as imaged using confocal microscopy and 1 µm
thick sections) that were ~ 1 µm in diameter, which are characteristic of
podosomes (15; 31). Interestingly, treatment of these cells with LY294002
blocked the ability of AFAP-110 to colocalize with LA29 and no disruption in actin
filament integrity was observed at permissive temperature (Figure 6B, panels ux). Collectively, these data indicate that colocalization between AFAP-110 and

102

LA29 occur in the perinuclear region of the cell and that PI3-kinase activity is
required for AFAP-110 colocalization, activation of cSrc and subsequent
translocation of cSrc to the cell periphery.

PMA treatment induces PI3-Kinase activation. Our data indicated that PI3kinase activation occurs downstream of PMA treatment and upstream of cSrc
activation. Therefore, we predicted that PMA should be able to induce activation
of PI3K. Although there are several reports in the literature that indicate PI3kinase activation can lead to subsequent PKC activation (as a result of PDK1
phosphorylation) (3); it is not clear whether PMA and PKCα activation can
function as upstream activators of PI3K. To test this, we performed a PI3-kinase
lipid kinase activity assay, as previously described (23). SYF/cSrc cells were
serum-starved and then stimulated with either serum or PMA for 5 or 15 minutes.
The lipid kinase assay demonstrates that there is a significant increase in PI3kinase activity after 5 or 15 minutes of treatment with PMA (Figure 7A). These
data indicate that PMA treatment can induce PI3-kinase activity.
To corroborate our results observed in vitro, we stimulated SYF/cSrc cells
with PMA and measured the production of PtdIns-3,4,5-P3, the predominant lipid
product generated by PI3-kinase upon activation. PtdIns-3,4,5-P3 production was
measured using the anti-PtdIns-3,4,5-P3 antibody (Echelon, inc.) for analysis by
immunofluorescence and contrasted with stress filament integrity, measured
using TRITC-phalloidin as previously described (8; 19). SYF/cSrc cells were left
untreated or treated with serum as controls for PI3-kinase activation. Serum was

103

able to direct up-regulation of PtdIns-3,4,5-P3 (25) and the PI3-kinase inhibitor
LY294002 was able to block serum-induced PtdIns-3,4,5-P3 production (Figure
7B, panels c-f). In addition, SYF/cSrc cells were stimulated with PMA for 5 or 15
minutes. The data indicate that PMA was able to induce PtdIns-3,4,5-P3
production within 5 minutes of treatment concomitant with significant changes in
cell shape and actin filament organization (Figure 7B, panels g and h).
Interestingly, PtdIns-3,4,5-P3 levels were consistently reduced after 15 minutes of
treatment with PMA, although cell shape changes and actin filament
reorganization were still apparent (Figure 7B, panels i and j). Pretreatment with
either bisindolylmaleimide [I] or wortmannin blocked PMA-induced PtdIns-3,4,5P3 production (Figure 7B, panels k-n) and similar results were observed with
LY294002 (data not shown). Based on these results, we predicted that PKCα
and PI3-kinase signaling were upstream of cSrc in response to PMA treatment.
To address this, cells were pre-treated with the cSrc inhibitor PP1 prior to PMA
treatment. PP1 did not block PMA-induced PtdIns-3,4,5-P3 production (Figure
7B, panels o and p), although PMA-directed changes in stress filaments and cell
shape were impeded. Collectively, these data indicate that PMA treatment
induces activation of PI3-kinase and that activation is dependent on PKC activity,
but independent of cSrc activation.

cSrc, PI3K and AFAP-110 are required for migration. Several studies have
shown that cSrc is required for the ability of cells to migrate into a wound of a
scratch assay (27). Therefore, we wanted to address the question: does PI3-
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kinase regulate cell migration in our mouse embryo fibroblast system. We
developed a Tet-Off system to express both wild-type AFAP-110 and the cSrc
SH3 binding mutant AFAP-11071A, which we predict acts as a dominant-negative
construct. To confirm expression can be induced, western blot analysis was
performed for AFAP-110, which demonstrated that removal of doxycycline
correlates with induction of AFAP-110 or AFAP-11071A (Figure 8A). A scratch
assay was performed and the distance migrated over 6 hours measured (Figure
7B-C). The average migration was graphed and a one-way ANOVA (p<0.05)
performed to determine significance. SYF/cSrc cells had the highest rate of
migration and this increase was impeded with inhibition of PI3-kinase activity by
LY294002 (Figure 8B). However, cells that failed to express cSrc (SYF) or the
regulatory subunits of PI3-kinase (p85-/-) displayed a reduced ability to migrate
as compared to the SYF/cSrc control cells. Interestingly, expression of wild-type
AFAP-110 did not promote a significant increase in the distance migrated as
compared to control (Figure 8C) However, cells expressing the cSrc SH3 binding
mutant did result in a significant reduction in migration as compared to the control
. These data indicate that PI3-kinase, cSrc and AFAP-110 may function in
regulating the ability of mouse embryo fibroblast to migrate.
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Discussion
Recent evidence indicates that PKCα can direct activation of cSrc, and
this activation requires the presence of AFAP-110 (5; 7; 15). Upon activation,
PKCα will bind to, and direct an increase in serine/threonine phosphorylation, of
AFAP-110 (35). This interaction affects a conformational change upon AFAP-110
that relieves intramolecular interactions that autoinhibit AFAP-110 function (38).
In response to these signals, AFAP-110 then colocalizes with and directs
activation of cSrc. Colocalization required the integrity of the PH1 domain. Here,
we show that colocalization appears to occur in the perinuclear region of the cell
where cSrc resides in an inactive state on endosomal vesicle membranes. This
is demonstrated by co-expressing AFAP-110 with the temperature-sensitive vSrc
construct, LA29 and showing that colocalization does not occur at nonpermissive temperature; however, at when PMA is applied to the cells,
colocalization occurs at the perinuclear membrane. In this system, LA29 remains
perinuclear even upon colocalization with AFAP-110. We predict that LA29
remains inactive regardless of contacting AFAP-110 as mutations which render it
temperature sensitive would be dominant over the ability of AFAP-110 to engage
the LA29 SH3 domain and induce activation. These mutations are found in the
catalytic domain and likely govern access of ATP to the ATP binding site in the
catalytic domain of LA29. Therefore, we predict that PMA directs AFAP-110 to
move to cSrc. Thus, AFAP-110 and cSrc likely colocalize on the membranes of
perinuclear vesicles, where inactive cSrc resides. Colocalization is dependent
upon the integrity of the PH1 domain while activation is dependent upon the
ability of AFAP-110 to bind to the cSrc SH3 domain through its SH3 binding
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motif. The result of cSrc activation is a change in actin filament integrity and the
formation of ventral membrane associated structures predicted to be either
podosomes or precursors to invadopodia (15; 31). In this report, we sought to
determine what cellular signals promote colocalization between AFAP-110 and
cSrc, and subsequent activation of cSrc in response to PMA treatment or PKCα
activation. The focus of this study was the role of PI3-kinase in PMA-induced
cSrc activation as mediated by AFAP-110. The reason for this focus was
because (a) there is significant evidence for cross-talk between PKC, cSrc and
PI3-kinase, (b) the integrity of the PH domain in AFAP-110 is required for
colocalization with cSrc and (c) the PH domain has the capability to bind PI3kinase generated phospho-lipids.
The data presented in this manuscript indicated that PMA, and by
extension, PKCα, has the ability to induce activation of PI3-kinase. The ability of
PKCα to direct PI3-kinase activation has been controversial. Although there is
much evidence to indicate that PI3-kinase can direct activation of PKCα via its
ability to direct activation of PDK-1 (12), it has not been clear if PKCα can in turn,
act upstream and direct PI3K activation. Huang and colleagues were able to
demonstrate that PMA treatment of JB6 epidermal cells stimulated PI3-kinase
activation and AP-1 formation, while pretreatment with bisindolylmaleimide or
LY204002 blocked AP-1 formation, indicating that PKC could contribute to PI3K
activation in JB6 epithelial cells (22). However, further studies using a dominantnegative form of PKCα failed to abrogate the effects of PMA-directed activation
of PI3-kinase activation in this system, indicating that perhaps PMA induced
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activation of PKC-epsilon (PKCε) which in turn activated PI3-kinase (21). Our
MEF cells do express low levels of PKCε (35), thus it is possible that PMA
directed activation of PI3-kinase could occur as a result of novel PKC family
activation. Thus, although PMA will stimulate activation of PI3-kinase, it is
possible that PMA could direct activation of PI3-kinase via another classical or
novel PKC family member. To determine if PMA could activate PI3-kinase in our
MEF system, we employed a classic lipid kinase assay, which demonstrated
upregulation of PI3-kinase activity. To verify this result, we employed the antiPtdIns-3,4,5-P3 antibodies and used immunofluorescence to demonstrate
production of PtdIns-3,4,5-P3 in cells treated with PMA. These data indicated
that both serum induction and PMA were able to direct an increase in PtdIns3,4,5-P3 production similar to those observed in the lipid kinase assay. We
observed that PtdIns-3,4,5-P3 production was consistently higher at 5 minutes
compared to 15 minutes post-treatment. Interestingly, we noticed that serum
appeared to induce production of PtdIns-3,4,5-P3 in both the perinuclear region
as well as along the cytoplasmic membrane; whereas PMA only seemed to
induce PtdIns-3,4,5-P3 production in the perinuclear region of the cell. Serum
likely contains growth factors that can activate growth factor receptors as well as
other cellular signals, while PMA directs activation of a more narrow spectrum of
signaling proteins (14; 18; 46; 49). Thus, serum could activate PI3-kinase
populations that exist at the cell periphery and along internal membranes, while
PMA may direct activation of a more limited population of PI3-kinase that might
localize to internal membranes. As inactive cSrc is found primarily along
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perinuclear vesicles (40), the ability of PtdIns-3,4,5-P3 to be generated in the
perinuclear region of the cell may be consistent with activation of cellular signals
which promote cSrc activation. PMA will direct activation of the classical and
novel PKC isoforms. An inhibitor of PKC catalytic activity, bisindolylmaleimide [I]
also blocked PMA-directed colocalization between AFAP-110 and cSrc,
indicating that PMA was sending these signals via its’ capacity to activate a PKC
family member’s catalytic activity. However, within our MEF cell system, PKCα is
the only member of the classical and novel PKC’s that is expressed that will also
bind to AFAP-110 (15; 35). Our data also indicate that in cells pretreated with the
PI3-kinase inhibitors LY294002 and wortmannin, PMA was unable to induce
colocalization between AFAP-110 and cSrc. In support of this, PMA failed to
direct colocalization between AFAP-110 and cSrc and cSrc activation in MEF
cells that lack the p85α and β regulatory subunits of PI3-kinase (4). In the
absence of the p85 regulatory subunit, the p110 catalytic subunit is destabilized
and degraded in agreement with our observations (51). These data indicate that
the presence of PI3-kinase is required for PMA directed colocalization between
AFAP-110 and cSrc, and subsequent activation of cSrc by AFAP-110.
The link between PKC and PI3-kinase has also been addressed. Most
PKC isoforms can be activated by PI3-kinase effector, PDK-1, by
phosphorylation of key regulatory serine/threonine residues within the activation
loop of PKC resulting in a confirmation change and subsequent activation (3; 29;
33). Further, the additions of exogenous PI3-kinase generated lipid products
were able to activate PKC by binding the C2 domain resulting in the formation of
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motility structures, such as lamellipodia (10). Thus, we attempted to determine
the ability of AFAP-110, cSrc and PI3-kinase to modulate cell motility using a
scratch motility assay. Here, wounding has been shown to activate endogenous
PKC’s (34), thus, we did not treat with PMA as that would have been redundant.
The data presented here indicate that effective migration of mouse embryo
fibroblast into a wound is dependent on both the presence of cSrc and the ability
of AFAP-110 to associate with cSrc. Further, cells that fail to express the p85
regulatory subunit exhibited reduced migration similar to that observed when
PI3K activity is inhibited.
These results raised the question, how does PI3-kinase mediate AFAP110 and cSrc colocalization in response to PMA treatment? Pleckstrin homology
domains are self-folding, modular domains that interact with a variety of protein
and lipid binding partners, including PKC isoforms, small G-proteins and lipids (1;
50). Of the latter, many PH domains have been shown to bind phospholipids that
are generated upon activation of PI3K (e.g., PIP3). PH domains that interact with
phospholipids have a binding groove that contains positively charged amino
acids in the base of the groove. In theory, phospholipid binding would be
coordinated by interactions between the negatively charged phospho-head group
of the phospholipid with positive charges in the base of the groove, and could be
further stabilized through hydrophobic interactions between the wall of the groove
and the hydrophobic tail(s) of the lipid. The PH1 domain of AFAP-110 is most
homologous with the PH domain found in Bruton’s Tyrosine Kinase (BTK), both
of which also contain positively charged amino acids positioned to coordinate
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interactions with negatively charged, phospholipid head groups (2). Indeed, we
have demonstrated that the PH1 domain can bind to several phospho-lipids in
vitro, including PIP3 (Jett, Zot and Flynn, unpublished data). Work done by our
laboratory indicates that deletion of the PH1 domain blocked the ability of PMA to
induce colocalization between AFAP-110 and cSrc and subsequent cSrc
activation (15). Thus, we hypothesize that the ability of AFAP-110 to colocalize
with cSrc (in response to PKCα activation or PMA treatment) might be dependent
upon interactions with either protein binding partners or lipid binding partners that
facilitate translocation to cSrc at perinuclear membranes. Collectively, these
data indicate that when PMA directs activation of PKCα, PI3-kinase is
concomitantly activated and these signals work cooperatively to direct AFAP-110
to move to and bind cSrc. Subsequently, cSrc is activated and cells exhibit
podosome formation and an increase in migratory potential. Thus, we
hypothesize that cSrc, PI3-kinase and AFAP-110 work together to promote
migration of mouse embryo fibroblasts.
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Figures

Figure 1: LY294002 blocks PMA-induced colocalization between AFAP-110
and cSrc, and subsequent cSrc activation. SYF cells transiently coexpressing GFP-AFAP-110 and cSrc were untreated (panels a-d), treated with
100 nM PMA for 30 minutes (panels e-h), or treated with PMA and either 6 µM
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bisindolylmaleimide (panels i-l), 10 µM LY294002 (panels m-p) or 50nM
Wortmannin (panels q-t). Fixed cells were immunolabeled with avian specific
cSrc antibody, EC10 (1:500), and phospho-Src-family (Tyr416) (1:250) as
described in the methods section. Secondary antibodies used were Alexa 546
anti-mouse for EC10 and Alexa 647 anti-rabbit for phospho-Src-family (Tyr416).
PMA treatment resulted in a disruption of actin into punctate structures and an
increase in cSrc activation. The majority of active cSrc is localized to these
structures; however a very small population is localized to the membrane (as
indicated by the arrow, panels e-h). A merged image was generated to determine
colocalization between AFAP-110 and cSrc. Bars represent 20µm.
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Figure 2: p85 knockout mouse embryo fibroblasts express AFAP-110 but
not the p110α catalytic subunit. A) Western blot analysis using 40 µg of protein
was performed as described in the method section. p85 knockout cells (p85-/-)
were compared to system control cells SYF and SYF/cSrc. Membranes were
probed with antibodies to AFAP-110, p85α, PKCα and cSrc. Membranes were
stripped and re-probed with anti-β-actin as a loading control. B) Western blot
analysis using 40 µg of protein was performed as described in the method
section. Knockout cells (p85-/-) and cells that express the p85α isoform of the
PI3K regulatory subunit (p85α+/+) were compared to system control cells
SYF/cSrc. Membranes were probed with an antibody that recognizes p85α and
re-probed with anti-β-actin. C) Western blot analysis using 40 µg of protein was
performed as described in the method section. Knockout cells (p85-/-) and cells
that express the p85α isoform of the PI3K regulatory subunit (p85α+/+) were
compared to system control cells SYF and SYF/cSrc. Membranes were probed
with an antibody that recognizes p110α and re-probed with anti-β-actin.

114

Figure 3: PMA fails to induce cSrc activation in cells that do not express
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the p85α regulatory subunit. A) SYF, SYF/cSrc, and p85-/- were treated with
100nM PMA for 15 minutes, 40 µg cell lysate resolved by SDS-PAGE and
western blot analysis performed to evaluate phospho-Src family (Y416)(1:1000)
and cSrc (1:500) as described in the methods section. β-actin (1:5000) was used
as a loading control. B) p85 knockout MEFs (p85-/-) and mouse embryo
fibroblast cells that express only the p85α isoform of the PI3K regulatory subunit
(p85α+/+) were transfected with GFP-AFAP-110 and cSrc; followed by a 30
minute treatment with PMA. Fixed cells were immunolabeled with EC10 (1:500)
and phospho-Src-family (Tyr416) (1:250) as described in the methods section.
Secondary antibodies used were Alexa 546 anti-mouse for EC10 and Alexa 647
anti-rabbit for phospho-Src-family (Tyr416). Images were merged to determine
colocalization of cSrc and GFP-AFAP-110. Bars represent 20µm.
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Figure 4: PI3K activity is required for myrPKCα directed cSrc activation. A)
SYF/cSrc cells transfected with GFP-AFAP-110 with or without Flag-tagged
myrPKCα. The cells were fixed and immunolabeled with Flag antibody (1:1000),
and phospho-Src-family (Tyr416) (1:250) as described in the methods section.
Secondary antibodies used were Alexa 546 anti-mouse for Flag and Alexa 647
anti-rabbit for phospho-Src (Tyr416). A merged image used to determine
colocalization between AFAP-110 and myrPKCα. Controls without myrPKCα
untreated (panels a-d) or treated with 20µM LY294002 (panels i-l) showed no
change in actin filament integrity. Cells co-expressing GFP-AFAP-110 and
myrPKCα show an increase in cSrc phosphorylation and colocalization between
myrPKCα and AFAP-110 (panels e-h). Treatment of cells treated with 20µM
LY294002 abrogated colocalization and cSrc phosphorylation (panels m-p). B)
Mouse embryo fibroblast p85-/- cells expressing myrPKCα were fixed and
immunolabeled with Flag antibody (1:1000), TRITC-phalloidin (1:500) and
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phospho-Src-family (Tyr416) (1:250) as described in the methods section.
Secondary antibody used was Alexa 488 anti-mouse for FLAG. A merged image
was generated to determine colocalization between actin and myrPKCα. The
myrPKCα failed to induce an increase in cSrc activation (panels f) or disruption of
the actin cytoskeleton (panel h) in knockout cells as compared to the controls.
Bars represent 20µm.
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Figure 5: PI3K is required for PMA-induced colocalization of AFAP-110 with
cSrc. SYF and p85-/- null cells were transiently transfected with cSrc and labeled
for avian cSrc using EC10, an avian-specific monoclonal antibody (1:500). EC10
was visualized with anti-mouse Alexa Fluor 488 (false colored red for
consistency). Cells treated with 100 nM PMA for 10 minutes (panel b) induced
translocation of cSrc to the cell periphery as indicated by the white arrows.
Yellow arrows denote early forming podosomes. However, cells treated with 100
nM PMA in conjunction with 6 µM bisindolylmaleimide (panel c) or 10 µM LY
(panel d) blocked the translocation of cSrc as indicated by the arrows. In p85-/null cells that were treated with 100 nM PMA (panel f) failed to induce the
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translocation of cSrc to the cell periphery, as indicated by the arrows.
(n=nucleus) Bars represent 20µm.
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Figure 6: AFAP-110 colocalizes with LA29 in the perinuclear region of cells.
A) SYF cells were transiently transfected with CMV-tsLA29, maintained at
39.5°C, and then either shifted to 35°C. Cells were lysed and western blot
analysis performed. Control lysates of SYF were used to verify expression and
activation. Membranes were probed with phospho-cSrc (Y418) (1:1000).
Membranes were stripped and reprobed using avian specific cSrc antibody,
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EC10. B) SYF cells were transiently transfected with a CMV dual expression
vector encoding both AFAP-110 and tsLA29 were fixed and immunolabeled with
anti-AFAP-110 (F1), anti-avian cSrc (EC10) and TRITC-phalloidin. Secondary
antibody for Anti-cSrc (EC10) was Alexa Fluor 647 anti-mouse and AFAP-110
(F1) was Alexa Fluor 488 Goat anti-rabbit IgG. Merged images of AFAP-110 and
cSrc were generated using the Zeiss confocal software. Cells remaining at
39.5°C were left untreated (data not shown), treated with DMSO (panels a-d),
100nM PMA (panels e-h), or 100nM PMA in conjunction with 6µM
Bisindolylmaleimide (panels i-l) or 10µM LY294002 (panels m-p). Cell shifted to
35°C were either untreated (panels q-t) or treated with 10µM LY294002 (panels
u-x). LY blocked the translocation of cSrc or colocalization of AFAP-110 with
cSrc. Bars represent 20µM.
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Figure 7: PMA treatment results in an increase in PI3K activation. A)
SYF/cSrc cells were cultured under serum-free conditions for 24 hours. Cells
were unstimulated or stimulated with 10% serum (positive control), 100 nM PMA
for 5 or 15 minutes. Cells were then lysed in kinase assay buffer and a PI3K
kinase activity assay performed using anti-p110α immunoprecipitates to measure
PMA-induced incorporation of [32P] into phosphoinositide substrates. B)
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SYF/cSrc cells were serum-starved for 24 hours. Cells stimulated with 10%
serum (panels c-f), 100 nM PMA for 5 (panels g-h), or 15 minutes (panels i-j); as
well as treated with 100 nM PMA for 5 minutes in combination with 6 µM
bisindolylmaleimide [I] (panels k-l) or 50nM wortmannin (panels m-n). Cells
treated with 100 nM PMA for 5 minutes in combination with 5 µM PP1 (panel o-p)
and PtdIns-3,4,5-P3 levels evaluated. Cells were immunolabeled with a PI-3,4,5P3-specific antibody (1:100) and TRITC-phalloidin (1:500). Secondary antibody
for anti-PI-3,4,5-P3 (1:100) was Alexa IgM 647 anti-mouse (1:200). Bars
represent 20 µm.
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Figure 8: Both cSrc and PI3K are required for migration. A) Western blot
analysis was performed to determine the expression levels AFAP-110 of the TetOff cells 8-10 days following the removal of doxycycline and re-probed with antiβ-actin. B) SYF/cSrc, SYF, p85-/- culture media was replaced with carbon
dioxide independent media then cells were untreated, treated with 20µM
LY294002 following a scratch through the confluent monolayer. Distance
migrated was measure using the AxioVision 4.4 software (Zeiss) and averages
were analyzed using Excel. Statistical significance was determined using a Oneway ANOVA (*p<0.05; +/-SD). C) Uninduced control Tet-Off and induced (AFAP110 and AFAP-11071A) Tet-Off clones culture media in the presence (+) or
absence (-) of doxycycline. The cells were washed and this media was replaced
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with carbon dioxide independent media then a scratch was made in the confluent
monolayer. Distance migrated was measure using the AxioVision 4.4 software
(Zeiss) and averages were analyzed using Excel. Statistical significance was
determined using a One-way ANOVA (*p<0.05; +/-SD).
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Abstract
Podosomes are actin-rich structures that form on the ventral membrane and
promote cell adhesion and invasive potential. Activation of the Src non-receptor
tyrosine kinase is sufficient to induce podosome formation. The ability of PKCα to
induce cSrc activation requires the presence of the adaptor protein, AFAP-110.
Both PKCα and PI3-kinase induce podosome formation in a cSrc dependent
fashion. In this report, we sought to determine how PI3-kinase functions in
PKCα-induced podosome formation. We previously determined that activation of
PI3-kinase activity was required for cSrc activation in response to PMA
treatment. In this report we show that the phosphatidylinositol-3-kinase (PI3kinase) inhibitor, LY294002, blocked PMA-induced activation of podosome
formation. In addition, treatment of MEF cells that lack the regulatory subunit of
PI3-kinase failed to form podosomes following treatment with PMA. Thus, we
hypothesize that PKCα directs activation of cSrc and subsequent podosome
formation in a PI3-kinase-dependent fashion. These data indicate that PI3kinase plays a central role in integrating PKCα and cSrc signals that direct the
formation of podosomes.

134

Introduction
Podosomes were initially discovered as components of malignant B cells
and Src-transformed fibroblasts. They are prominent, actin-rich components of
the cell membrane found in a variety of cells, including monocyte-derived and
transformed cells (47; 51; 53; 64). Podosomes are formed on the cytoplasmic
face of the ventral membrane where they promote both cell adhesion and cell
invasion. Early reports pointed to a central and important role for Src kinases in
podosome formation and the concomitant appearance of tyrosine
phosphorylation in podosomes. Transformation of cells with v-Src oncogene
resulted in efficient podosome formation (50; 64). Similarly, treatment of
transformed cells with phosphotyrosine phosphatase inhibitors such as sodium
vanadate lead to an activation of tyrosine kinases and the formation of
podosomes, while tyrosine kinase inhibitors will block v-Src induced podosome
formation (21; 48; 52; 63). Immunofluorescence (IF) analysis indicates that cSrc,
the Src regulating proteins, such as CSK and Shp2, as well as other tyrosine
phosphorylated proteins can be localized to podosomes (13; 29; 34; 55; 60; 64).
Activation of either PKCα or cSrc results in similar effects on cell
morphology, including a loss in actin filament integrity, changes in cell shape and
stimulation of signals associated with increased motility and invasion (33; 35; 38).
Several studies support the existence of cross-talk between cSrc and PKCαmediated signaling pathways. Constitutive activation of cSrc or stable
expression of vSrc will concomitantly stimulate an increase in PKCα signaling,
suggesting that PKCα could function downstream of cSrc (22; 59; 67). Others
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have shown that PKCα may function upstream as an activator of cSrc. Brandt et
al. demonstrated that PKCα can directly stimulate cSrc activity in A7r5 rat aortic
smooth muscle cells, and the induction of Src kinase activity is necessary for
PKC-mediated actin reorganization (8). Although several studies have
documented that PKCα activation results in the activation of cSrc, this remains
controversial (8; 9; 11). The ability of PKCα to activate cSrc is not due to direct
interactions between these two kinases. Although PKCα can phosphorylate cSrc
in vitro studies using purified cSrc and PKCα demonstrated that PKCα was
unable to directly activate cSrc (9). Further, our laboratory has shown that
activation of PKCα promotes that activation of cSrc via an adaptor protein,
AFAP-110 resulting in a marked disruption of actin stress filaments and
podosome formation. Thus, the ability of PKCα to activate cSrc requires AFAP110 relay signals from PKCα, which in turn directed activation of cSrc.
Activated Src (e.g., vSrc or constitutively active cSrc527F) will induce
changes in cell morphology that are characterized by a loss of actin filament
integrity, increased podosome formation and an associated development of
motility structures. Activators of cSrc tyrosine kinase fall into two main categories
– either (a) tyrosine phosphatases which can remove the phosphate group from
the regulatory phosphotyrosine in the carboxyl terminus, such as pTyr527 of cSrc,
or (b) adaptor proteins that can bind to the cSrc SH3 domain with higher affinity,
which would competitively displace intramolecular autoinhibitory interactions
between the SH3 domain and linker region of cSrc. Examples of the former
include Shp-2 (60), while examples of the latter include AFAP-110 and pp130Cas
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(2; 3). Activation of cSrc is required for podosome formation (28). In this regard,
it is compelling that known cSrc activators, such as AFAP-110, pp130Cas or
Shp-2 are components of podosomes.
Studies have shown that expression of activated PKCα, or activation by
treatment with PMA, results in significant changes in actin filament integrity,
including a loss of actin filament organization, changes in cell morphology and
generation of cell motility structures, such as lamellipodia (27; 40). In addition,
PKCα activation has been shown to induce cell motility and invasive potential
(19; 25). Although PKCα can direct a reduction in general actin filament
organization, it also directs the formation of motility structures which are rich in
cross linked F-actin (19; 20; 25). Studies have shown that some PKC isoforms
are able to directly interact with small GTPases, such as Rho and Cdc42. It has
been demonstrated that PKCα is able to bind RhoA in a GTP-dependent manner
to act downstream of Rho (16). Finally, Atypical PKC isoforms, λ and ζ, associate
with Cdc42 in a GTP-dependent fashion to mediate loss of stress fibers (19).
These studies indicate that PKCs are able to direct both loss of actin filament
integrity and the formation of motility structures, as well as generalized loss of
actin filament organization.
In this report, we sought to determine the role of PI3-kinase in regulating
the ability of PKCα to activate cSrc and promote subsequent podosome
formation in our cell system. Previous work indicates a role for
phosphatidylinositol-3-Kinase (PI3-kinase), as the PI3-kinase inhibitor LY294002
blocked PKCα induced activation of cSrc. These data indicate that PKCα may
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be capable of activating PI3-kinase directly. Previous reports have demonstrated
that PI3-kinase can direct activation of cSrc and in turn, cSrc can activate PI3kinase (10; 49). PI3-kinase can also direct activation of PKCα via PDK1 (24);
however, it is not clear whether PKCα can in turn direct activation of PI3-kinase.
Work published by our laboratory demonstrated that PMA directs PI3-kinase
activation in mouse embryo fibroblasts (65). Here, we demonstrate the role of
PI3-kinase in PMA-induced podosome formation. We previously demonstrated
that PMA treatment resulted in a marked disruption in actin and subsequent
podosome formation (28).
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Methods and Materials:
Reagents: Dulbecco’s modified Eagle’s medium (DMEM), Rhodamine-phalloidin,
TRITC-anti-Mouse IgG, TRITC-anti-Rabbit IgG, both anti-cortactin polyclonal and
monoclonal antibodies, and Bovine serum albumin were purchased from Sigma.
Protein A/G PLUS agarose beads, and polyclonal cSrc antibody were purchased
from Santa Cruz biotechnology. LipofectAMINE™ was purchased from
Invitrogen. Phorbol 12-myristate 13-acetate (PMA), LY294002, and
Bisindolylmaleimide [I] were obtained from Calbiochem. Monoclonal p85α
antibody and anti-phosphotyrosine monoclonal and polyclonal antibodies were
obtained from BD Transduction Laboratories. Monoclonal avian cSrc antibody
EC10 was obtained from Upstate. Phospho-Src family (Tyr416) antibody was
purchased from Cell Signaling. Horseradish peroxidase-conjugated anti-rabbit
and anti-mouse antibodies were obtained from Amersham Biosciences. All Alexa
Fluor antibodies used in the paper were purchased from Molecular Probes. All
chemical used throughout this manuscript, except where otherwise stated, were
purchased from J.T. Baker.

Cell Lines and Culture: Mouse embryo fibroblast SYF/cSrc (ATCC) cells were
used throughout this manuscript, except were indicated. SYF/cSrc are derived
from a SYF parental cell line that is devoid of Src family of non-receptor tyrosine
kinase members fyn, and c-yes genes but engineered to re-express cSrc (41).
Mouse embryo fibroblasts derived from Pik3r1 (encodes p85α genes) knock-out
129 C57BL/6 mice were kind gift from Saskia Brachman, PhD (Harvard) (7). All
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cell lines were grown at 37°C with 5% CO2 in DMEM supplemented with 10%
(v/v) fetal calf serum, 1% (v/v) L-glutamine, and 1% penicillin/streptomycin.

Constructs: The pEGFP-c3 Expression system from Clontech was used to
express GFP-tagged forms of AFAP-110. AFAP-110 was cloned into this vector
as previously described (58). The wild-type (p85α) and the dominant-positive
mutant K227E (Lys227→Glu) of the p110α catalytic subunit all were gifts from Dr.
Bing-Hua Jiang (West Virginia University). All PI3-kinase constructs were cloned
into the pSG5 vector for expression in mammalian cells.

Immunofluorescence and Transfection: SYF, SYF/cSrc, and p85-/- cells were
cultured in DMEM supplemented with 10% fetal calf serum. Transient
transfection of SYF, SYF/cSrc and p85-/- cells for immunofluorescence was
carried out using Lipofectamine Reagent (Invitrogen) as previously described
(28). Briefly, approximately 5.0-8.0 x 104 cells per well were transfected at 5070% confluent on coverslips in 6-well culture plates with 2-4 µg of plasmid DNA
and incubated for 3½ hours. Thirty-six hours after transfection, SYF, p85-/- and
SYF/cSrc cells were serum starved for 12 hours, and fixed and permeablized as
previously described (57). Prior to fixing cells were treated with a PKC activator,
100nM PMA for 30 minutes, a PKC inhibitor, 6µM bisindolylmaleimide [I] for six
hours, and/or PI3-kinase inhibitor, 10µM LY294002 for six hours as indicated in
the figure legends. For actin labeling, a 1:500 dilution of TRITC-phalloidin was
used as labeled in the figures. Primary antibody concentrations used were diluted
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in 5% Bovine Serum Albumin (BSA): Anti-cortactin mAb, 1:250; EC10, 1:500;
Phospho-Src Family (Y416), 1:250; Anti-AFAP-110 pAb – 1:1000; Anti-AFAP100 mAb – 1:1000; Anti-cSrc pAb – 1:500. All fluorescent secondary antibodies
were diluted 1:200 in 5% BSA, and are labeled according to use in the figure
legends. Cells were washed and mounted on slides with Fluoromount-G (Fisher).
A Zeiss LSM 510 microscope was used to gather images, which represent
confocal slices of about 1 µM in thickness. To prevent cross-contamination
between the different fluorochromes, each channel was imaged sequentially
using the multitrack recording module before merging the images. Scale bars
(20µm) were generated and inserted by LSM 510 software. For all figures,
representative cells are shown (>100 cells examined per image shown).
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Results
PI3-kinase activity is required for PMA-induced podosome formation. Our
laboratory has demonstrated that PKCα activation by phorbol esters (i.e. PMA) or
expression of a constitutively active PKCα (myrPKCα) resulted in podosome
formation (28). In order to determine the role of PI3-kinase in PMA-induced
formation of podosomes, SYF/cSrc cells were either unstimulated, treated with
vehicle, 100nM PMA alone, or a combination of 100nM PMA with either 10µM
LY294002 or 6µM bisindolylmaleimide. To confirm the presence of podosomes,
cells were stained for a podosome-associated protein, cortactin (47). The
treatment of cells with 100nM PMA showed a loss of actin stress fibers and
formed podosomes (Figure 1 panel c and d). Similarly, bisindolylmaleimide or
LY294002 pretreatment of SYF/cSrc cells blocked PMA-mediated loss in stressfibers and subsequent podosome formation (Figure 1 panels e-h). However,
these data indicate that PI3-kinase activity is required for PMA-induced
podosome formation.
To further evaluate to role of PI3-kinase in PKC mediated podosome
formation, we obtained mouse embryo fibroblasts that were the p85 regulatory
subunit (double knockouts) of PI3-kinase. Previous data has shown that PI3kinase is required for the ability of PMA or PKCα to induce cSrc activation in
these cells. Previous studies by us demonstrated that expression of myrPKCα in
p85-/- cells failed promote the disruption in actin filament integrity (65). Cells
were treated with 100nM PMA or a combination of PMA and 6µM
bisindolylmaleimide. Treatment of p85-/- cells with PMA failed to induce

142

podosomes or promote disruption in stress fibers (Figure 1 panel k-l).
Pretreatment of the cells with bisindolylmaleimide also abrogated podosome
formation in response to PMA treatment (Figure 1 panel m and n) as compared
to untreated controls (Figure 1 panel i-j). These data indicate that the p85
regulatory subunit and subsequent PI3-kinase activity is required for mediating
PMA induced alteration in actin filament integrity and the formation of
podosomes.

PI3-kinase activity results in upregulation of cSrc activation and podosome
formation. Previous work done by us, has indicated that PI3-kinase activity is
unregulated by PMA treatment and this activity appears to independent of cSrc
activation, which would place PI3-kinase upstream of cSrc in this pathway (65).
To determine the role of PI3-kinase in cSrc activation and podosome formation,
mouse embryo fibroblast cells were transiently transfected to express dominantpositive PI3-kinase (p110α K227E) or wild-type p85α and evaluated for cSrc
activation or podosome formation. Cells expressing K227E induced a marked
increase in cSrc activation (Figure 2A panel f) as compared in wild-type
expressing controls (Figure 2A panel b). Further, cells expressing K227E
displayed a marked disruption of actin filaments a formation of podosomes
(Figure 2B panel a-d). These data indicate that PI3-kinase can induce both an
increase in cSrc activation and promote the disruption of the actin cytoskeleton
into podosomes. Collectively, these data indicated that PI3-kinase activity is
sufficient to activate cSrc and promote disruption in actin filament integrity.
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Discussion
There is significant evidence to indicate the existence of cross talk
between PKCα and cSrc, as well as PI3-kinase and cSrc. Activation of each of
these kinases results in substantial changes in actin filament integrity and cell
morphology. Furthermore, these kinases will stimulate increased cell motility and
invasive potential (reviewed in (15; 30; 36; 61)). Extensive studies by other
laboratories have shown that many cancers, including breast, prostate and
ovarian, exhibit higher than normal levels of cSrc, PKCα, and PI3-kinase (42;
61). In this study we wanted to determine the role of PI3-kinase in podosome
formation in response to PMA treatment.
The ability of PKC to function upstream of PI3-kinase has been in
question. Several studies demonstrate that PI3-kinase can promote PKC
activation however the ability of PKC to activate PI3-kinase is been elusive.
Further, numerous studies have shown a strong link between cSrc and PI3kinase. In addition, our laboratory confirmed that PKCα could direct activation of
cSrc, in vivo. Using mouse fibroblast cells, expression of constitutively activated
PKCα (myrPKCα) was sufficient to direct an increase in cellular tyrosine
phosphorylation and cSrc activation. An analysis of actin filament organization
in these cells revealed the formation of actin-rich structures that were
approximately 0.2-0.5 µm in diameter and which could be detected on the
cytoplasmic face of the ventral membrane using confocal microscopy and
scanning Z-planes with a thickness of 1 µm (28). In addition, these structures
contained a known podosome associated protein, cortactin.
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Previous work by us demonstrated that AFAP-110 has an intrinsic ability
to cross link actin filaments and activate cSrc. Amino terminal to the actinbinding domain are a series of protein binding modules that likely serve to link
signaling molecules to actin filaments. These domains include a proline-rich SH3
binding motif (SH3bm) that is able to contact the opposing SH3 domains of cSrc,
Fyn and Lyn (31; 62). AFAP-110 is also an SH2 binding partner for cSrc, Fyn
and Lyn. The SH3 binding motif serves to present AFAP-110 for tyrosine
phosphorylation by constitutively activated Src527F and also plays a central role in
stable complex formation with Src527F (31). In addition, AFAP-110 contains two
pleckstrin homology domains (PH1 and PH2). Furthermore, molecular modeling
studies indicate that the amino terminal PH1 domain contains conserved
residues predicted to bind to phospholipids or membranes, a feature common to
many PH domains (4; 45). Previous work by others demonstrated that the PH
domains of BTK and pleckstrin bind to PKCα in addition to lipid products as with
Akt (1; 66). Data published by our laboratory has demonstrated that AFAP-110
moves into motility structures concomitant with PKC activation, and mutants of
AFAP-110 that fail to bind to PKCα block activated myrPKCα from directing
changes in actin filament integrity and the formation of motility structures (56).
AFAP-110 was demonstrated to be both a binding partner and substrate for
PKCα. We have shown that (a) PKCα can activate cSrc, (b) AFAP-110 has an
intrinsic ability to activate cSrc and (c) PKCα can affect conformational changes
upon AFAP-110 therefore AFAP-110 can modulate PKCα-directed activation of
cSrc and subsequent changes in the actin-based cytoskeleton that are hallmarks
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of cSrc activation. Further, deletion of the PH1 of AFAP-110 blocked the ability
of AFAP-110 to colocalize with cSrc, indicating that the integrity of this domain is
required for cellular targeting (28). PH domains have been shown to be important
for membrane localization of several well-studied proteins, including Akt (37; 46).
Therefore, we hypothesized that the translocation of AFAP-110 to the perinuclear
region in order to activate cSrc may require a lipid second messenger.
The link between PKC and PI3-kinase has also been addressed. Most
PKC isoforms can be activated by PI3-kinase effector, PDK-1, by
phosphorylation of key regulatory serine/threonine residues within the activation
loop of PKC resulting in a confirmation change and subsequent activation (5; 44;
54). Further, the additions of exogenous PI3-kinase generated lipid products
were able to activate PKC by binding the C2 domain resulting in the formation of
motility structures, such as lamellipodia (23). Thus, we attempted to determine
the requirement PI3-kinase in PMA induced podosome formation. The data
presented here indicate that podosome formation of mouse embryo fibroblast in
response to PMA treatment is dependent on both the activity of cSrc and PI3kinase. Further, cells that fail to express the p85 regulatory subunit exhibited
reduced podosome formation in response to PMA treatment similar to that
observed when PI3-kinase activity is inhibited.
The use of either inhibitors, or constitutively active and dominant negative
mutants, illustrated the importance of PI3-kinase in cytoskeletal regulation (12;
14; 39). Work by others has shown that PI3-kinase activation can result in
podosome formation in osteoclasts in response to osteopontin binding to αvβ3
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integrins, activation of cSrc and gelsolin (6; 17; 18). Furthermore, treatment of
osteoclasts with PI3-kinase inhibitor, wortmannin, blocked podosome formation
mediated by αvβ3 integrins (43). In this report we were able to show that the
expression of a dominant-positive form of PI3-kinase was able to induce both
cSrc activation and disruption of actin filament integrity to promote podosome
formation. The pretreatment of mouse embryo fibroblasts with LY294002 blocked
the effects of PMA-induced (a) cSrc activation, (b) colocalization of cSrc with
AFAP-110, and (c) actin filament disruption. Our data demonstrate that inhibition
of PI3-kinase activity not only blocked the ability of PKCα to activate cSrc but it
also inhibited the formation of podosomes. Overexpression of a dominantpositive PI3-kinase (K227E) in mouse embryo fibroblasts was sufficient to induce
an increase in cSrc activation and promote the formation of podosomes. Further,
we sought to determine if PKCα could direct activation of cSrc and podosome
formation in the absence of PI3-kinase. For this analysis, we utilized p85 null
double knockout mouse fibroblast cells, which fail to expression the p85
regulatory subunits and their splice variants. The data indicate that PMA failed to
induce a disruption in the actin stress fibers or form podosomes. These data
confirm that PI3-kinase plays an important role in relaying signals from PKCα
that directs activation of cSrc and podosome formation.
Collectively, these data indicate that PKCα directs activation of cSrc and
promotes podosome formation in PI3-kinase-dependent manner. We
hypothesize the following model: Activation of PKCα displaces autoinhibitory
interactions between the Lzip motif and the PH1 domain of AFAP-110. This
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enables AFAP-110 to move to and colocalize with cSrc in a PI3-kinasedependent fashion. AFAP-110 then initiates activation of cSrc through SH3
binding. Activated cSrc then stimulates signals that direct the formation of
podosomes. These data are significant for several reasons. First, they establish
a mechanism by which PI3-kinase activates cSrc. Second, they establish
another mechanism by which PI3-kinase can direct the formation of podosomes.
Podosomes are actin-rich structures that form on the ventral membrane and are
hypothesized to play an important role in modulating the invasive potential of a
tumor cell (47). PKCα, cSrc and PI3-kinase activation are sufficient to induce an
increase in cell motility and invasive potential. Indeed, it has been hypothesized
that activation of cSrc occurs concomitant with acquisition of the invasive
phenotype (26). Interestingly, AFAP-110 may contribute to the formation of
podosomes in two ways. Here, PKCα would affect a conformation change upon
AFAP-110 that allows it to colocalize with and activate cSrc in a manner
dependent of PI3-kinase directly or it lipid product, which our data indicated are
sufficient to initiate signals that direct podosome formation. In addition, the
conformational change directed upon AFAP-110 that allows it to activate cSrc is
also sufficient to increase the ability of AFAP-110 to cross link F-actin (58).
Cross-linked F-actin exists in the core of the podosome. Although our analysis
does not distinguish the localization of AFAP-110 in the core or fringe of a
podosome, it is possible that AFAP-110 may be positioned to facilitate actin
cross-linking within the newly formed podosome core. However, it has been
established that PI3-kinase is localized to the ring of the podosome (47). It is also
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possible that AFAP-110 colocalization to podosomes may be required to facilitate
cSrc and PI3-kinase colocalization to podosomes, as AFAP-110 is a binding
partner for activated Src (32). Here, we demonstrated that PI3-kinase activation
occurred prior to cSrc activation and that its activation does not appear to be
dependent on activation of cSrc. Furthermore, we showed that constitutively
active mutant of PI3-kinase were able to induce cSrc activation, as well as,
podosome formation. Thus, it is possible that PI3-kinase itself or its lipid products
are acting to localize AFAP-110 to cSrc. In addition, the requirement of AFAP110 for podosome formation in response to PI3-kinase activation shows a
divergence of AFAP-110. Further studies to determine the exact mechanism are
currently under investigation. The mechanism by which PI3-kinase may enable
AFAP-110 to move to and activate cSrc is not clear. It is possible that PI3-kinase
activation produces a lipid product that would promote AFAP-110 transit to cSrc.
This would not be without precedence, as PI3-kinase produced lipid products are
required for Akt transit to membranes and subsequent activation. AFAP-110 has
the capacity to bind PI3-kinase lipid products (4) (Walker, Zot & Flynn, unpub
data). Investigations are ongoing to determine whether lipid binding is required
for colocalization. However, AFAP-110 also has the capacity to bind the p85
regulatory subunit of PI3-kinase (Qian, Walker, Hanson and Flynn, unpublished
data). Thus, it is also possible that a protein chaperone could foster
colocalization between AFAP-110 and cSrc in response to PKC or PI3-kinase
activation.
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In summary, we predict that AFAP-110 is capable of integrating signals
between PKC, PI3-kinase and cSrc. These data also have implications for signal
transduction and possibly cancer. Given that PKCα, PI3-kinase and cSrc
expression levels and activation states are increased in a variety of human
cancers that are also invasive, it may be possible that AFAP-110 expression
levels in these same cancers could facilitate the relay of signals that direct
activation of cSrc and acquisition of the invasive phenotype.
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Figures

Figure 1: PI3-kinase is required for PMA-induced podosome formation.
SYF/cSrc and double knockout cells were either untreated or treated with 100nM
PMA for 30 minutes, pre-treated for six hours with 6µM bisindolylmaleimide or
10µM LY294002 prior to PMA treatment. Cells were fixed and stained with anticortactin mAb (1:250) and TRITC-phalloidin (1:500) as described in the methods
section. Secondary antibodies used were Alexa 647 anti-mouse (1:500) for anticortactin. Merged images were generated to determine colocalization between
actin and cortactin.
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Figure 2: PI3-kinase activity results in upregulation of cSrc activation.
SYF/cSrc cells transiently expressing pSG5-p85α or pSG5-K227E were cSrc
activation and actin filament integrity examined. A) Cells expressing either pSG5p85α or pSG5-K227E were fixed and stain with anti-p85α or p110α mAb and
anti-phospho-Src pAb (1:250), and TRITC-phalloidin. Secondary antibodies used
Alexa 488 anti-mouse for anti-p85α or p110α mAb and Alexa 647 anti-rabbit for
anti-phospho-Src. B) Cells expressing either pSG5-p85α or pSG5-K227E were
fixed and stain with anti-p85α or p110α mAb and anti-cortactin pAb (1:250), and
TRITC-phalloidin. Secondary antibodies used Alexa 488 anti-mouse for antip85α or p110α mAb and Alexa 647 anti-rabbit for anti-cortactin. Merged images
were generated to determine colocalization between actin and cortactin.
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Abstract
Tumor cell migration is a regulated by dynamic changes in the actin
cytoskeleton and rapid breakdown and formation of focal contacts. Tumor cells
that exhibit an elevation in the ability to migrate also display a higher rate of
invasion and metastatic potential. We have previously shown that AFAP-110
serves to link the PKC signaling pathway with both cSrc and PI3-kinase
pathways. In addition, activation of PKC leads to activation of both PI3-kinase
and cSrc resulting in a marked change in actin filament integrity. In this study we
wanted to examine the role this proposed pathway in migration of ovarian cancer
cells. In this report we demonstrated that stable expression of AFAP-110 in
CaOV3 cancer cells resulted in an increase in migration. In addition, inhibition of
PI3-kinase activity by LY294002 markedly decreased the ability of these cells to
migrate. Site-directed mutation of the conserved tryptophan within the PH1
domain abrogated this increase in migration similar to that observed when PI3kinase activity was inhibited. Indicating that the possible association of AFAP-110
with PI3-kinase generated lipid products may regulate the ability of AFAP-110 to
promote invasion of ovarian cancer cells. Collectively, this study demonstrated
that PI3-kinase plays a role in regulating AFAP-110 mediated migration of
ovarian cancer cells.

160

Introduction
Cell migration is required during development in which different cell types
work together to regulate the formation and growth of tissues. In response to its
environment, cells respond to signals derived from ECM components, growth
factors and chemokines by extending membrane sheets (lamellipodia) or cellular
protrusions (filopodia) at the leading edge (34). These structures are composed
of highly organized actin filaments that generate a force that allows the cell to
migrate. At the same time, actin networks retract at the lagging edge of the cell,
resulting in a forward propulsion of the cell body (34). Alternatively, actin
filaments can be assembled into bundles (stress fibers) anchored to focal
contacts on the periphery of the cell (26; 34). A balance between a stress fiberrich and a lamellipodia-rich phenotypes is required for cell motility. The alteration
between these phenotypes is achieved through actin filament reorganization,
which is regulated by the activity several signaling proteins, including cSrc, PI3kinase, and PKC. During tumor progression, these pathways function abnormally
and can promote the formation of cancer and increase in metastatic potential.
Previous work done by our laboratory has shown that AFAP-110 both
multimerize and directly bind to and cross-links actin filaments (22). Further,
Qian et al. demonstrated that AFAP-110 binds directly to actin filaments via a
carboxy terminal actin binding domain (24). The actin binding domain is both
necessary and sufficient for AFAP-110 to bind the actin cytoskeleton. Previous
work by others demonstrated that multimeric actin filament binding proteins are
able to cross-link actin filaments; however, smaller multimers cross-link actin
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filaments more efficiently because they form more ordered arrays. In quiescent
cells, AFAP-110 is found in self-associated complexes of trimers, tetramers, and
larger multimers (23). Expression of AFAP-110∆Lzip in cells resulted in a cellular
phenotype similar to Src transformed cells. Actin stress fibers were lost, and
instead actin filaments were repositioned into podosomes and motility structures
(23).
The role of PI3-kinase activity in the alteration of the actin cytoskeleton
has been linked to those changes elicited by EGF and other growth factors. Work
by Hill et al. demonstrated that PI3-kinase is required for EGF-induced
lamellipodia formation and extension in MTLn3 adenocarcinoma cells. The data
presented by these authors indicate that the proline-rich and BCR domains of
p85 are required for EGF-stimulated lamellipodia extension and believed to
couple the PI3-kinase to the actin cytoskeleton. Until recently, the role of PI3kinase on the actin cytoskeleton was thought to be associated with its function on
GEF and GAP in small GTPase and Arf activity. The domain structure of these
exchange factors and activation proteins contain a PH domain, indicating that
PI3-kinase may function upstream of these proteins. These proteins in turn
activate PI3-kinase resulting in a positive feedback loop (27; 32; 38).
Numerous extracellular signals can promote the activation of PKCα
(39)(28). The activation of PKCα results in the stimulation of several
downstream effector proteins involved in gene transcription regulation, cell cycle
progression, and alteration of the actin cytoskeleton. Upon PKC activation, there
is a breakdown in actin stress fibers that is concomitant with the formation of
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motility structures, such as lamellipodia and filopodia (6; 14). PKC appears to
affect these changes through the phosphorylation of several actin binding
proteins, including VASP, Facin, Tau, LSP1, MARCKS, and AFAP-110 (7; 10;
11; 21; 35). PKC-mediated phosphorylation of these proteins correlates with
their decreased ability to cross-link actin filaments. Similarly, Src-mediated
tyrosine phosphorylation of cortactin causes a decrease in the ability of this
protein to cross-link actin filaments. Indicating, that each of these signaling
proteins function in regulating migration mainly through the ability of regulate
actin filament cross-linking proteins.
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Materials and Methods
Reagents: Dulbecco’s modified Eagle’s medium (DMEM), Rhodamine (TRITC)phalloidin, beta actin (β-actin), L-α-Lysophosphatidic acid (L7260), and bovine
serum albumin (BSA) were purchased from Sigma (St. Louis, MO). Protein A/G
PLUS agarose beads and polyclonal cSrc antibody were purchased from Santa
Cruz biotechnology (Santa Cruz, CA). Fugene™ transfection reagent was
purchased for Roche. LipofectAMINE™ reagent was purchased from Invitrogen
(Carlsbad, CA). Phorbol-12-myristate-13-acetate (PMA), LY294002, wortmannin
and bisindolylmaleimide [I] (Bis) were obtained from Calbiochem. Monoclonal
p85α antibody, monoclonal PKCα antibody antibodies were obtained from BD
Transduction Laboratories (San Diego, CA). The monoclonal and polyclonal
AFAP-110 antibodies (4C3 and F1) were generated and characterized as
previously described (25). Monoclonal avian cSrc antibody (EC10) was obtained
from Upstate (Charlottesville, VA). Phospho-Src family (Tyr416) antibody was
purchased from Cell Signaling (Beverly, MA). Horseradish peroxidaseconjugated anti-rabbit and anti-mouse IgG secondary antibodies, and γ32P-ATP
were obtained from Amersham Biosciences (Piscataway, NJ).
Phosphatidylinositol (PI) used in the PI3K kinase assay was purchased from
Matreya LLC (Pleasant Gap, PA). QuikChange® II XL site-directed mutagenesis
kit was obtained from Stratagene, while the AFAP-110W169A primers were
purchased from IDT. All Alexa Fluor antibodies used in the paper were
purchased from Molecular Probes (Invitrogen). Chemiluminescence reagent was
purchased from Pierce Biochemical (Rockford, IL). All chemical used throughout
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this manuscript, except where otherwise stated, were purchased from J.T. Baker
(VWR-West Chester, PA).

Cell Lines and Culture: Human ovarian carcinoma cells, CaOV3 (ATCC), cells
were used throughout this study. The above cell lines were grown at 37°C with
5% CO2 in DMEM supplemented with 10% (v/v) fetal calf serum, 1% (v/v) 200
mM L-glutamine and 1% (v/v) penicillin/streptomycin.

Constructs: The pEGFP-c3 (green fluorescence protein) expression system
from Clontech (Mountain View, CA) was used to express GFP-tagged full-length
and mutant forms of AFAP-110. AFAP-110 was cloned into this vector as
previously described (24). Avian cSrc was subcloned from Rous Sarcoma Virus
(RSV) into pCMV-1 as previously described (9). GFP-tagged AFAP-110W169A was
developed by mutating the tryptophan169 residue to an alanine in full-length GFPAFAP-110 using the QuikChange® II XL site-directed mutagenesis kit as per
manufacturer’s protocol. These clones were screened using Ava II restriction
enzyme from Roche.

Stable clone selection: Stable selection of CaOV3 cells expressing the GFPtagged full-length and W169A mutant form of AFAP-110 in the presence of
450µg/ml neomycin (G418). CaOV3 cells were transfected using Fugene6
(Roche) per manufacturer instructions. Briefly, cells were seeded into 60mm
plates and transfected with 15µg DNA at 50% confluency and incubated

165

overnight. Sixteen hours post-transfection the media was changed and replaced
with culture media containing 450µg/ml neomycin (G418). Colonies were
harvested and screened over a three week period. Clones were selected for
expression levels similar to the SYF/cSrc control cell line.

Immunofluorescence and Transfection: Parental and stable CaOV3 cells were
cultured in standard culture media. Transient transfections of cells for
immunofluorescence were carried out using LipofectAMINE™ Reagent
(Invitrogen) as per manufacturer’s protocol. Briefly, approximately 5.0-8.0 x 104
cells per well were transfected at 50-70% confluent on coverslips with 2-4 µg of
plasmid DNA and incubated for 3-4 hours. Thirty-six hours after transfection,
cells were serum starved for 12 hours, treated, and subsequently fixed and
permeablized as previously described (23). Cells were treated with a PKC
activator, 100 nM PMA for 5-30 minutes or in combination with the following
pretreatments; a PKC inhibitor, 6 µM bisindolylmaleimide [I] for six hours; or PI3K
inhibitor, 10-20 µM LY294002 for six hours or 50nM Wortmannin for 30 minutes,
or 30µM LPA for 3 hours. For actin labeling, a 1:500 dilution of TRITC-phalloidin
was used as labeled in the figures. Primary antibody concentrations used were
diluted in 5% Bovine Serum Albumin (BSA) dissolved in 1X phosphate-buffered
saline (PBS): EC10 mAb - 1:500; Phospho-Src Family (Y416) pAb - 1:250; AntiPI-3,4,5-P3 mAb - 1:100; Anti-AFAP-110 (F1) pAb - 1:1000; Anti-cSrc pAb 1:500. All fluorescent secondary and phalloidin antibodies were diluted 1:200 in
5% BSA, and are labeled according to figure legends. Cells were washed and
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mounted on slides with Fluoromount-G (Fisher). A Zeiss LSM 510 confocal
microscope was used to scan images of about 1 µm in thickness. To prevent
cross-contamination between the different fluorochromes, each channel was
imaged sequentially using the multitrack recording module before merging the
images. For all figures, representative cells are shown (>100 cells examined per
image shown).

Immunoblot Assay: All cells were cultured to 70-80% confluence, serum-starved
for 16 hours, and treated as described above. The cells were lysed and western
analysis performed as previously described (8). Membranes were probed using
the following antibodies diluted in 1X Tris-buffered saline plus 0.1% Tween-20
(TBS-T) containing 5% nonfat milk, except were indicated: 1:10000 AFAP-110
(F1 and 4C3), 1:1000 Phospho-Src family Tyrosine 416 (Cell Signal) in 5% BSA,
1:500 cSrc (clone N-16), 1:1000 p85α, 1:1000 PKCα and 1:5000 β-actin in 1%
BSA.

Scratch Assay: Parental CaOV3 and AFAP-110 stable CaOV3 clone were
culture in glass bottom 35mm plates under standard conditions and a method as
previously described (12). A scratch was made using a 200µl pipet tip in the
confluent monolayer and a gentle wash with 1XPBS to remove dislodged cells.
Serum-free CO2 retaining culture media was added and wound closure was
imaged over 6 hours. Images were gathered every 5 minutes for the 6 hour
incubation period. Wound widths at time 0 and at end were measured using the
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Zeiss software. Post-wounding cells were either left untreated or treated with
100µM PMA or 20µM LY294002. Average distances were analyzed in Excel and
a one-way ANOVA (p<0.05) performed to determine statistical significances.
Each experiment was performed a minimum of three times.

Transwell Assay: CaOV3 and stable AFAP-110 CaOV3 clones were serumstarved and a transwell assay performed as previously described (12). Briefly,
transwell membranes (8.0µm diameter) were coated overnight with 10µg/µl
collagen type I. Cells were serum-starved for 16 hours and 2x105 cells in serumfree media were seeded in the washed upper chamber transwell (Corning). The
lower chambers were also filled with serum-free media. Cells were either left
untreated, treated with 100nM PMA, 10µM LY294002, 6µM bisindolylmaleimide
[I], or 100nM PMA in conjunction with 10µM LY294002 or 6µM
bisindolylmaleimide [I]. PMA was used as a chemoattractant and diluted in the
media of the lower chamber. The assay was incubated for 6-16 hours at 37°C,
fixed, upper membrane cells removed with a cotton swab, and stained with 0.1%
crystal violet. Inserts were washed several times in water, dried and destained in
10% acetic acid and OD600 measured. Absorbance were analyzed in Microsoft
Excel and a one-way ANOVA (p<0.05) performed to determine statistical
significances. Each experiment was performed in triplicate and repeated three
times.
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Results
PI3-Kinase inhibition blocks PKCα-induced activation of cSrc in ovarian cancer
cells. Our laboratory has previously demonstrated that PKCα activation can
direct the activation of cSrc through its interaction and phosphorylation of an
actin cross-linking protein (AFAP-110) (7; 22). Further, we have shown that PI3kinase is required for PMA-directed activation of cSrc (33). Several studies have
shown that ovarian cancers exhibit an increase in both cSrc and PI3-kinase
activation. Further, these kinases and in some cases PKC have been shown to
correlate with an increase in chemoresistance and invasive potential of ovarian
carcinoma. Therefore, we wanted to determine if our proposed pathway functions
in promoting an increase in migration of ovarian cancer cells. These cells are
less metastatic and are sensitive to chemotherapeutic drugs, such as cisplatin.
Further, we determined that PI3-kinase is required for PKCα-induced cSrc
activation in mouse embryo fibroblast (33). To determine the role of AFAP-110 in
PMA-induced PI3-kinase activation, ovarian cancer cell lines were analyzed.
Several ovarian cancer cell lines were evaluated for expression of AFAP-110
(Figure 1A). CaOV3 cells were utilized for this manuscript because previous work
done by our laboratory demonstrated that these cells do not express detectable
levels of AFAP-110 and express low levels of cSrc (7); as confirmed in Figure
1A. Studies have shown that numerous ovarian and breast cancer cell lines
express multiple copies of the PIK3CA gene which encodes the p110α catalytic
subunit of PI3-kinase (29). Western blot analyses indicate that CaOV3 cells
express slightly higher levels p85α as compared to the SYF mouse embryo

169

fibroblast. CaOV3 cells were transiently co-transfected with GFP-tagged wildtype AFAP-110 and CMV-cSrc. Cells treated with PMA resulted in a marked
disruption in actin filament integrity, activation of cSrc and AFAP-110 colocalizes
with cSrc (Figure 1B panels m-p). As previously demonstrated cells that lack
AFAP-110, fail to exhibit an increase in cSrc activation or disruption of the actin
filament integrity following PMA treatment (Figure 1B panels e-h). These data
indicate that AFAP-110 is required for PMA-induced cSrc activation and actin
filament disruption in ovarian cancer cells.

AFAP-110 is required for PMA-induced PI3-Kinase activation. PH domains have
been shown to bind both lipid and proteins. Based on this, the PH domains were
evaluated for their ability to bind lipid products, and the data indicate that the PH1
domain of AFAP-110 is capable of a physical interaction with several lipid
products, including those generated by PI3-kinase. The amino terminal PH
domain of AFAP-110 contains the consensus sequence of known lipid binding
proteins, such as Akt ((13); http://scansite.mit.edu). We utilized site-directed
mutagensis mutate the conserved tyrptophan to an alanine (W169A) at position
169. We hypothesized that mutation of this residue will block the proposed ability
of this domain to bind lipid products. Further, we developed CaOV3 cells that
stably express wild-type GFP-tagged AFAP-110 and PH1 point mutant which we
predict fails to bind lipid products, including those generated by PI3-kinase. To
confirm expression, western blot analysis was performed for AFAP-110, which
demonstrated the expression of GFP-tagged AFAP-110, AFAP-11071A or AFAP-
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110W169A (Figure 2A). As previously demonstrated, Immunofluorescence studies
show that both wild-type (Figure 2B panels c-d) and the PH1 point mutant (Figure
2B panels e-f) forms of AFAP-110 localize with actin filament stress fibers.
To determine if PKC activation would promote PI3-kinase activity in
ovarian cancer cells a PI3-kinase kinase assay was performed. CaOV3 were
treated with serum (positive control) and 100nM PMA for 5 or 15minutes. PMA
treatment resulted in an slight increase in PIP3 production as early as five
minutes in cells expressing wild-type AFAP-110 (Figure 3A). However, these
cells do have a high baseline of PI3-kinase. These data indicate that PMA
treatment results in an increase in PI3-kinase activity in ovarian cancer cells and
this activation requires AFAP-110. To verify the results observed in vitro, cells
were transiently transfects with cSrc alone or both cSrc and GFP-AFAP-110 and
then left untreated or treated with PMA for 5 minutes. Our laboratory has shown
that PMA treatment will lead to PI3-kinase activation within 5 minutes in a
manner independent of cSrc activity (33). To determine the requirement of
AFAP-110 in PMA-induced PI3-kinase activation and subsequent PIP3
production, CaOV3 cells expressing CMV-cSrc only failed to exhibit an increase
in PIP3 levels in response to PMA at either 5 minutes (Figure 3B panels e-h) or
15 minutes (data not shown) post-treatment, resembling those observed in the
untreated control (Figure 3B panels a-d). To verify the necessity for AFAP-110 in
PI3-kinase activation, CaOV3 cells were transiently co-transfected with GFPtagged wild-type AFAP-110 and CMV-cSrc. Cells expressing both AFAP-110 and
cSrc displayed an increase in cellular PIP3 levels following 5 minutes of PMA
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treatment (Figure 3B panels m-p) but these levels returned to near baseline by
15 minutes (data not shown). These data indicate that AFAP-110 is required for
PMA-induced PI3-kinase activity in our system. Collectively, these data indicate
that PMA treatment resulted in an increase in PIP3 production in an AFAP-110
dependent manner.
AFAP-110 and PI3-kinase are required for migration. Several studies have
shown that cSrc is required for the ability of cells to migrate into a wound of a
scratch assay (16). We have previously shown that expression of induction of the
cSrc binding mutant of AFAP-110 blocked migration of mouse embryo fibroblast.
Further, treatment of cells with LY294002 or cells that lack the p85 regulatory
subunit of PI3-kinase showed a marked reduction in the ability to migrate into a
wound (33). Therefore, we wanted to the significance of this pathway. We asked
the question; is PI3-kinase required for migration in ovarian cancer cells.
Two methods were used to determine migration both a scratch assay and
a transwell assay to address the requirements of cSrc activation in these cells. A
scratch assay was performed and the distance migrated over 6 hours measured
(Figure 4A). The average migration was graphed and a one-way ANOVA
(p<0.05) performed to determine significance. Cell that express wild-type AFAP110 had the highest rate of migration and this increase was impeded with
inhibition of PI3-kinase activity by LY294002. However, expression of the point
mutant displayed a reduced ability to migrate similar to parental control cells.
Interestingly, not reduction in migration was noted following treatment with the
PI3-kinase inhibitor LY294002 as compared to controls. These data indicate that
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AFAP-110 may function in regulating the ability of ovarian cancer cells to migrate
in a manner dependent on PI3-kinase activity. In addition, we wanted to evaluate
the ability of these cells to migrate through a membrane (transwell assay) (Figure
4B). Similar to data observed in the scratch assay, re-expression of wild-type
AFAP-110 promoted an increase in migration and this was markedly reduced
when cells were treated with LY294002. Interestingly, cells expressing the
mutant form of AFAP-110 exhibited similar migration to controls and LY294002
had not effect on these cells.
Therefore, we wanted to determine the possible mechanism by which
AFAP-110 is promoting cell migration. Previous studies by our laboratory have
shown that AFAP-110 mediated disruption of actin filament stress fibers was
dependent on the inactivation of RhoA by cSrc (3). Several studies have also
indicated that the treatment of cells with LPA results in the activation of RhoA
and subsequent formation of stress fibers (5). Further, AFAP-110 is an actin
filament cross-linking protein. Thus, we wanted to determine if there was a
significant difference of actin cross-linking function in cells that expressed wildtype AFAP-110 in response to LPA treatment. Treatment of cells expressing
either wild-type (Figure 5 panels g and h) or the mutant form (Figure 5 panels k
and l) of AFAP-110 exhibited an increase in stress fiber formation as compared
to controls. These data indicate that AFAP-110 is required for the formation of
stress fibers in response to LPA treatment, but this is independent of its ability to
bind phospholipid products. Collectively, these data indicate that AFAP-110
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promotes an increase motility of ovarian cancer cells and this is dependent the
integrity of the phospholipid binding site, as well as PI3-kinase activity.
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Discussion
There is significant evidence to indicate the existence of cross talk
between PKCα, cSrc and phosphatidylinositol-3-kinase (PI3-kinase). Activation
of each of these kinases results in substantial changes in actin filament integrity
and cell morphology concomitant with increased cell motility and invasive
potential (6; 15; 31). Extensive studies by other laboratories have shown that
many cancers, including ovarian, exhibit higher than normal levels of cSrc,
PKCα, and PI3-kinase (17; 30). Amplification and mutations of the catalytic
subunit of PI3-kinase has been identified in 40% of ovarian carcinomas which
results in an increase in protein expression and function (20; 29). This increase in
PI3-kinase correlates with an increase in ovarian cancer progression (37).
Further, previous studies by our laboratory demonstrated that AFAP-110 is able
to link the PI3-kinase to the PKC and cSrc signaling pathways. In mouse embryo
fibroblast, activation of PKCα by PMA treatment results in the activation of PI3kinase, which is required for the ability of AFAP-110 to colocalize with and
activate cSrc (33). Therefore, we hypothesized that PI3-kinase activity was also
required for this pathway in ovarian cancer cells which would result in an
increase in motility of these cells.
Pleckstrin homology domains are self-folding, modular domains that
interact with a variety of protein and lipid binding partners, including PKC
isoforms, small G-proteins and lipids; (1; 2; 18; 19; 36). Of the latter, many PH
domains have been shown to bind phospholipids that are generated upon
activation of PI3-kinase (e.g., PIP3). PH domains that interact with lipids have a
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binding groove that contains positively charged amino acids in the base of the
groove. In theory, lipid binding would be coordinated by interactions between the
negatively charged phospho-head group of the lipid with positive charges in the
base of the groove, and could be further stabilized through hydrophobic
interactions between the wall of the groove and the hydrophobic tail(s) of the
phospholipid. The PH1 domain of AFAP-110 is most homologous with the PH
domain found in Bruton’s Tyrosine Kinase (BTK), both of which contain positively
charged amino acids positioned to coordinate interactions with negatively
charged, phospholipid head groups (4). PH domains have been shown to bind
both lipid and proteins. The amino terminal PH domain of AFAP-110 contains the
consensus sequence of known lipid binding proteins, such as Akt ((13);
http://scansite.mit.edu). The data indicate that point mutation of the PH1 domain
abrogates the ability of ovarian cancer cells to migrate as compared to those
expressing wild-type AFAP-110, further strengthen this link to PI3-kinase.
Collectively, these data indicate that when PMA directs activation of
PKCα, PI3-kinase is concomitantly activated, which is consistent with our data
that predict the ability of PMA to direct AFAP-110 to colocalize with and
subsequently activate cSrc is dependent upon the presence and catalytic activity
of PI3-kinase. Thus, we predicted that the PH1 domain of AFAP-110, which is
required for colocalization with cSrc, may have the capacity to bind to PI3-kinasegenerated phospholipid products such as PIP3 or other phospholipids that might
be generated as a result of PI3-kinase activation. This interaction might be
important for colocalization, much as PIP3 binding to the PH domain of Akt is
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important for colocalization at the cytoplasmic membrane with PDK-1. To
address the possibility that a phospholipid, such as a lipid second messenger
generated by PI3-kinase, could direct AFAP-110 to colocalize with cSrc, we
employed a tryptophan to alanine point mutant in the PH1 domain, as well as a
deletion mutant of PH1 domain, both of which are predicted to be unable to bind
phospholipids and both of which failed to colocalize with cSrc or activate cSrc in
response to PMA treatment. Thus, we hypothesize that PMA-directed activation
of PI3-kinase results in the generation of a lipid product that could bind to the
PH1 domain of AFAP-110, which would facilitate colocalization with cSrc.
Subsequently, AFAP-110 would engage the SH3 domain of cSrc and activate it.
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Figures
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Figure 1: AFAP-110 is required for PMA-induced activation of cSrc in
ovarian cancer cells. A) Endogenous levels of cSrc, AFAP-110, PKCα, and
p85α were determined in ovarian cancer cell lines, CaOV3 and SKOV3, and
compared to SYF and SYF/cSrc fibroblast cells. Cells were lysed with RIPA
buffer and a western blot performed. Membranes were probed with AFAP-110
pAb, F1 (1:10000), cSrc pAb (1:500), PKCα mAb (1:1000), and p85α mAb
(1:1000). Stripped membranes were reprobed with β-actin mAb (1:1000). B)
CaOV3 cells transiently expressing either a dual expression vector AFAP-110
and CMV-cSrc or CMV-cSrc only were fixed and stained with avian specific
AFAP-110 antibody, 4C3 (1:1000), phospho-Src-family (Tyr416) (1:250) and
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TRITC-phalloidin (1:500) as described in the methods section. Secondary
antibodies used were Alexa 546 anti-mouse for 4C3 and Alexa 647 anti-rabbit for
phospho-Src-family (Tyr416). A merged image was generated to determine
colocalization between AFAP-110 and actin. Untreated (panels a-d) or cells
expressing cSrc only (panels e-h) displayed no increase in colocalization or cSrc
activation. However, treatment of cells expressing AFAP-110 with 100nM PMA
for 15 minutes (panels m-p) induced an increase in cSrc phosphorylation and
colocalization between actin and AFAP-110.
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Figure 2: Stable expression of the PH1 phospholipid binding mutant of
AFAP-110 localizes to the actin cytoskeleton in ovarian cancer cells. A)
CaOV3 cells were transfected and selected to stability express GFP-AFAP-110
and a proposed phospholipid binding point mutant (W169A). Following selection
clones were lysed and screened for expression of GFP-AFAP-110, GFP-AFAP11071A or GFP-AFAP-110W169A using polyclonal AFAP-110 antibody (1:10000).
Stripped membranes were reprobed with β-actin mAb (1:1000). B) To determine
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and verify that the expressed AFAP-110 was localized with the actin
cytoskeleton. Cells were fixed and stain with TRITC-phalloidin (1:500). Images
were examined for colocalization between AFAP-110 and actin. Phospholipid
binding mutant (panel e-f) localized to actin filaments similar to wild-type AFAP110 (panel c-d).
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Figure 3: AFAP-110 is required for PMA-induce activation of PI3-Kinase in
ovarian cancer cells. A) A classical PI3-kinase kinase assay was performed on
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CaOV3 cells that express either GFP-AFAP-110 or GFP-AFAP-W169A mutant.
B) CaOV3 cells transiently expressing with cSrc alone or both GFP-tagged
AFAP-110 with cSrc. Cells were treated with 100nM PMA for 5 minutes. Fixed
cells were stained with avian specific cSrc antibody, EC10 (1:500) and a specific
PI-3,4,5-P3 antibody (1:100). Secondary antibodies used were Alexa IgM 647
anti-mouse (1:500) for PI-3,4,5-P3 and Alexa 546 anti-mouse IgG for EC10. PMA
treatment induced PIP3 production in cells that expressed AFAP-110 (panel m-p)
in contrast to cells expressing cSrc alone (panel e-h).
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Figure 4: Expression of the PH1 binding mutant blocks AFAP-110 induced
motility of ovarian cancer cells. A) Stable clones and parental cells were
seeded on 35mm glass bottom plates and a scratch assay performed, as
described in the methods section. Expression of wild-type AFAP-110 promoted
an increase in distance migrated and this was abrogated with LY294002
treatment. However, W169A cells failed to exhibit this increase in motility and
treatment with LY294002 had not effect. B) To confirm results observed in
scratch assay a transwell assay was performed, as described in methods
section. Similarly, expression of AFAP-110 promoted an increase in migration
which was blocked with inhibition of PI3-KINASE activity. Again, W169A
abrogated this increase in migration, but treatment with LY294002 resulted in a
further reduction in migration.
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Figure 5: Re-expression of AFAP-110 promotes an increase in stress fiber
formation in response to LPA treatment. A) Stable clones and parental cells
were left untreated, treated with 10% serum or 30µM LPA. Cells were fixed and
stained with TRITC-phalloidin (1:500). Merged images were generated to show
colocalization between GFP-tagged AFAP-110 and actin. Expression of either
wild-type AFAP-110 (panels g-h) or W169A mutant (panels k-l) with LPA resulted
in a marked increase in actin stress fibers.
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CHAPTER 5: GENERAL DISCUSSION
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The work presented in this dissertation addresses the role of PI3-kinase in
relaying signals mediated by the adaptor protein AFAP-110, to the non-receptor
tyrosine kinase Src in response to signals from PKCα. Further, to address the
effects of this signaling in promoting cross-talk of three major signaling molecules
that regulate alterations in actin arrangement and cell migration in ovarian
cancer. While these proteins are important signaling kinases involved in a
plethora of cellular functions, and are were viewed as regulators of distinct
separate pathways. Several studies in the mid to late 1990’s highlighted the
ability of lipid kinases, such as PI3-kinase, to promote the formation of lipid
products that act as second messengers and the protein modules that bind these
lipids. The major upstream receptors and SFK that regulates the activation of
PI3-kinase has been the focus of many studies, but a mechanism of activation by
PKCα has remained elusive. The ability of PKCα and SFK member cSrc, to
interact has been well studied but this interaction is not direct. Our laboratory has
shown that the ability of PKCα to activate cSrc requires the adaptor protein
AFAP-110 (2; 9; 13). It is well established that activation of PI3-kinase, cSrc and
PKCα result in moderate changes in actin filament integrity, including the
formation of lamellipodia and podosomes (5; 8; 18). In this discussion, I will
focus on the ability of PI3-kinase activity to direct AFAP-110 to colocalize with
and activate cSrc resulting in the disruption of actin filaments. Further, I am going
to hypothesize the mechanism of how PI3-kinase promotes translocation of
AFAP-110 to inactive cSrc.
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Recent evidence indicates that PKCα can direct activation of cSrc, and
this activation requires the presence of AFAP-110 (9; 13). Upon activation, PKCα
will bind to and direct an increase in serine/threonine phosphorylation of AFAP110. This interaction affects a conformational change upon AFAP-110 that
relieves intramolecular interactions that autoinhibit AFAP-110 function, exposing
the PH1 domain. In response to these signals, AFAP-110 then colocalizes with
and directs activation of cSrc. The ability of AFAP-110 to colocalize and activate
cSrc in response to PKCα activation required the integrity of the PH1 domain (9;
13); (14). So the main question addressed in this dissertation, is what cellular
signals are required for AFAP-110 to colocalize with and activate cSrc?
To determine what cellular signals regulate the ability of PKCα that direct
cSrc activation via AFAP-110. We hypothesized that lipid signals, such as those
generated by PI3-kinase may function in localizing AFAP-110 with inactive cSrc
resulting activation. This was hypothesized by looking at the domain structure of
AFAP-110 and previous studies from our laboratory. AFAP-110 contains two
pleckstrin homology domains (PH1 and PH2). Pleckstrin homology (PH)
domains are protein modules indicated in regulating protein function and cellular
localization. These domains have been identified in over 100 proteins that are
involved in various cell signaling processes within the cell and found in many
vertebrates and only 10% of these proteins recognize phospholipids with high
affinity. The amino acid consensus sequence of known PH domains varies and
shows less than 10-20% homology. A highly conserved carboxy terminal
tryptophan residue usually downstream of 1-3 negatively charged amino acids
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and was found to be required for PH domains to bind phosphatidylinositols. All
known PH domains have a similar structure consisting of 7 anti-parallel βstrands, 7 linker regions and a carboxy terminal α-helix which contains the
conserved Trp residue (16; 19). The recognition and substrate specificity of PH
domains for lipid products has remained elusive. The ability of PH domains to
specifically bind PI3-kinase generated phospholipids, mainly PtdIns-3,4,5-P3 has
been shown to be dependent on several conserved amino acid residues. Work
done by Isakoff et al. and others indicate that six highly conserved amino acids in
the amino terminal portion of PH domains, and the PH1 domain of AFAP-110
contains this conserved sequence (6; 10). In addition, significant data exists to
link PH domain containing proteins to the actin cytoskeleton and binding of these
proteins to PI3-kinase generated phosphoinositides results in their activation and
subsequent actin filament rearrangement. Molecular modeling studies of these
domains indicate that the amino terminal PH1 domain contains conserved
residues predicted to bind to phospholipids or membranes, a feature common to
many PH domains (3; 11). Further, we have shown that the integrity of the PH1
domain is required for PKC directed colocalization and subsequent cSrc
activation (9; 13). Thus, we sought to determine if PI3-kinase activity was
required for colocalization between AFAP-110 and cSrc, and subsequent
activation of cSrc in response to PMA treatment or PKCα activation.
The focus of chapter 2 of this dissertation addressed the requirement of
PI3-kinase activity in PMA-induced cSrc activation as mediated by AFAP-110.
The data indicated that PI3K activity was required for PKCα-induced
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colocalization between AFAP-110 and cSrc and subsequent cSrc activation. In
addition, we were able to determine where colocalization between AFAP-110 and
cSrc occurred and if this required PI3-kinase activity. To determine where
colocalization between AFAP-110 and cSrc occurs in response to PKCα
activation, we utilized the temperature-sensitive form of viral-Src, LA29 (17; 20).
A single point mutation at amino acid 507 (alanine to proline residue) resulted in
this temperature-sensitive form of vSrc. LA29 exists in perinuclear regions of the
cell at non-permissive temperatures (39.5°C) and moves to the cell periphery at
permissive temperature (35°C) where it induces the characteristic cell shape
changes associated with transformation, including the formation of motility
structures and podosomes (12; 21). Here we showed that colocalization appears
to occur in the perinuclear region of the cell where cSrc resides in an inactive
state on endosomal vesicle. Following PMA treatment, AFAP-110 and LA29
colocalized at the perinuclear membrane at the non-permissive temperature.
Interestingly, inhibition of PI3-kinase activity blocked the ability of AFAP-110 and
LA29 to colocalize in response to PMA-treatment of activation of LA29. Thus,
AFAP-110 and cSrc likely colocalize on the membranes of perinuclear vesicles,
where inactive cSrc resides. These data indicate that AFAP-110 and cSrc
colocalize in the perinuclear region in response to PMA treatment and
localization was dependent on the activity of PI3-kinase activity.
Further, the data presented in this chapter indicated that PMA, and by
extension PKCα, has the ability to induce activation of PI3-kinase. The ability of
PKCα to direct PI3K activation has been controversial. Although there is much
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evidence to indicate that PI3-kinase can direct activation of PKCα via its ability to
direct activation of PDK-1 (7), it has not been clear if PKCα can in turn, act
upstream and direct PI3K activation. To determine if PMA could activate PI3kinase in our MEF system, we employed both the classic lipid kinase assay and
an anti-PtdIns-3,4,5-P3 antibodies, which demonstrated upregulation of PI3kinase activity. We observed that PtdIns-3,4,5-P3 production was consistently
higher at 5 minutes compared to 15 minutes post-treatment. Interestingly, we
noticed that serum appeared to induce production of PtdIns-3,4,5-P3 in both the
perinuclear region as well as along the cytoplasmic membrane, whereas PMA
only seemed to induce PtdIns-3,4,5-P3 production in the perinuclear region of the
cell. Thus, serum could activate PI3-kinase populations that exist at the cell
periphery and along internal membranes, while PMA may direct activation of a
more limited population of PI3-kinase that might localize to internal membranes.
As inactive cSrc is found primarily along perinuclear vesicles (15), the ability of
PtdIns-3,4,5-P3 to be generated in the perinuclear region of the cell may be
consistent with activation of cellular signals which promote cSrc activation. Our
data also indicate that in cells pretreated with the PI3-kinase inhibitors LY294002
and wortmannin, PMA was unable to induce colocalization between AFAP-110
and cSrc. In support of this, PMA failed to direct colocalization between AFAP110 and cSrc and cSrc activation in MEF cells that lack the p85α and β
regulatory subunits of PI3-kinase (4). In the absence of the p85 regulatory
subunit, the p110 catalytic subunit is destabilized and degraded in agreement
with our observations (23). These data indicate that the presence of PI3-kinase
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is required for PMA directed colocalization between AFAP-110 and cSrc, and
subsequent activation of cSrc by AFAP-110. Thus, we attempted to determine
the ability of AFAP-110, cSrc and PI3-kinase to modulate cell motility using a
scratch motility assay. The ability of MEF cells to effectively migration into a
wound was dependent on both the presence of cSrc and the ability of AFAP-110
to associate with cSrc. Further, cells that fail to express the p85 regulatory
subunit exhibited reduced migration similar to that observed when PI3-kinase
activity is inhibited. Collectively, these data indicate that when PMA directs
activation of PKCα, PI3-kinase is concomitantly activated and these signals work
cooperatively to direct AFAP-110 to move to and bind cSrc. Thus, these data
indicated that AFAP-110’s ability to associate with cSrc is dependent on the
activation of PI3-kinase; and that this can promote an increase in cell migration of
mouse embryo fibroblast.
Our laboratory has demonstrated that PMA treatment promoted the
formation of podosomes in a manner that was dependent on the presence of
both AFAP-110 and cSrc (9). Further, I have presented that PI3-kinase is
required for PMA-directed activation of cSrc, so that the following questions
remain: a) can PI3-kinase direct cSrc activation in MEF cells and b) is PI3-kinase
activity required for PMA-induced podosome formation? This will further establish
the significant of PI3-kinase in our pathway. Several studies have indicated that
both cSrc and PI3-kinase are required for podosome formation in MEF cells; this
was confirmed in chapter 3 of this dissertation. We wanted to address the role of
PI3-kinase in PMA-induced podosome formation. We were able to show that
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PI3-kinase does modulate cSrc activation and subsequent disruption in actin
using two different techniques. Firstly, overexpression of a dominant-positive
PI3K (K227E) in mouse embryo fibroblasts was sufficient to induce an increase
in cSrc activation similar to that observed following PMA-treatment and both
effects were blocked by pre-treatment with a PI3-kinase inhibitor. To verify the
effects of the inhibitor, we utilized p85 null mouse fibroblast cells, and showed
that PMA failed to induce disruption in the actin stress fibers or form podosome.
These data confirm that PI3-kinase plays an important role in relaying signals
from PKCα that directs activation of cSrc and podosome formation. Further,
these studies indicate that PI3-kinase activity is required for PMA-induced
podosome formation in mouse embryo fibroblast cells and that constitutively
active PI3-kinase can activate cSrc in our system. These data further support our
hypothesis that PI3-kinase is required for AFAP-110 mediated cSrc activation in
response to PKCα.
What is the significance of this pathway? Thus far I have demonstrated
that PI3-kinase activity is required for AFAP-110 to colocalize with and activate
cSrc in response to PKCα activation. To address the significance of this pathway
and to further determine the mechanism of PI3-kinase activation; we focused our
attention to ovarian cancer. Ovarian cancer is the eighth most common cancer
among women. The high mortality rate of this disease is associated with the
spread of these cells to distant locations resulting is dysfunction of that organ
system. The ability of these cells to migrate and invade is regulated by
rearrangement in the actin cytoskeleton. Tumor cell migration is a regulated by
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dynamic changes in the actin cytoskeleton and rapid breakdown and formation of
focal contacts. Further, elevations in kinase activities of cSrc and PI3-kinase
have been identified and are known to be associated with an increase in invasion
and metastatic potential. Thus we hypothesize that AFAP-110 may be
functioning in promoting cell migration of ovarian cancer cells. This was
addressed in chapter 4 of this dissertation where we wanted to further determine
the significance of this pathway in regulating motility and invasion potential of
ovarian cancer cells. We have previously shown that AFAP-110 serves to link the
PKC signaling pathway with both cSrc and PI3-kinase pathways. In addition,
activation of PKC leads to activation of both PI3-kinase and cSrc resulting in a
marked change in actin filament integrity. In this report we demonstrated that
stable expression of AFAP-110 in CaOV3 ovarian cancer cell resulted in an
increase in migration. Inhibition of PI3-kinase activity by LY294002 markedly
decreased the increase of these cells to migrate. Site-directed mutation of the
conserved tryptophan within the PH1 domain abrogated this increase in
migration similar to that observed when PI3-kinase activity was inhibited,
indicating that the possible association of AFAP-110 with PI3-kinase generated
lipid products may regulate the ability of AFAP-110 to promote invasion of
ovarian cancer cells. Collectively, this study demonstrated that PI3-kinase plays
a role in regulating AFAP-110 mediated migration of ovarian cancer cells.
In summary, data presented in this dissertation indicate that PI3-kinase is
required for the ability of AFAP-110 to colocalize with and activate cSrc in
response to PMA treatment. In addition, we demonstrated that this colocalization
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occurs in the perinuclear region where inactive cSrc is located. Upon activation,
cSrc translocated to the cell periphery resulting in subsequent disruption in the
actin cytoskeleton and podosome formation. In ovarian cancer cells, stable
expression of AFAP-110 promotes an increase in cell migration in a manner
dependent on PI3-kinase activity. These results raised the question, how does
PI3-kinase mediate AFAP-110 and cSrc colocalization in response to PMA
treatment? As previously demonstrated, activation of PKCα will induce the cSrc
binding partner, AFAP-110, to colocalize with and activate cSrc. The ability of
AFAP-110 to colocalize with cSrc is contingent upon the integrity of the amino
terminal PH1 domain, while the ability to activate cSrc is dependent upon the
integrity of its’ SH3 binding motif, which engages the cSrc SH3 domain. The
outcome of AFAP-110-directed cSrc activation is a change in actin filament
integrity and the formation of ventral membrane structures that resemble
podosomes or precursors to invadopodia. Pleckstrin homology domains are selffolding, modular domains that interact with a variety of protein and lipid binding
partners, including PKC isoforms, small G-proteins and lipids (1; 22). Of the
latter, many PH domains have been shown to bind phospholipids that are
generated upon activation of PI3-kinase (e.g., PIP3). PH domains that interact
with phospholipids have a binding groove that contains positively charged amino
acids in the base of the groove. In theory, phospholipid binding would be
coordinated by interactions between the negatively charged phospho-head group
of the phospholipid with positive charges in the base of the groove, and could be
further stabilized through hydrophobic interactions between the wall of the groove
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and the hydrophobic tail(s) of the lipid. As stated earlier, AFAP-110 consists of
two PH domains with the amino terminus PH1 domain being required for its’
association with PKC isoforms. Therefore, we predicted that the requirement of
the PH domain of AFAP-110 for cSrc colocalization and subsequent activation
might be dependent of a lipid signal. Furthermore, molecular modeling studies
indicate that the amino terminal PH1 domain contains conserved residues
predicted to bind to phospholipids or membranes, a feature common to many PH
domains (3; 11). Previous studies by our laboratory indicates that deletion of the
PH1 domain blocked the ability of PMA to induce colocalization between AFAP110 and cSrc and subsequent cSrc activation (9). The PH1 domain of AFAP-110
is most homologous with the PH domain found in Bruton’s Tyrosine Kinase
(BTK), both of which also contain positively charged amino acids positioned to
coordinate interactions with negatively charged, phospholipid head groups (3). In
agreement, The amino terminal PH domain of AFAP-110 contains the consensus
sequence of known lipid binding proteins, such as Akt ((10);
http://scansite.mit.edu) (Figure 1A-B). In addtition, this domain contains the
conserved tryprophan residue located at position 169, which I mutated to an
alanine. The significance of this mutation was discussed in chapter 4 of this
dissertation, however the effects of this mutation on lipid binding is currently
under investigation. Indeed, preliminary studies show that the PH1 domain can
bind to several phospholipids in vitro, including PIP3 (Figure 2). Thus, we
hypothesize that the ability of AFAP-110 to colocalize with cSrc (in response to
PKCα activation or PMA treatment) might be dependent upon interactions with
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either protein binding partners or lipid binding partners that facilitate translocation
to cSrc at perinuclear membranes.
Finally, the second SH3 binding motif of AFAP-110 contains the known
consensus sequence for the p85α regulatory subunit of PI3-kinase (Figure 3A).
Here preliminary studies indicate that AFAP-110 has the ability to bind the amino
terminal region p85α regulatory subunit. This association appears to be
dependent on the integrity of the second SH3 binding motif of AFAP-110 is both
chicken embryo fibroblasts and Cos-7 cells (Figure 3B-C). In addition, AFAP-110
can bind PI3-kinase lipid products, as well as other lipids, in vitro. These data
indicate that AFAP-110 can associate with both the regulatory subunit of PI3kinase and PI3-kinase-generated lipid products. Thus, AFAP-110 may be in a
position to link PI3-kinase to the actin cytoskeleton and may function to localize
PI3-kinase to specific subcellular compartments. Collectively, we propose that
phosphorylated AFAP-110 associates with the regulatory subunit of PI3-kinase
resulting in activation and targeting of this complex to the trans-golgi network.
Here, the PH1 domain of AFAP-110 binds PI3-kinase generated lipid products
within ciM6P containing vesicle where it interacts with and active cSrc. Upon
activation, cSrc translocated from this perinuclear region to the cell periphery and
subsequently leads to actin filament disruption and podosome formation (Figure
4).
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Figures

Figure 1: Evaluation of the PH1 domain protein sequence of AFAP-110. A)
The PH1 domain contains the required sequence identified to be required for the
ability of these domains to bind PI3-kinase generated lipid products. B)
Screening of the PH1 sequence against known PIP3 binding PH domains (using
scansite website) confirmed possible lipid association. The conserved tryptophan
(bold) was identified at position 169, which was mutated to an alanine.
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Figure 2: The PH1 domain of AFAP-110 has the ability to bind PI3-Kinase
generated lipid products. Various phospholipids were spotted onto PVDF
membrane and dried. Membranes were exposed with either GST-PH1 or GSTDAPP (positive control) and probed with anti-GST antibody. Membranes were
developed for signal.
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Figure 3: The second SH3 binding motif of AFAP-110 contains the
conserved recognition sequence for p85 regulatory subunit of PI3-Kinase.
A) Examination of the SH3 binding motif sequences of AFAP-110 demonstrates
that the SH3bmI (amino acids 62-71) and the SH3bmII (amino acids 76-85)
match that of cSrc and p85α, respectively. B) GST pulldown of the amino
terminal region of p85α (1-333) against chicken embryo fibroblast cells lysates
and probed for AFAP-110. AFAP-110 has the ability to bind the amino terminal
region of p85α, similar to the SH3 domain of cSrc (positive control). (Lanes: 1cell lysate; 2- GST-amino terminal region of p85α; 3- GST-SH3 domain of cSrc
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(positive control); 4- GST-SH3 domain of Yes (negative control)). C) GST
pulldown of the SH3 domain of p85α against Cos-7 cells lysates and probed for
AFAP-110. AFAP-110 has the ability to bind the SH3 domain of p85α, similar to
the SH3 domain of cSrc (positive control). (Lanes: 1-negative control; 2- GST
alone; 3- GST-SH3 domain of p85α; 4- GST-SH3 domain of cSrc (positive
control)).
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Figure 4: Schematic illustration of the proposed pathway model. Illustration
of the hypothesized pathway leading to cSrc activation and subsequent
podosome formation. A) PMA treatment binds to and activates PKCα; B) Active
PKCα then associates with and phosphorylates serine/threonine residues on
AFAP-110 resulting in a conformational change exposing the second SH3
binding motif. C) AFAP-110 associates with the p85 regulatory subunit of PI3kinase, which results in activation and targeting the complex/AFAP-110 to
perinuclear vesicles containing inactive cSrc. D) AFAP-110 binds with cSrc
resulting in it translocation to the cell periphery. This complex localizes to the
ventral membrane resulting in the formation of podosomes.
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Abstract

Ovarian cancer is one of the most common cancers among women. Recent
studies demonstrated that the gene encoding the p110α catalytic subunit of
phosphatidylinositol 3-kinase (PI3K) is frequently amplified in ovarian cancer
cells. PI3K is involved in multiple cellular functions, including proliferation,
differentiation, antiapoptosis, tumorigenesis, and angiogenesis. In this study, we
demonstrate that the inhibition of PI3K activity by LY-294002 inhibited ovarian
cancer cell proliferation and induced G1 cell cycle arrest. This effect was
accompanied by the decreased expression of G1-associated proteins, including
cyclin D1, cyclin-dependent kinase (CDK) 4, CDC25A, and retinoblastoma
phosphorylation at Ser780, 795, and Ser807/811. Expression of CDK6 and β-actin
was not affected by LY-294002. Expression of the cyclin kinase inhibitor p16INK4a
was induced by the PI3K inhibitor, whereas steady-state levels of CIP1/WAF1 were
decreased in the same experiment. The inhibition of PI3K activity also inhibited
the phosphorylation of AKT and p70S6K1, but not extracellular regulated kinase
1/2. The G1 cell cycle arrest induced by LY-294002 was restored by the
expression of active forms of AKT and p70S6K1 in the cells. Our study shows
that PI3K transmits a mitogenic signal through AKT and mammalian target of
rapamycin (mTOR) to p70S6K1. The mTOR inhibitor rapamycin had similar
inhibitory effects on G1 cell cycle progression and on the expression of cyclin D1,
CDK4, CDC25A, and retinoblastoma phosphorylation. These results indicate that
PI3K mediates G1 progression and cyclin expression through activation of an
AKT/mTOR/p70S6K1 signaling pathway in the ovarian cancer cells.
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Introduction
Ovarian cancer is the leading cause of death from gynecolog¬ical
malignancy and the fourth most common cause of cancer death among
American women (40). Recent observations indicate that the gene encoding the
p110α catalytic subunit of phosphatidylinositol 3-kinase (PI3K) is increased in
copy number in ~40% of primary ovarian cancer cells and several ovarian
epithelial carcinoma cell lines. The PI3K inhibitor LY-294002 has been shown to
inhibit growth of an ovarian cancer cell line in vitro (48). PI3K is a heterodimeric
enzyme composed of 110-kDa catalytic and 85-kDa regulatory subunits (3). PI3K
phosphorylates the D3 hydroxyl of phosphoinositi¬des and produces
phosphatidylinositol-3-phosphate. PI3K binds to and is activated by several
receptor and nonreceptor protein tyrosine kinases (5, 8, 18, 25). The oncogenic
form of PI3K, v-p3k, was first discovered in avian sarcoma virus 16 (6). The
expression of v-p3k can induce cellular transformation and induce tumors when
the transformed cells are injected into chickens (6). The best known downstream
target of PI3K is the serine-threonine kinase AKT, which transmits survival
signals from growth factors (5, 11, 23). The v-p3k transmits the angiogenic and
oncogenic signals through its downstream target, AKT (1, 20). In addition,
overexpression of active forms of PI3K and AKT can directly induce
angiogenesis in vivo (20).
PI3K is involved in cell proliferation and differentiation. The addition of the
PI3K inhibitor LY-294002 induced G1 cell cycle arrest and the expression of the
cyclin-dependent kinase (CDK) inhibitor p27 in melanoma and osteosarcoma cell
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lines (4, 52). We hypothesized that PI3K and AKT activities were also important
for the G1 cell cycle progression in ovarian cancer cells and for the expression of
proteins associated with the G1 progression.
A downstream target of AKT, the serine/threonine kinase p70S6K1, is a
highly conserved element in a wide array of cellular processes, including the
mitogenic response to growth factors (13, 30, 42, 47). The mammalian target of
rapamycin (mTOR)-p70S6K1 signaling was also constitutively activated in
several cancer cell lines, including small cell lung cancer cells and pancreatic
cancer cells (15, 46). Therefore, p70S6K1 may be an important signaling
molecule downstream of PI3K and AKT in the cell proliferation and cell cycle
progression.
Progression through the cell cycle is regulated by CDKs, whose activity is
inhibited by the CDK inhibitors. Cyclins, CDKs, and CDK inhibitors are frequently
deregulated in cancers (53). Activation of cyclin/CDK activities is required for cell
cycle progression and G1/S transition in response to growth factor stimulation.
The expression of cyclin D and CDK4/6 in G1 cell cycle acts as the primary
sensors of positive and negative environmental signals (31, 49, 50). The cyclin
D/CDK4/6 complexes induce the phosphorylation of retinoblastoma (Rb) protein
and the release of E2F, which trigger G1 cell cycle progression. Normally, Rb
binds to the members of the E2F family of transcription factors. In response to
the growth factors, the Rb protein is phosphorylated and dissociated from E2F,
which triggers G1 cell cycle progression (21). On the other hand, the
upregulation of CDK inhibitors, such as CIP1/WAF1 and p16INK4a, is frequently
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responsible for the inhibition of G1 cell cycle progression and for withdrawal from
the cell cycle (38, 41, 51). p16INK4a is capable of binding to CDK4, thereby
inhibiting the catalytic activity of the CDK4/ cyclin D1 enzymes. p21CIP1/WAF1 also
interferes with CDK/ cyclin complexes and thereby blocks DNA replication (55).
PI3K signaling has been observed to play an important role in human
ovarian cancer cells (17, 48). However, the role of PI3K in cell cycle progression
in ovarian cancer cells is not well studied. Here we investigated the effect of PI3K
inhibitor LY294002 on cell proliferation and cell cycle progression in ovarian
cancer cells. We examined the expression of proteins associated with the cell
cycle and analyzed the downstream molecules involved in the PI3K-mediated
cell cycle progression.

Material and Methods
Reagents and cell culture. The PI3K inhibitor, LY-294002, and mTOR inhibitor,
rapamycin, were purchased from Calbiochem (San Diego, CA). Propidium iodide
(PI) was from Molecular Probes (Eugene, OR). The antibodies against p16, p21,
CDC25A, CDK4, CDK6, cycline D1, and β-actin were from Santa Cruz
Biotechnology (Santa Cruz, CA), and the antibodies against Rb, phospho-Rb
(Ser780), phospho-Rb (Ser795), phospho-Rb (Ser807/811), phospho-AKT (Ser473),
phospho-p44/42 MAPK, p70S6K1, phospho-p70S6K1 (Thr389), and phosphop70S6K1 (Thr421/Ser424) were from Cell Signaling Technology (Beverly, MA). The
horseradish peroxidase (HRP)-conjugated anti-rabbit IgG and anti-mouse IgG
were from Perkin Elmer Life Sciences (Boston, MA). The human ovarian cancer
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cell lines OVCAR-3 and A2780/CP70 (American Type Culture Collection,
Manassas, VA) were maintained in RPMI 1640 (GIBCO BRL, Grand Island, NY),
supplemented with 10% FBS, 2 mM L-glutamine, and 0.2% insulin, 100 U/ml
penicillin, and 100 µg/ml streptomycin, and cultured at 37°Cin5%CO2 incubator.
Trypsin (0.25%)/EDTA solution was used to detach the cells from the culture
flask for passing the cells.

Cell proliferation assays. Cells were seeded in a 60-mm dish at a density of 1 x
105 cells/dish in RPMI 1640 media supplemented with 10% FBS for 24 h at
37°Cin5%CO2 incubator, followed by the treatment of the cells with or without
LY-294002 (10 and 20 µM). After 24, 48, and 72 h of the treatment, cells were
scraped and washed twice with PBS and centrifuged at 1,000 rpm for 5 min.
Cells were resuspended in 1 ml of Hanks’ balanced salt solution and counted.
The total cell number was normalized to that in the control at 24 h. All samples
were assayed in duplicate. The proliferation assays were performed three times.

Cell cycle analysis. Cells were seeded in a 100-mm dish at a density of 5 x 105
cells/dish in RPMI 1640 media supplemented with 10% FBS for 24h at37°C in
5%CO2 incubator. Cells were then treated with or without LY-294002 (10 and 20
µM) for 6–48 h. For cell cycle analysis, cells were scraped and washed twice with
PBS. Then cells were fixed with 70% ice-cold ethanol, followed by the incubation
of the freshly prepared nuclei staining buffer (0.1% Triton X-100 in PBS, 200
µg/ml RNase, and 20 g/ml PI) for 15 min at 37°C. Cell-cycle histograms were
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generated after analysis of PI-stained cells by fluorescence-activated cell sorting
(FACS) with a Becton Dickinson FACScan. For each sample, at least 1 x 104
events were recorded. Histograms generated by FACS were analyzed by ModFit
Cell Cycle Analysis software (Verity, Topsham, ME) to determine the percentage
of cells in each phase (G1, S, and G2/M).
Plasmid constructs. The active form of AKT, Myr-AKT, was inserted into pBSFI
adaptor vector and then inserted into pEGFP-N vector (Clontech, San Francisco,
CA) to make the fusion protein of Myr-AKT upstream of enhanced green
fluorescent protein. A constitutive active rapamycin-resistant p70S6K1 with the
mutation of F5A, T389E, S411D, S418D, T421E, and S424D was inserted into
pRK7 vector (kindly provided by Dr. John Blenis).

Immunoblotting analysis. The cells were plated in a 100-mm culture dish in RPMI
1640 media supplemented with 10% FBS for 24 h at 37°C, followed by serum
starvation for 20 h. Cells were then treated with or without LY-294002 (10 and 20
µM) for 12 and 24 h, respectively. Cells were lysed on ice for 30 min in RIPA
buffer [150 mM NaCl, 100 mM Tris (pH 8.0), 1% Triton X-100, 1% deoxycholic
acid, 0.1% SDS, 5 mM EDTA, and 10 mM NaF], supplemented with 1 mM
sodium vanadate, 2 mM leupeptin, 2 mM aprotinin, 1 mM phenylmethylsulfonyl
fluoride, 1 mM dithiothreitol, and 2 mM pepstatin A. After centrifugation at 14,000
rpm for 15 min, the supernatant was harvested as the total cellular protein extract
and stored at -70°C. The protein concentration was determined by using Bio-Rad
protein assay reagent (Richmond, CA). The total cellular protein extracts were
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separated by SDS-PAGE and transferred to nitrocellulose membrane in 20 mM
Tris - HCl (pH 8.0), containing 150 mM glycine and 20% (vol/vol) methanol.
Membranes were blocked with 5% nonfat dry milk in PBS containing 0.05%
Tween 20 and incubated with antibodies against p16, p21, CDK4, CDK6, cycline
D1, β-actin, Rb, phospho-Rb (Ser780), phospho-Rb (Ser795), phospho-Rb
(Ser807/811), phospho-AKT (Ser473), phospho-p44/42 MAPK, p70S6K1, phosphop70S6K1 (Thr389), and phospho-p70S6K1 (Thr421/Ser424). Blots were washed
three times in PBS buffer, followed by the incubation with the appropriate HRPlinked IgG. The specific proteins in the blots were visualized by using the
enhanced chemiluminescence reagent (NEN, Boston, MA).

Results
PI3K activity is required for the cell proliferation and cell cycle progression. To
elucidate whether PI3K affects the proliferation of ovarian cancer cells, we
selected human ovarian cancer OVCAR-3 cells, in which the p110α catalytic
subunit of PI3K is amplified in high copy number (48), and A2780/CP70 cells,
which contain a mutation in the p53 gene and an elevated level of PI3K activity.
Thus OVCAR-3 cells are suitable for the investigation of PI3K activation and its
downstream targets. A2780/ CP70 cells permit an analysis of PI3K and its
downstream molecules in cells in combination with p53 deficiency, a common
mutation in many human cancers. OVCAR-3 and A2780/CP70 cells were seeded
and cultured for 24 h, followed by incubation in the presence or absence of the
PI3K inhibitor LY-294002. Total cell numbers were counted 24, 48, and 72 h after
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the incubation. As shown in Fig. 1A, the number of both OVCAR-3 and A2780/
CP70 cells was greatly increased over the period of 72 h in culture in the
absence of LY-294002. The proliferation of the cells was slightly decreased by
LY-294002 24 h after the treatment. However, after 48 and 72 h of the treatment,
the proliferation of the cells was significantly inhibited by LY-294002 in a dosedepen-dent manner. These results indicate that PI3K may play a role in the
proliferation of the ovarian cancer cell lines OVCAR-3 and A2780/CP70.
To determine whether the inhibition of PI3K activity by LY-294002 affects cell
cycle progression, OVCAR-3 and A2780/CP70 cells were treated as described
above, and the cell cycle distribution was analyzed by flow cytometry. A typical
histogram is shown in Fig. 1B. The treatment of the OVCAR-3 cells with 10 and
20 µM of LY-294002 for 24 h increased the percentage of the cell population to
53 and 58%, respectively, at the G1 phase compared with the control of 42%
(Fig. 1B). The inhibition of PI3K activity decreased the percentage of OVCAR-3
cells at the S phase. Similarly, the inhibition of PI3K activity induced the G1
arrest and decreased the number of cells at the S phase in A2780/CP70 cells
(Fig. 1B). Moreover, the increased percentage of cells at G1 phase and the
decreased percentage of cells at S phase were observed when we repeated the
experiment three times with duplicate samples per experiment in both OVCAR-3
and A2780/CP70 cells (Fig. 1C). These data indicate that PI3K is required for the
cell cycle entry from the G1 to S phase, and the increases in the cell population
at the G1 phase due to the inhibition of PI3K activity may account for the
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decrease in the cell population at S phase in the presence of the PI3K inhibitor
LY-294002 (Fig. 1, B and C).

Inhibition of PI3K led to G1 arrest through p16INK4a/CDK4/ cyclin D1/Rb pathway.
Cell cycle progression through G1 is regulated principally by the sequential
activation of the cyclin D/CDK4/CDK6, which induces the phosphorylation of Rb
and the release of E2F. To explore the mechanism by which the inhibition of
PI3K activity induced the cell cycle arrest at the G1 phase in OVCAR-3 and
A2780/CP70 cells, the cells were cultured and treated, as described above. The
total cellular proteins were prepared and analyzed by immunoblot assays for the
expression of cyclin D1, CDK4, CDK6, Rb, and phospho-Rb. The expression
levels of cyclin D1, CDK4, CDC25A, Rb, and phospho-Rb (Ser780, Ser795, and
Ser807/811) were inhibited by the treatment of cells with LY-294002 in a dosedependent manner (Fig. 2A), whereas the levels of CDK6 and β-actin remained
relatively unchanged in either the presence or absence of the PI3K inhibitor (Fig.
2A). CDK inhibitors are important negative regulators of cell cycle progression.
After binding to cyclin/CDK complexes at the G1 phase of the cell cycle, these
inhibitors block the CDK activity, preventing the phosphorylation of members of
the Rb gene family and the transition from the G1 to S phase. To determine
which CDK inhibitor was involved in the inhibition of CDK/cyclin complexes, we
analyzed the expression of p16INK4a, p15, p27kip1, CIP1/WAF1 in these two types of
ovarian cancer cells. The treatment of cells with LY-294002 increased the
expression of p16INK4a and decreased the expression of p21CIP1/WAF1 in a dose-
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dependent manner (Fig. 2A). To determine whether serum affects the expression
of these proteins associated with 1 cell cycle progression, OVCAR-3 and
A2780/CP70 cells were cultured in the serum-free medium for 16 h, followed by
the addition of serum. As shown in Fig. 2B, the expression levels of cyclin D1,
CDK4, CDC25A, p21CIP1/WAF1, Rb, and phospho-Rb (Ser780, Ser795, and
Ser807/811) were induced by serum and inhibited by LY-294002 in a dosedependent manner (Fig. 2B). Levels of CDK6 and β-actin were not induced by
serum or inhibited by the PI3K inhibitor. Expression of was induced by the
addition of LY-294002 to the cultured medium (Fig. 2B). The levels of p15 and
p27kip1 were below the limits of detection (data not shown). Although the
expression of p21CIP1/WAF1 is important for the cell cycle arrest induced by DNAdamaging agents, p21CIP1/WAF1 expression has been recently demonstrated to be
induced by serum and several growth factors in other cell lines in which the
CIP1/WAF1

level is not relevant to cell cycle progression (14, 26, 43, 57). These

recent reports are consistent with our study showing the decreased expression of
p21CIPI/WAFI by the LY-294002 treatment. These data indicate that p21CIP1/WAF1
expression may not be relevant for the G1 arrest induced by the PI3K inhibitor
LY-294002 in the ovarian cancer cells. Because the expression of Rb protein is
known to inhibit the p16INK4a transcriptional activation and expression (27, 44),
the inhibition of Rb expression by LY-294002 may result in the induction of
p16INK4a protein levels, which are involved in the LY-294002-induced G1 arrest in
the cells (Figs. 1 and 2).
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Serum-induced phosphorylation of AKT but not extracellular regulated kinase 1/2
was inhibited by LY-294002 in the ovarian cancer cells. It is known that serum
induces the activation and phosphorylation of AKT and extracellular regulated
kinase (ERK) 1/2 through PI3K signaling (9, 24). To determine whether LY294002 affects the serum-induced activation and phosphorylation of AKT or
ERK1/2, the serum-starved ovarian cancer cells were treated by the addition of
serum in the presence or absence of LY-294002 (20 µM) for various exposure
times. The phosphorylation of AKT and ERK1/2 was detected by Western blot.
As shown in Fig. 3, A and B, a high level of AKT phosphorylation was induced by
serum in both ovarian cancer cell lines and was inhibited by the addition of LY294002. Total AKT protein levels were not affected by the treatment of serum
and LY-294002. Whereas the ERK1/2 phosphorylation was also increased by the
addition of serum, it was not decreased by the treatment of LY-294002. These
data indicated that the activation and phosphorylation of AKT, but not ERK, were
involved in G1 cell cycle progression in the ovarian cancer cells. To further
confirm that the serum-induced activation of AKT was inhibited by LY-294002
during the prolonged treatment, these ovarian cancer cells were treated by the
addition of serum without or with LY-294002 for 12 and 24 h. Similarly, AKT
phosphorylation was inhibited by the treatment of LY-294002 for 12 and 24 h
(Fig. 3, C and D).

Expression of an active form of AKT reversed cell cycle arrest at the G1 phase
induced by the PI3K inhibitor LY294002. Inhibition of PI3K activity by LY-294002
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induced G1 cell cycle arrest. To study whether this inhibition could be reversed
by expression of AKT, we made a fusion of green fluorescent protein (GFP) into
Myr-AKT (GFP-Myr-AKT) driven by the cytomegalovirus promoter, which is a
constitutively active form of AKT in the cells (data not shown). We transfected
GFP alone or GFP-Myr-AKT expression plasmid into OVCAR-3 cells. The cells
transfected by GFP alone were used as a control. The cells were cultured for 36
h after transfection, followed by treatment for 12 h in the absence or presence of
10 µM of LY294002. Cells expressing GFP proteins were separated from
untransfected cells by FACS. Compared with the untransfected control, the
expression of active forms of AKT substituted for PI3K in the cells and reversed
the inhibition of LY-294002 on cell cycle progression (Fig. 3E). This result further
confirmed that AKT is a downstream target of PI3K, which is required for the G1
cell cycle progression in the ovarian cancer cells.

LY-294002 inhibited phosphorylation of p70S6K1 in the ovarian cancer cells.
p70S6K1 is a downstream target of PI3K and AKT. The activation of p70S6K1
depends on the phosphorylation of several residues in the pseudosubstrate
region, such as Ser389 and Ser421/Thr424. To determine whether the
phosphorylation of p70S6K1 was involved in LY-294002-induced G1 cell cycle
arrest in the ovarian cancer cells, these cells were treated with serum in the
absence or presence of different doses of LY-294002 for 12 h, and the
phosphorylation of p70S6K1 at Ser389 and Ser421/Thr424 was detected by using
Western blot. As shown in Fig. 4A, LY-294002 completely inhibited serum-
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induced phosphorylation of p70S6K1 at Ser389 and at Ser421/Thr424, whereas it did
not affect the expression of p70S6K1 total protein. These results suggest that the
p70S6K1 activation was associated with the inhibition of PI3K activity and the G1
growth arrest in the cells.

p70S6K1 is a potential target of AKT that mediates cell cycle progression. To
study whether the overexpression of AKT affects the activation of p70S6KI in the
absence or presence of LY-294002, the OVCAR-3 cells were transfected with an
active form of AKT, Myr-AKT, to establish a stable cell line expressing Myr-AKT.
The cells were also transfected by the vector to establish a cell line expressing
the vector alone as a control. As shown in Fig. 4B, overexpression of AKT greatly
increased the p70S6K1 phosphorylation in the absence of LY-294002 and
restored the p70S6K1 phosphorylation in the presence of 10 µM of LY294002 to
the similar level of vector control without the inhibitor (Fig. 4B). This result is
consistent with that of the cell cycle progression observed in Fig. 3E. These data
indicate that p70S6K1 is potentially involved in PI3K-and AKT-mediated cell
cycle progression.
To test whether mTOR mediates p70S6K1 activity in ovarian cancer cell
cycle progression, the cells were treated by the mTOR inhibitor rapamycin, as
indicated, for 12 h (Fig. 4C). The p70S6K1 phosphorylation indicates the
activation of its protein. The p70S6K1 phosphorylation was induced by serum
and inhibited in the rapamycin-treated cells, whereas total p70S6K1 protein
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levels were not affected (Fig. 4C). This result indicates that the addition of
rapamycin is sufficient to inhibit p70S6K1 activity in the ovarian cancer cells.

Inhibition of the mTOR-p70S6K1 activity led to cell cycle arrest in the G1 phase
through p16INK4a/CDK4/cyclin D1/Rb pathway. To investigate whether the
inhibition of mTOR and p70S6K1 affects G1 cell cycle arrest, the ovarian cancer
cells were treated with the mTOR inhibitor rapamycin, and cell cycle progression
was analyzed. Rapamycin induced the G1 cell cycle arrest in both OVCAR-3 and
A2780/CP70 cells (data not shown). The total cellular proteins were prepared
and subjected to immunoblotting assay for cyclin D1, CDK4, CDK6, Rb, and
phospho-Rb at Ser780, Ser795, and Ser807/811. The levels of cyclin D1, CDK4, Rb,
and phospho-Rb (Ser780, Ser795, and Ser807/811) were increased by serum in both
cell lines (Fig. 5A). Treatment of cells with rapamycin resulted in a decrease in
expression of cyclin D1, CDK4, Rb, and phospho-Rb (Ser780, Ser795, and
Ser807/811) induced by serum, whereas the levels of CDK6 and β-actin remained
unchanged (Fig. 5A). The expression of p16INK4a and p21CIP1/WAF1 was also
analyzed in the ovarian cancer cells in a similar experimental condition. The
results indicate that the treatment of cells with rapamycin increased the
expression of p16INK4a in a dose-dependent manner, whereas the expression of
p21CIP1/WAF1 was decreased, suggesting that, rather than expression of
p21CIP1/WAF1, expression of p16INK4a may play an important role in G1 cell cycle
arrest. Similar expression levels of the cell cycle-associated proteins were
inhibited by treatment of cells with rapamycin in the normal cultured condition
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(Fig. 5B). These results are consistent with the data obtained above with the use
of the PI3K inhibitor and suggest that p70S6K1 was a downstream molecule of
PI3K and AKT for regulating G1 cell cycle arrest and the expression of p16INK4a/
CDK4/cyclin D1/Rb. The Rb protein negatively regulates the INK4a expression in
the cells (27, 44); thus the decrease of Rb expression by rapamycin would lead
to the induction of p16INK4a protein expression (Fig. 5). These results indicate that
p70S6K1 regulates G1 cell cycle progression through the Rb/p16INK4a/
CDK4/cyclin D1 pathway.

Expression of an active form of p70S6K1 reversed cell cycle arrest at the G1
phase induced by PI3K inhibitor LY-294002. To determine the role of p70S6K1 in
G1 progression, we cotransfected OVCAR-3 cells with a 1:5 ratio of GFP and the
constitutively active form of p70S6K1 (S6K1-F5AE389D3E) expression plasmids.
The cells transfected by GFP alone were used as a control. The cells were
cultured for 36 h after transfection, followed by incubation for 12 h in the absence
or presence of 10 µM of LY294002. Cells expressing GFP proteins were
separated from untransfected cells by FACS analysis. The expression of the
active form of p70S6K1 reversed LY-294002-induced cell cycle progression (Fig.
5C), indicating that p70S6K1 is an essential target of PI3K for cell cycle
progression in the cells.

Expression of an active form of p70S6K1 reversed rapam-ycin-induced G1 cell
cycle arrest. To determine whether the overexpression of rapamycin-resistant
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p70S6K1 construct can restore rapamycin-induced G1 cell cycle arrest, we
cotransfected OVCAR-3 cells with a 1:5 ratio of GFP and the constitutively active
form of p70S6K1 expression plasmids. The cells transfected by GFP alone were
used as the control. The cells were cultured for 36 h after transfection, followed
by incubation for 12 h in the absence or presence of 10 µM of rapamycin. Cells
expressing GFP proteins were selected by FACS analysis. The expression of the
active form of p70S6K1 reversed rapamycin-induced cell cycle arrest (Fig. 5D),
indicating that p70S6K1 is an essential target of rapamycin for inhibiting the cell
cycle progression.

Discussion
PI3K is involved in many cellular functions in response to growth factors. PI3K
was initially observed to be required for cellular transformation induced by
several viral oncoproteins such as v-Src and v-Abl (16, 28, 56). Recent studies
indicate that the gene encoding the p110α catalytic subunit of PI3K is increased
in copy number in primary ovarian cancer cells and several ovarian carcinoma
cell lines (48). PI3K and AKT signaling has been shown to play an important role
in DNA repair and apoptosis induced by chemotherapy agents, including cisplatin
and paclitaxel in human ovarian cancer cells (34). Coexpression of an active
form of Akt with Myc and Ras was demonstrated to be sufficient to induce
ovarian tumor formation in a mouse model by using an avian retroviral gene
delivery technique (37). An oncogenic form of PI3K, v-p3k was discovered
recently in avian sarcoma virus 16, and v-p3k is the viral homolog of a gene
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encoding for PI3K catalytic subunit (6), which is amplified in human ovarian
carcinomas (48). Therefore, further study of PI3K could provide a better
understanding of the molecular mechanism for ovarian carcinoma development.
In this study, we have shown that inhibition of PI3K activity using LY294002 decreased the cell proliferation and induced the G1 cell cycle arrest in
the ovarian cancer cells OVCAR-3 and A2780/CP70. The data are consistent
with previous studies, suggesting that PI3K was required for cell proliferation in
different cell types, such as neutrophils, endothelial cells, and breast cancer cells
(10, 22, 39). To understand the mechanism by which PI3K regulated the G1 cell
cycle progression, we studied the role of PI3K in the expression of known
regulators associated with the G1 cell cycle in these cells. During the G1-to-S cell
cycle progression in response to a mitogen, levels of D-type cyclins increase,
bind to, and activate CDK4 and CDK6 (32). Our studies indicated that inhibition
of PI3K by LY-294002 greatly decreased the expression of cyclin D1 and CDK4
and the phosphorylation of Rb at Ser780, Ser795, and Ser807/811, whereas CDK6
activity remained relatively unchanged. These data indicated that PI3K was
required for cyclin D1/CDK4 interactions, which induces the Rb phosphorylation,
E2F release, and the G1 cell cycle progression. These results are consistent with
recent studies in other cell lines, indicating that PI3K/AKT was required for the
induction of cyclin D1 expression (36) and expression of E2F (2).
The tumor suppressor genes p16INK4a and p53 have been shown to
regulate the G1 cell cycle progression through different mechanisms. The p53
regulates the cell cycle at the G1 checkpoint and is primarily stimulated by DNA
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damage (12). Activation of p53 leads to G1 arrest through the induction of
CIP1/WAF1

(58). p16INK4a is a member of the INK4 cell cycle proteins. It encodes a

protein that inhibits cyclin D kinases, CDK4, and CDK6 (32, 33). CDK4 and
CDK6 are required for the phosphorylation of Rb. In the present study, we found
that the treatment of cells with LY-294002 markedly induced p16INK4a expression
in a dose-dependent manner, but decreased p21CIP1/WAF1 expression, suggesting
that the LY-294002-induced G1 cell cycle arrest in ovarian cancer cells requires
increased p16INK4a expression, but not p21CIP1/WAF1 expression. The expression of
p21CIP1/WAF1 is known to be induced by p53-induced cell cycle arrest, associated
with the treatment of DNA-damaging agents. However, p21CIP1/WAF1 expression
was recently demonstrated to be induced by serum and several growth factors in
different cell lines and regulated independently of the p53 level in the cells and of
cell cycle progression (14, 26, 43, 57). These results and our study indicate that
neither p21CIP1/WAF1 nor p53 is involved in the G1 arrest induced by blocking PI3K
activity in the cells. Our results are consistent with previous reports that indicate
that overexpression of p16INK4a alone is more effective than p53 CIP1/WAF1 in the
inhibition of the cancer cell growth (35, 45). The Rb protein is known to inhibit the
transcriptional activation of p16INK4a expression in the cells, and the genetic
mutation of the pRb gene resulted in high levels of p16INK4a expression (27, 44).
Our data showed that the inhibition of PI3K and p70S6K1 activities in the cells
decreased the expression of Rb protein levels and induced the expression of
INK4a

expression (Figs. 2 and 5). These data are consistent with other recent

reports, suggesting the negative regulatory role of Rb on the p16INK4a expression.
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The above results indicated that PI3K regulated p70S6K1, which, in turn, mediates the 16INK4a/CDK4/cyclin D1/Rb pathway in G1 cell cycle progression in the
ovarian cancer cells.
The results obtained from the present study demonstrate that treatment of
cells with LY-294002 markedly inhibited AKT phosphorylation, whereas it has no
effect on the activation of ERK1/2, suggesting that the activation of AKT but not
ERK1/2 was involved in PI3K-dependent cell cycle regulation. A major
downstream target of AKT is mTOR, which regulates p70S6K1. p70S6K1 was
found to be constitutively phosphorylated in the ovarian cancer cells by the
addition of serum. The activation of p70S6K1 is accompanied by the
phosphorylation at multiple Ser/Thr residues, such as Ser389 and Ser421/Thr424.
The phosphorylation of p70S6K1 was markedly inhibited by treatment of cells
with the PI3K inhibitor LY-294002 and mTOR inhibitor rapamycin. PI3K inhibitor
LY-294002-in-duced G1 cell cycle arrest was restored by the forced expression
of active forms of AKT and p70S6K1 in the cells. These results suggest that
mTOR and p70S6K1 are downstream of PI3K and AKT in regulating G1 cell
cycle progression in the ovarian cancer cells. We predicted that the inhibition of
mTOR and p70S6K1 would have a similar effect on the inhibition of PI3K and
AKT in these ovarian cancer cells. This is further confirmed by our studies that
indicated treatment of the cells with rapamycin markedly induced p16INK4a
expression in a dose-dependent manner and inhibited p21CIP1/WAF1, cyclin D1,
CDK4, and the phosphorylation of Rb at Ser780, Ser795, and Ser807/811 (Fig. 5).
The level of CDK6 remained relatively unchanged in the presence of rapamycin.
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These results were similar to those obtained by treatment of cells with LY294002 (Figs. 1 and 2). To study the effect of rapamycin on p70S6K1, the
rapamycin-resistant p70S6K1 constructs were recently generated by several
groups, which demonstrated that expression of rapamycin-resistant p70S6K1
constructs restored rapamy-cin-induced G1 cell cycle arrest (7, 19, 29, 54). Our
result indicated that rapamycin-resistant p70S6K1 restored rapamycin-inhibited
cell cycle progression (Fig. 5D). Our data are consistent with these studies,
supporting a role of p70S6K1 in PI3K-mediated cell cycle progression. These
data suggest that p70S6K1 and p16INK4a/CDK4/cyclin D1/Rb pathways play an
important role in G1 cell cycle arrest induced by rapamycin in ovarian cancer
cells.
In summary, the present study demonstrates that the PI3K inhibitor LY294002 inhibited ovarian cancer cell proliferation by inducing G1 cell cycle arrest.
The inhibition of PI3K activity by LY-294002 inhibited the phosphorylation of AKT
and p70S6K1, but not ERK1/2. LY-294002 and mTOR inhibitor rapamycin have
similar inhibitory effects on the phosphorylation of p70S6K1 at Ser389 and
Ser421/Thr424, on the expression of CDK4 and cyclin D1, and on Rb
phosphorylation at 780, Ser795, and Ser807/811. Our results indicate that PI3K
signaling regulates G1 cell cycle progression through the increased expression of
cyclins and CDKs. The inhibition of PI3K activity is able to induce the expression
of p16INK4a, leading to inhibition of the expression of CDK4 and cyclin D1, and Rb
phosphorylation in the ovarian cancer cells. PI3K transmits the mitogenic signal
through AKT and mTOR to p70S6K1 (Fig. 6). These results suggest that the
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PI3K/AKT/ mTOR/p70S6K1 signaling pathway could serve as a novel target for
therapeutic intervention in the ovarian cancer.
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Figures

Figure. 1. Phosphatidylinositol 3-kinase (PI3K) is required for the proliferation and
G1 progression of ovarian cancer cells. A: OVCAR-3 and A2780/CP70 cells were
seeded in a 60-mm dish at a density of 1 x 105 cells/dish in RPMI 1640 media
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supplemented with 10% FBS for24hat37°C in 5% CO2 incubator. Cells were then
cultured in the absence or presence of PI3K inhibitor LY-294002 (10 and 20 µM) for
different times as indicated. Cells were harvested, stained with Trypan blue, and
counted by using a hemocytometer. The number of total cells was counted and
normalized to the number obtained in the control. Values are means ± SE from 3
independent experiments. The proliferation assays were performed in triplicate.
Normalized cell number was significantly decreased compared with the control at the
same time point: *P < 0.05 and **P < 0.01, respectively (Student’s test). B: inhibition
of PI3K leads to G1 arrest in OVCAR-3 and A2780/CP70 cells. Cells were cultured
in a 100-mm dish at a density of 1 x 106 cells/dish in RPMI 1640 media
supplemented with 10% FBS for 24 h at 37°C in 5% CO2 incubator. The cells were
then cultured in the absence or presence of LY-294002 (10 and 20 µM) for 12, 24,
and 48 h. Cells were washed with 1x PBS, fixed, stained, and analyzed by flow
cytometry. Typical cell cycle histograms were recorded (B) 24 h after treatment.
Gates were configured manually to determine the percentage of cells at G1,S, and
G2/M phases based on DNA content. C: the percentage of cells at G0/G1,S, and
G2/M phases was obtained from 3 replicate experiments.
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Figure. 2. Role of PI3K in the expression of proteins associated with the cell cycle of
OVCAR-3 and A2780/CP70 cells. A: OVCAR-3 cells were cultured in the RPMI 1640
media supplemented with 10% FBS for 24 h at 37°C in 5% CO2 incubator, followed
by the addition of solvent alone or 10 or 20 µM of LY-294002 (LY) for 12 h. The total
cellular protein extracts were prepared and subjected to immunoblotting analysis by
using specific antibodies against phospho-retinoblastoma (Rb) (Ser795, Ser780, and
807/811

), Rb, cyclin D1, cyclin-dependent kinase (CDK) 4, CDK6, CDC25A, p21, p16,

and β-actin. B: OVCAR-3 and A2780/CP70 cells were cultured in a 100-mm dish at a
density of 1

106 cells/dish in RPMI 1640 media supplemented with 10% FBS for 24

h at 37°C in 5% CO2 incubator, followed by the incubation with serum-free media for
16 h. Cells were switched to the media in the presence (+) or absence (-) of 10%
FBS and LY-294002 for 12 and 24 h, as indicated. The proteins were analyzed by
immunoblotting, as described in MATERIALS AND METHODS.
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Figure. 3. AKT is a downstream target of PI3K in mediating the cell cycle
progression. A and B: effects of LY-294002 on the phosphorylation of AKT and
extracellular regulated kinase (ERK). OVCAR-3 and A2780/CP70 cells were cultured
for 24 h in a 100-mm dish at a density of 1 x 106 cells/dish in RPMI 1640 media
supplemented with 10% FBS for 24 h at 37°C in 5% CO2 incubator, followed by
starvation for 16 h with the use of serum-free media. Cells were switched to the
media in the absence (-) or presence (+) of 10% FBS and LY-294002, as indicated
(20 µM), for 30 min, 1 h, and 2 h, respectively. The whole cell lysates were prepared
and subjected to immunoblotting assay by using specific antibodies against
phospho-AKT at Ser473 and phospho-p44/42 ERK1/2. C and D: after the cells were
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cultured in serum-free medium for 16 h, the cells were switched to the media in the
absence or presence of 10% FBS and LY-294002, as indicated for 12 h (C) or 24h
(D). The phospho-AKT at Ser473 and total AKT were analyzed by immunoblotting, as
described in MATERIALS AND METHODS. E: overexpression of an active form of
AKT reverses the inhibition of PI3K that had led to cell cycle arrest in G1 in OVCAR3 cells. The cells were cultured in a 100-mm dish at a density of 1 x 106 cells/dish in
RPMI 1640 media supplemented with 10% FBS for 24 h at 37°C in a 5% CO2
incubator. The cells were transfected with green fluorescent protein (GFP) alone or
GFP-Myr-AKT expression plasmids and cultured for 36 h. The cells were then
cultured in the absence or presence of LY-294002 (10 µM) for 12 h. The cells
expressing GFP proteins were separated and analyzed by FACS analysis. Typical
cell cycle histograms were recorded.
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Figure. 4. The activation of p70S6K1 was affected by PI3K and mammalian target of
rapamycin (mTOR). A: the phosphorylation of p70S6K1 was inhibited by LY-294002.
OVCAR-3 and A2780/CP70 cells were cultured and subjected to serum starvation
for 16 h, followed by incubation in the presence (+) or absence (-) of 10% FBS
and/or LY-294002 for 12 h. The total cellular protein extracts were prepared and
analyzed for the phosphorylation of p70S6K1 by using specific antibodies against
phospho-p70S6K1 at Ser389 and at Ser421/Thr424 and against p70S6K1 as a control.
B: OVCAR-3 cells were transfected with pNeoSRα vector alone or pNeoSRα-MyrAKT plasmids, followed by the G418 selection for 2 wk. The cells expressing vector
alone or Myr-AKT were incubated with the solvent or 10 or 20 µM of LY-294002 for
12 h. The levels of total p70S6K1 and phosphorylation of p70S6K1 at Ser389 were
analyzed by immunoblotting, as described in MATERIALS AND METHODS. C: cells

were cultured and subjected to serum starvation, as described in MATERIALS
AND METHODS. The cells were switched to the media in the presence or
absence of 10% FBS and mTOR inhibitor rapamycin (10 ng/ml and 20 ng) for 12
h. The total cellular protein extracts were prepared and subjected to immunoblot
assay by using specific antibodies against phospho-p70S6K1 at 389 and at
Ser421/Thr424 and against total p70S6K1.

240

Figure. 5. PI3K signaling regulated cell cycle progression through p70S6K1. A:
effects of rapamycin on protein expression associated with G1 cell cycle in OVCAR3 and A2780/CP70 cells. The cells were cultured and subjected to serum starvation
for 16 h, as described in MATERIALS AND METHODS. The cells were switched to
the media in the presence (+) or absence (-) of 10% FBS and rapamycin (10 ng/ml
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and 20 ng) for 12 h. The total cellular protein extracts were prepared and subjected
to immunoblot assay. The protein expression associated with G1 cell cycle was
studied by using specific antibodies against phospho-Rb at Ser795, Ser780, and 807/811,
Rb, cyclin D1, CDK4, CDK6, CDC25A, p21, p16, and β-actin. B: OVCAR-3 cells
were cultured in the media supplemented with 10% FBS for 24 h at 37°Cin5%CO2
incubator, followed by the addition of solvent alone or 10 or 20 ng/ml of rapamycin
for 12 h. The cell cycle-associated proteins were analyzed by immunoblotting, as
described in MATERIALS AND METHODS. C: overexpression of an active form of
p70S6K1 reversed the inhibition of PI3K, leading to G1 arrest in OVCAR-3 cells. The
cells were cotransfected with GFP/active p70S6K1 (S6K1-E389D3E) expression
plasmids (1:5) and cultured for 36 h. The cells were then cultured in the absence or
presence of LY-294002 (10 µM) for 12 h. The cells expressing GFP proteins were
separated from untransfected cells by FACS. Typical cell cycle histograms were
recorded. D: expression of an active form of p70S6K1 reversed the inhibition of G1
cell cycle progression induced by rapamycin in OVCAR-3 cells. The cells were
transfected with GFP alone or with GFP/p70S6K1 plasmids, as described in
MATERIALS AND METHODS, and then cultured for 36 h after transfection. The
cells were treated with or without 10 µM rapamycin for 12 h. The cells expressing
GFP were separated from the untransfected cells by FACS analysis, and the cell
cycle progression was analyzed, as described in Fig. 1B.
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Figure. 6. Schematic model for a mechanism of PI3K/AKT/mTOR/p70S6K1
signaling pathway involved in cell proliferation and G1 cell cycle progression in
ovarian cancer cells. The activation of the PI3K signaling pathway in human ovarian
cancer cells induces the activation of AKT and PDK1. AKT and PDK1 transmit the
PI3K activation signal to p70S6K1, which, in turn, induces G1 cell cycle progression
and inhibits p16INK4a expression in the ovarian cancer cells. PI(3,4)P2,
phosphatidylinositol 3,4-bisphosphate; PI(3,4,5)P3, phosphatidyl-inositol 3,4,5trisphosphate; FRAP, fluorescence recovery after photo bleaching; PDK1,
phosphatidylinositol-dependent kinase.
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Abstract
We report that the actin filament-associated protein, AFAP-110, is required to mediate
PKCα activation of the non-receptor tyrosine kinase cSrc and the subsequent formation
of podosomes. Immunofluorescence analysis demonstrate that activation of PKCα by
PMA, or ectopic expression of constitutively activated PKCα, directs AFAP-110 to
colocalize with and bind to the cSrc SH3 domain, resulting in activation of the tyrosine
kinase. Activation of cSrc then directs the formation of podosomes, which contain
cortactin, AFAP-110, actin, and cSrc. In a cell line that has very low or no detectable
AFAP-110 (CaOV3), PMA treatment was unable to activate cSrc or affect podosome
formation. Ectopic expression of AFAP-110 in CaOV3 cells rescues PKCα-mediated
activation of cSrc, elevated tyrosine phosphorylation levels and subsequent formation of
podosomes. Neither expression of activated PKCα nor treatment with PMA are able to
induce these changes in CAOV3 cells expressing mutant forms of AFAP-110 that are
unable to bind to, or colocalize with, cSrc. We hypothesize that one major function of
AFAP-110 is to relay signals from PKCα that direct activation of cSrc and the formation
of podosomes.
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Introduction
Activation of either PKCα or cSrc result in similar effects on cell morphology,
including changes in actin filament integrity, cell shape changes and stimulation of
signals associated with increased motility and invasion (20,21,23). Several studies
support the existence of cross talk between cSrc and PKCα-mediated signaling
pathways. Constitutive activation of cSrc or stable expression of v-Src will
concomitantly stimulate an increase in PKCα signaling (8,37,44). These data indicate
that PKCα could function downstream of cSrc. However, other data support a
hypothesis that PKCα can signal upstream of cSrc and stimulate cSrc activity.
Activation of PKCα has been demonstrated to initiate changes in actin filaments that
resemble those that occur in Src527F-transformed cells (7,9,11,16). Likewise, it was
demonstrated that stimulation of cells with phorbol esters will direct activation of cSrc in
SH-SY5Y cells (5), while treatment of mouse epidermis with the tumor promotor TPA
induced a dose-dependent increase in cSrc kinase activity and phosphotyrosine content
of the ErbB2 receptor, which correlated with tumor promoting ability (43). Further, it
was demonstrated that PKCα can directly stimulate cSrc activity in A7r5 rat aortic
smooth muscle cells, and the induction of Src kinase activity is necessary for PKCmediated actin reorganization (3). Thus, these data indicate that PKCα may function
upstream, as an activator of cSrc. Although PKCα is able to phosphorylate cSrc
(15,31), in vitro studies indicate that PKCα does not activate cSrc directly (4,29). Thus,
although these reports demonstrate the ability of PKCα to direct activation of cSrc, the
mechanism of PKCα-mediated cSrc activation is unclear.
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AFAP-110 is an adaptor protein that has been demonstrated to bind to Src via
SH2 and SH3 interactions (17,18), and will bind to PKCα via the amino terminal
pleckstrin homology (PH1) domain (32). A carboxy terminal leucine zipper motif (Lzip)
stabilizes AFAP-110 multimer formation and provides an autoinhibitory, regulatory
function for AFAP-110 (1,32,33,35). While expression of wild type AFAP-110 has little
effect on cell morphology. However, deletion of the leucine zipper motif (AFAP-110∆Lzip)
followed by ectopic expression of AFAP-110∆Lzip results in significant changes in cell
morphology, including loss of actin filament organization and podosome formation, a
feature common to Src-transformed cells (10,26,28,30,32-34,39). The ability of AFAP110∆Lzip to alter actin filament integrity was attributed to an ability to activate cSrc via
SH3 binding, a function wild type AFAP-110 was unable to accomplish (1). Point
mutations that abrogated the ability of AFAP-110 to bind to the Src SH3 domain
(Pro71→Ala) also prevented AFAP-11071A/∆Lzip from activating cSrc (1,17). Thus, AFAP110 has an intrinsic ability to activate cSrc as an SH3 binding partner, and this function
is regulated by the Lzip motif.
Changes in the conformation of AFAP-110 and its ability to multimerize via the
Lzip motif occur in transformed cells, indicating that specific cellular signals may direct
AFAP-110 to activate cSrc by relieving the autoinhibitory function of the Lzip motif.
Recent work by our lab indicated that PKCα may be positioned to fulfill this function
(32). The stability of the AFAP-110 multimer is hypothesized to be governed by
interactions between the Lzip motif and the amino terminal pleckstrin homology (PH1)
domain (35). PKCα will bind to the PH1 domain and these sequences overlap with
sequences that bind to the Lzip motif (32,35). Thus, PKCα binding and subsequent
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phosphorylation could displace the Lzip motif from intra- or intermolecular interactions
and affect a conformational change that relieves the autoinhibitory function of the Lzip
motif. Therefore, we hypothesized that the deletion of the Lzip motif of AFAP-110
mimicked the conformation and activity of PKCα-phosphorylated AFAP-110 and
resulted in a “dominant positive” form of AFAP-110 capable of independently activating
cSrc.
These data led us to hypothesize that PKCα may induce activation of cSrc in an
AFAP-110-dependent fashion. We predicted that PKCα would be able to direct a
conformational change upon AFAP-110 similar to the effects of deleting the Lzip motif,
which would enable AFAP-110 to direct activation of cSrc. One major characteristic of
cSrc activation is the formation of podosomes, actin-rich structures approximately 0.5
µm in diameter that exist on the cytoplasmic face of the dorsal membrane and facilitate
the invasive potential of a cell (reviewed in (26)). In Src-transformed cells, podosomes
are known to contain a variety of proteins, including actin, cortactin, AFAP-110, and
cSrc. In this report, we demonstrate that PKCα is able to activate cSrc and direct
podosome formation in an AFAP-110 dependent fashion.
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Materials and Methods
Reagents: Dulbecco’s Modified Eagle’s Medium (DMEM), Rhodaminephalloidin, TRITC-anti-Mouse IgG, TRITC-anti-Rabbit IgG, anti-cortactin monoclonal
antibody (mAb), and anti-Flag polyclonal and monoclonal antibodies were purchased
from Sigma. Phorbol 12-myristate 13-acetate (PMA) and bisindolylmaleimide [I] were
obtained from Calbiochem. PKC isoform antibodies (PKC sampler kit) and antiphosphotyrosine monoclonal and polyclonal antibodies were obtained from BD
Transduction Laboratories. AFAP-110 antibodies F1 and 4C3 were generated and
characterized as previously described (36). Anti-Src (N-18) and anti-Src (N-16)
polyclonal antibodies were purchased from Santa Cruz, while EC10 mAb and
recombinant cSrc used in the Src kinase assay were obtained from Upstate. Phosphosrc family (Tyr416) antibody was purchased from Cell Signaling. Cy5 anti-Mouse IgG
and Cy5 anti-Rabbit IgG were obtained from Rockland. All Alexa Fluor antibodies used
in the paper were purchased from Molecular Probes.
AFAP-110 expression vectors: The pEGFP-c3 Expression system from
Amersham was used to express GFP-tagged forms of AFAP-110. AFAP-110 was
cloned into this vector as previously described (34). CMV-1-AFAP-110∆180-226 was
previously described (1). Fragments from CMV-AFAP-110, CMV-1-AFAP-110∆180-226,
and GEX-6P-AFAP-11071A were subcloned into pEGFP-c3-AFAP-110 to create full
length, GFP-tagged forms of these mutants. CMV-AFAP-11071A/∆Lzip and CMV-AFAP110∆180-226/∆Lzip were generated as previously described (1). Flag-myr-PKCα and Flagd/nPKCα were a kind gift from Alex Toker.
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Src Kinase Assay. The ability of rAFAP-110 and rAFAP-110∆Lzip to activate
cSrc was assessed using a modified Src kinase assay protocol from Upstate. Briefly,
GST-AFAP-110, GST-AFAP-110∆Lzip and GST-Csk were immobilized on glutathionesepharose 4B beads from Amersham as previously described (17). Recombinant cSrc
(Upstate) was inactivated by incubation with GST-Csk in Csk buffer (10 mM Hepes, pH
7.4, 5 mM MnCl2, 100 µM ATP) for 30 minutes at 30°C. The GST-Csk was removed by
centrifugation, and the inactive cSrc was aliquoted into 1.5mL tubes. The GST-AFAP110 and GST-AFAP-110∆Lzip were washed in MT-PBS with 1% triton-X and then Src
kinase buffer (100 mM Tris-HCl, 125 mM MgCl2, 25 mM MnCl2, 2mM EGTA, pH 8.0,
250 µM NaOV3, 2 mM DTT). The Src kinase reaction was carried out for 1 minute in
the presence of Mg-ATP. The reactions were stopped by the addition of 0.5 M EGTA,
and the samples were separated by 8% SDS-PAGE and transferred to PVDF
membrane. The membranes were probed with anti-phosphotyrosine antibody to
demonstrate AFAP-110 phosphorylation.
Cell culture and immunofluorescence: SYF, SYF/cSrc, and CaOV3 cells were
cultured in DMEM supplemented with 10% FCS. Transient transfection of SYF,
SYF/cSrc, and CaOV3 cells for immunofluorescence was carried out using
Lipofectamine Reagent (Invitrogen) as per manufacturer’s protocol. Thirty-six hours
after transfection, SYF and SYF/cSrc cells were serum starved for 12 hours, while
CaOV3 cells were serum-starved for 18 hours, and all cells were subsequently fixed
and permeablized as previously described (33). For actin labeling, a 1:1000 dilution
TRITC-phalloidin was used. Antibody concentrations used: F1, 1:200 in 5% milk-TBST; anti-Flag mAb, 1:1000 in 5% BSA; anti-Flag pAb, 1:200 in 5% BSA; EC10, 1:500 in
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5% BSA; anti-phosphotyrosine pAb, 1:100 in 5% BSA; anti-phosphotyrosine mAb, 1:200
in 5% BSA; phospho-Src family (Y416), 1:250 in 5% BSA; anti-Src (N18), 1:500 in 5%
milk-TBS-T; anti-cortactin pAb, 1:1000 in 5% BSA; anti-cortactin mAb, 1:500 in 5%
BSA. All fluorescent secondary antibodies were diluted 1:200 in 5% BSA, and labeled
according to use in the figure legends. Cells were washed and mounted on slides with
Fluoromount-G (Fisher). A Zeiss LSM 510 microscope was used to gather images,
which represent confocal slices of about 1 µM in thickness. To prevent crosscontamination between the different fluorochromes, each channel was imaged
sequentially using the multitrack recording module before merging the images. Scale
bars were generated and inserted by LSM 510 software. For all figures, representative
cells are shown (>100 cells examined per image shown).
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Results
PKCα requires the presence of cSrc to affect changes in actin filament integrity
and podosome formation. It was previously demonstrated that PKCα can direct the
activation of cSrc in A7r5 rat aortic smooth muscle cells in response to phorbol ester
treatment (3). We sought to verify this finding in our cell system using SYF cells, which
are derived from mouse embryo fibroblasts engineered to contain null mutations in the
c-src, fyn, and c-yes genes (24), and therefore do not express Src family tyrosine
kinases. We also utilized SYF/cSrc cells, which are derived from SYF cells and express
only the cSrc tyrosine kinase family member, to examine the effects of expressing a
constitutively active form of PKCα (myrPKCα) upon cSrc activation and changes in actin
filament organization. Expression of myrPKCα in SYF/cSrc cells resulted in altered
actin stress filament integrity, with actin filaments reorganized into actin-rich, podosomelike structures (Figure 1A, panels b and f). These actin-rich structures were between
0.2 and 0.5 µm in diameter and were apparent on the cytoplasmic face of the dorsal
membrane, consistent with the definition of a podosome (26). There was also an
increase in cellular tyrosine phosphorylation (Figure 1A, panel c), as well as activation
of cSrc (Figure 1A, panel g). To confirm that these actin-rich, podosome-like structures
generated in response to myrPKCα were actually podosomes, SYF/cSrc cells
expressing myrPKCα were labeled for cortactin, a protein known to be present in
podosomes subsequent to cSrc activation (Figure 1B, panel k) (reviewed (26)). The
data demonstrate that cortactin colocalizes with actin in these structures, confirming
their identity as podosomes (Figure 1B, panel l). Lastly, expression of a dominant
negative form of PKCα (Figure 1, panel m) was unable to affect actin-rich podosome
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formation or direct an increase in cellular tyrosine phosphorylation (Figure 1B, panels
m-p). These results confirm that cSrc is activated in response to PKCα activity and this
correlates with elevated levels of cellular tyrosine phosphorylation and changes in actin
filament integrity, including the formation of podosomes.
In order to determine if PKCα requires the presence of cSrc to affect changes in
actin filament integrity, cSrc and myrPKCα were expressed together or separately in
SYF cells in the presence of green fluorescent protein (GFP) epitope-tagged AFAP-110,
which has previously been shown to colocalize with actin filaments (34). In SYF cells
expressing GFP-AFAP-110 and cSrc (Figure 2, panels a-d), GFP-AFAP-110 highlights
the cortical actin matrix and stress filaments that span the length of the cell (Figure 2,
panel a) while cSrc exhibits a perinuclear staining pattern (Figure 2, panel b), consistent
with previous reports that inactive cSrc is located on perinuclear vesicles (38). In the
absence of cSrc, myrPKCα was unable to affect changes in AFAP-110 localization
(Figure 2, panels e-h), and GFP-AFAP-110 localized to well-formed stress filaments and
cortical actin filaments. The presence of well-formed actin filaments in these cells may
be facilitated by an increased ability of AFAP-110 to cross-link actin filaments upon
phosphorylation by PKCα, as noted previously (32). However, co-expression of GFPAFAP-110 and myrPKCα with cSrc in SYF cells resulted in a complete disruption of
actin filament integrity and the formation of actin-rich punctate structures, as well as the
formation of motility structures, a phenotype that is a hallmark of cSrc transformation
(Figure 2, panels i-l). These data indicate that myrPKCα requires cSrc in order to affect
major changes in cell shape and the actin cytoskeleton.
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AFAP-110 activates cSrc by colocalizing with and binding to the cSrc SH3
domain. Previous studies by our lab demonstrated that wild type AFAP-110 is unable to
stimulate activation of cSrc in fibroblast cells, while co-expression of the dominantpositive AFAP-110∆Lzip was able to direct activation of cSrc in cell culture (1,32). The
ability of AFAP-110∆Lzip to activate cSrc was dependent upon SH3 interactions with the
cSrc SH3 domain. Mutations that abrogate SH3 binding to cSrc (Pro71→Ala71) will
prevent both stable complex formation with cSrc and the ability of AFAP-110∆Lzip/71A to
activate cSrc, in cell culture (1). In order to clarify the mechanism by which AFAP-110
may be directed to activate cSrc in cell culture, we utilized confocal microscopy to
analyze GFP-AFAP-110, GFP-AFAP-110∆Lzip and cSrc for colocalization and activation
of cellular tyrosine phosphorylation in SYF cells (Figure 3). Figure 3A, panels a-d
demonstrated that AFAP-110 is unable to colocalize with cSrc, and confirms that wild
type AFAP-110 is incapable of stimulating an increase in cellular tyrosine
phosphorylation. Further, there was no evidence for podosome formation based on
GFP-AFAP-110 localization, which decorates actin filaments. AFAP-110∆Lzip
demonstrated strong colocalization with cSrc and was able to direct activation of cellular
tyrosine phosphorylation (Figure 3A, panels e-h). GFP-AFAP-110∆Lzip transfected into
SYF cells in the absence of cSrc display no increased immunoreactivity to the
antiphosphotyrosine antibody or evidence for podosome formation (Figure 3A, panels il), indicating that AFAP-110∆Lzip activates cSrc and not another tyrosine kinase present
in these cells and that AFAP-110∆Lzip requires cSrc to direct podosome formation. In the
presence of cSrc, AFAP-110∆Lzip was able to colocalize with cortactin in podosomes that
were detected on the cytoplasmic face of the dorsal membrane of SYF/cSrc cells
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(Figure 3B, panels m-p). Mutants of AFAP-110 that were unable to either interact with
the cSrc SH3 domain (AFAP-11071A), or that contained deletions in the PH1 domain and
were unable to bind with PKCα (AFAP-110∆180-226), have each been shown to abrogate
the ability of AFAP-110∆Lzip to activate cSrc and alter actin filament integrity, in vivo (1).
AFAP-11071A/∆Lzip was unable to direct an increase in cellular tyrosine phosphorylation,
although it was able to colocalize with cSrc (Figure 3C, panels q-t). The inability to
enhance cellular tyrosine phosphorylation was most likely due to its inability to engage
the cSrc SH3 domain. Interestingly, AFAP-110∆180-226/∆Lzip was also unable to direct
elevation of cellular tyrosine phosphorylation; however, unlike AFAP-110∆Lzip/71A, there
was no evidence for colocalization with cSrc (Figure 3C, panels u-x). These cellular
effects indicate that deletion of the leucine zipper domain de-represses an intrinsic
ability of AFAP-110 to activate cSrc kinase via SH3 binding, while the integrity of the
PH1 domain is required to facilitate colocalization between AFAP-110 and cSrc.
We had previously hypothesized that deletion of the leucine zipper motif may
affect a structural change that placed the SH3 binding motif in a more favorable
conformation which facilitated binding to the cSrc SH3 domain and activation of cSrc
(33). The data shown in Figure 3 indicate that colocalization between AFAP-110 and
cSrc may also be important. Recently it was reported that recombinant, wild type
AFAP-110 (rAFAP-110) could stimulate activation of cSrc in vitro, based on in vitro
kinase assays (27). Thus, our initial hypothesis concerning how AFAP-110∆Lzip could
activate cSrc may not have been fully correct. To address this concern, we performed
an in vitro kinase assay using rAFAP-110 or rAFAP-110∆Lzip and incubated each with
recombinant cSrc that had been phosphorylated by CSK to inactivate the kinase, in
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vitro. A measurement of tyrosine phosphorylation of rAFAP-110 or rAFAP-110∆Lzip
indicated that cSrc was able to become activated by, and stimulate tyrosine
phosphorylation of, either rAFAP-110 or rAFAP-110∆Lzip (Figure 4). Furthermore,
phosphorylation of rAFAP-110 by rPKCα did not enhance the ability of AFAP-110 to
activate cSrc, relative to unphosphorylated rAFAP-110, in vitro (M. Liu, personal
communication). Thus, our analysis indicate that both AFAP-110∆Lzip and AFAP-110 are
capable of activating cSrc activity, in vitro; however, only AFAP-110∆Lzip activates cSrc,
in vivo. Thus, we predict that the ability of AFAP-110 to activate cSrc is dependent
upon its ability to (a) colocalize with cSrc and (b) bind to the cSrc SH3 domain.
Therefore, deletion of the Lzip motif and release of its autoinhibitory function must allow
AFAP-110 to colocalize with cSrc by an unknown mechanism and it is this event that
enables it to bind to and activate cSrc.
PKCα activates cSrc in an AFAP-110-dependent fashion. AFAP-110 is a binding
partner for both PKCα and cSrc. We have previously demonstrated that AFAP-110 is
able to activate cSrc in cell culture upon removal of the autoinhibitory leucine zipper
motif (AFAP-110∆Lzip) (1,33,35). PKCα is able to bind to sequences in the PH1 domain
of AFAP-110 that overlap with the Lzip binding motif (32,35). Because PKCα can direct
activation of cSrc and affect a conformational change upon AFAP-110 that correlates
with its intrinsic ability to activate cSrc, we hypothesized that AFAP-110 may be
positioned to relay signals from PKCα that direct activation of cSrc. To test this
hypothesis, SYF/cSrc cells were cotransfected with myrPKCα and AFAP-110. As a
control, two mutant forms of AFAP-110 were also cotransfected with myrPKCα, AFAP11071A or AFAP-110∆180-226. AFAP-11071A fails to bind to the cSrc SH3 domain and
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would fail to initiate activation of cSrc (1), while AFAP-110∆180-226 contains a deletion in
the PH1 domain which was previously shown to prevent AFAP-110∆Lzip/∆180-226 from
activating cSrc (32) and modulate localization with cSrc. The data demonstrate that
myrPKCα can direct an increase in cellular tyrosine phosphorylation (Figure 5, panels ac) and cSrc activation (Figure 5, panels j-l). In addition, as AFAP-110 colocalizes with
actin filaments (34), it is apparent that PKCα can direct AFAP-110 associated actin
filaments into structures that resemble podosomes in both size and localization (Figure
5, panels a and j). However, both AFAP-11071A (Figure 5, panel d-f, m-o) and AFAP110∆180-226 (Figure 5, panels g-i, p-r) blocked the ability of myrPKCα from directing actin
filament reorganization. These data indicate that AFAP-11071A and AFAP-110∆180-226
have a dominant-negative function over PKCα in terms of activating cSrc, cellular
tyrosine phosphorylation, and directing AFAP-110 to colocalize with structures that
resemble podosomes. Therefore, we speculate that AFAP-110 can mediate PKCα
directed activation of cSrc and subsequent changes in actin filament organization.
To explore this further, we sought to activate endogenous PKCα with PMA and
determine whether it could direct AFAP-110 to colocalize with cSrc. PMA is a phorbol
ester that directs activation of classical (α, β and γ) and novel (δ, ε and η) PKC family
members (45)(reviewed in (2)). In order to verify the expression pattern of PKC family
members in SYF cells, we performed western blot analysis of SYF cell lysates with
antibodies that immunoreact with individual PKC isoforms (Figure 6). The data
demonstrate that among the PKC family members, PKCα is strongly represented, as
are PKCδ and λ and, to a lesser extent, PKCε. Previous data indicate that AFAP-110 is
a substrate and binding partner for PKCα and is a potential binding partner for PKCβ, γ
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and λ, as well (32). These data indicate that the PKCα isoform is the only one present
in SYF cells that can (i) bind AFAP-110 and (ii) be activated by PMA. cSrc was then coexpressed with AFAP-110 in SYF cells and the cells were treated with 100nM of PMA
for 30 minutes to activate endogenous PKCα. Immunofluorescence analysis
demonstrates that in the presence of PMA, there is a loss in actin filament organization
(as evidenced by AFAP-110 localization), with podosome-like structures present,
increased cellular tyrosine phosphorylation and AFAP-110 and cSrc colocalization
(Figure 7A, panels a-d). However, cells expressing mutants unable to bind cSrc (AFAP11071A), or PKCα (AFAP-110∆180-226), retained normal actin filament integrity after PMA
treatment and background levels of cellular tyrosine phosphorylation (Figure 7A, panels
e-l), indicating that interactions with both PKCα and cSrc are required for cSrc activation
and alterations in actin filament integrity. Further, AFAP-110∆180-226 failed to colocalize
with cSrc in response to PMA stimulation (Figure 7A, panel l). As a control, a six-hour
pretreatment with 6µM bisindolylmaleimide [I] was used to block PKCα activity, resulting
in AFAP-110 being unable to colocalize with cSrc in response to PMA and also blocked
the PMA-mediated increase in cellular tyrosine phosphorylation (Figure 7B, panels m-x).
These data suggest that the ability of PMA to mobilize colocalization of AFAP-110 with
cSrc is dependent upon activation of PKCα and not upon other PMA inducible proteins
(2).
To verify that PKCα activation was directing interactions between AFAP-110 and
cSrc, SYF/cSrc cells were treated with DMSO or 100 nM PMA and lysates were
subjected to immunoprecipitation and western blot analysis. Treatment with PMA
resulted in a relative increase in endogenous AFAP-110 tyrosine phosphorylation
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(Figure 8A), as well as the direct association of AFAP-110 and cSrc, as demonstrated
by the ability to immunoprecipitate endogenous cSrc and western blot for bound,
endogenous AFAP-110 (Figure 8B). Pre-treatment with bisindolylmaleimide [I] resulted
in an abrogation in cSrc and AFAP-110 tyrosine phosphorylation to levels equivalent to
the DMSO control lane. Likewise, bisindolylmaleimide [I] treatment resulted in the
abrogation of binding between cSrc and AFAP-110. These data are in agreement with
the immunofluorescence microscopy data and indicate that in response to PKCα
activation, AFAP-110 forms a direct interaction with cSrc that correlates with increased
tyrosine phosphorylation of AFAP-110.
The presence of AFAP-110 is required for PKCα-directed cSrc activation and
podosome formation. Because dominant-negative AFAP-11071A and AFAP-110∆180-226
were able to block PKCα directed activation of cSrc, we sought to determine whether
the presence of AFAP-110 was required for myrPKCα directed activation of cSrc and
subsequent podosome formation. We hypothesized that if AFAP-110 was required,
then in cells that lack AFAP-110, activation of PKCα would fail to direct an increase in
cSrc activation and subsequent podosome formation. We screened various human
cancer cell lines for steady state expression levels of AFAP-110 and found that in
A2780 and CaOV3 cells, AFAP-110 expression levels were at or below detection limits
(Figure 9A). CaOV3 cells do express detectable levels of cSrc and PKCα, although
expression levels were relatively low (Figure 9B). Thus, we chose to utilize the human
ovarian cancer CaOV3 cell line to determine whether activation of PKCα required
AFAP-110 to activate cSrc and affect podosome formation.
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In each case where AFAP-110 constructs are able to activate cSrc, there is a
concomitant increase in cellular tyrosine phosphorylation. As endogenous cSrc levels
are low in CaOV3 cells, we ectopically expressed cSrc and used the mAb EC10 to
visualize the localization of cSrc. However, it was first important to demonstrate that the
expression of exogenous cSrc did not stimulate an increase in cellular tyrosine
phosphorylation upon activation of PKCα. Treatment of CaOV3 cells expressing cSrc
alone with DMSO (the solvent for PMA) did not significantly increase cellular
phosphotyrosine levels relative to background (Figure 10A, panels a-d). Likewise,
treatment with PMA was also unable to affect significant changes in cellular
phosphotyrosine levels (Figure 10A, panels 7e-h). As a control, we pretreated CaOV3
cells with bisindolylmaleimide [1] to block PMA-directed PKCα signaling (Figure 10A,
panels i-l). Expression of myrPKCα into CaOV3 cells was also unable to affect
significant changes in cellular tyrosine phosphorylation or podosome formation (based
on the appearance of F-actin) above background (Figure 10B, panels m-p). Therefore,
we conclude that activation of PKCα in CaOV3 cells over-expressing exogenous cSrc
does not lead to a significant increase in cellular tyrosine phosphorylation or the
formation of podosomes.
In order to determine if AFAP-110 could mediate cSrc activation in CaOV3 cells,
we transfected vectors expressing GFP-AFAP-110 or GFP-AFAP-110∆Lzip into CaOV3
cells and examined cellular tyrosine phosphorylation levels and podosome formation. In
the presence of wild-type GFP-AFAP-110, no elevation in cellular tyrosine
phosphorylation or podosome formation was observed (Figure 11A, panels a-d).
However, expression of the dominant positive AFAP-110∆Lzip construct resulted in an
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increase in cellular tyrosine phosphorylation, as well as the formation of AFAP-110∆Lzipassociated podosomes (Figure 11A, panels e-h), a phenotype similar to cSrc activation.
Similarly, AFAP-110∆Lzip and cSrc co-expression also resulted in an increase in cSrc
activation as revealed by anti-phospho (Y416) antibodies (data not shown).
Immunostaining with a polyclonal cortactin antibody demonstrated that in response to
AFAP-110∆Lzip expression, AFAP-110∆Lzip and cortactin co-localized in podosomes
(Figure 11B, panels l-n), unlike AFAP-110 and cortactin (Figure 11B, panels i-k). These
data indicate that dominant positive AFAP-110∆Lzip is capable of stimulating an increase
in cellular tyrosine phosphorylation and podosome formation in CaOV3 cells.
To address the issue of whether the presence of AFAP-110 could rescue the
ability of PKCα to stimulate cSrc activation and podosome formation in CaOV3 cells, we
ectopically expressed both AFAP-110 and cSrc in these cells using a dual expression
vector to ensure successful co-expression in all transfected cells. The cells were then
stimulated with DMSO, 100 nM PMA, or 100 nM PMA plus 6 µM bisindolylmaleimide [I].
Transfected cells treated with DMSO displayed no change in cellular phosphotyrosine
levels (Figure 12, panel a-d), or colocalization of AFAP-110 and cSrc (data not shown).
However, PMA treatment directed an increase in cellular tyrosine phosphorylation and
the formation of podosomes (Figure 12, panels e-h). AFAP-110 and cSrc also
colocalized in response to PMA treatment (data not shown). Pretreatment with
bisindolylmaleimide [I] resulted in a complete abrogation of PMA-induced affects on
AFAP-110 and cSrc colocalization, cellular tyrosine phosphorylation, and podosome
formation (Figure 12, panels i-l). Likewise, PMA treatment also resulted in an increase
in cSrc activation (Figure 12, panels q-t), and this elevation in cSrc activation is
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abrogated by pre-treatment with bisindolylmaleimide [I] (Figure 12, panels u-x).
Collectively, these data indicate that AFAP-110 plays an important role in relaying
signals from PKCα that direct activation of cSrc and podosome formation.
As the expression of exogenous AFAP-110 in CaOV3 cells made the cells
sensitive to treatment with PMA, we next asked if mutants of AFAP-110 that were
unable to either interact, or colocalize, with cSrc could abrogate the effects we observed
following treatment with PMA. CaOV3 cells transiently transfected with the Src binding
mutant AFAP-11071A displayed normal cell morphology and no elevation in cellular
tyrosine phosphorylation in response to treatment with DMSO and AFAP-11071A and
cSrc do not appear to colocalize in the merged image (Figure 13A, panels a-d). In
response to treatment with 100nM PMA, actin filament integrity is unchanged and there
is no elevation in cellular tyrosine phosphorylation (Figure 13A, e-h); however, AFAP11071A and cSrc colocalize. This affect was abolished upon pre-treatment with 6µM
bisindolylmaleimide [I] (Figure 13A, panels i-l). In a similar manner, expression of the
PKCα binding mutant AFAP-110∆180-226 did not alter actin filament integrity or cellular
tyrosine phosphorylation in response to 100nM PMA treatment (Figure 13B, panels mx). However, unlike AFAP-11071A, AFAP-110∆180-226 and cSrc were not colocalized in
response to PMA treatment, indicating that AFAP-110 is capable of relaying signals
from PKCα to cSrc, resulting in cSrc activation, increased cellular tyrosine
phosphorylation and the formation of podosomes.
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Discussion
There is significant evidence to indicate the existence of cross talk between
PKCα and cSrc. Activation of each of these kinases results in substantial changes in
actin filament integrity and cell morphology. Both cSrc and PKCα activation will direct
the formation of motility structures (lamellipodia and filopodia) and both kinases can be
detected in podosomes (26). In fact, cSrc and PKCα activation are sufficient to induce
the formation of podosomes (19,26,42). Further, both kinases will stimulate increased
cell motility and invasive potential (reviewed in (6,14,22,40)). Although several studies
have documented that activation of cSrc results in the subsequent activation of PKCα,
other studies have conversely demonstrated that PKCα can direct activation of cSrc (35). The ability of PKCα to activate cSrc is not due to direct interactions between these
two kinases. Although PKCα can phosphorylate cSrc, in vitro studies using purified cSrc
and PKCα demonstrated that PKCα was unable to directly activate cSrc (4). Thus, the
ability of PKCα to activate cSrc was likely due to the activity of other proteins that
relayed signals from PKCα, which in turn directed activation of cSrc. In this report, we
sought to determine whether the cSrc and PKCα binding partner AFAP-110 was
responsible for mediating PKCα-directed activation of cSrc and the subsequent
changes in the cytoskeleton that are hallmarks of Src activation, namely, podosome
formation.
Previous work by us demonstrated that AFAP-110 has an intrinsic ability to cross
link actin filaments and activate cSrc, and both of these functions were regulated by the
leucine zipper motif, which provides an autoinhibitory function (1,35). Mechanistic
studies demonstrated that the Lzip motif contacted sequences in the PH1 domain that
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also overlapped with the PKCα binding site (32,35). Activation of PKCα was sufficient
to displace these interactions, which in turn destabilized the AFAP-110 multimer,
revealing its intrinsic abilities to activate cSrc and cross link actin filaments (32,33,35).
Given that (a) PKCα can activate cSrc, (b) AFAP-110 has an intrinsic ability to activate
cSrc and (c) PKCα can affect conformational changes upon AFAP-110 that are
hypothesized to release autoinhibition by the Lzip motif, we hypothesized that AFAP110 could modulate PKCα-directed activation of cSrc and subsequent changes in the
actin-based cytoskeleton that are hallmarks of cSrc activation.
Our data confirm that PKCα can direct activation of cSrc, in vivo. Using murine
embryo fibroblast cells, ectopic expression of constitutively activated PKCα (myrPKCα)
was sufficient to direct an increase in cellular tyrosine phosphorylation and cSrc
activation. An analysis of actin filament organization in these cells revealed the
formation of actin-rich, punctate structures that were approximately 0.2-0.5 µm in
diameter and which were located on the cytoplasmic face of the dorsal membrane using
confocal microscopy and scanning Z-planes with a thickness of 1 µm. In addition, these
structures contained cortactin. Each of these features is defining for podosomes in cells
where Src is activated. The ability of PKCα to direct podosome formation and cSrc
activation was dependent upon its kinase activity, as kinase-dead PKCα was unable to
activate cSrc or affect podosome formation. Interestingly, the ability of activated PKCα
to affect significant changes in stress filament organization and podosome formation
was also dependent upon the presence of cSrc. Thus, PKCα can activate cSrc and
direct podosome formation, and further, that PKCα requires cSrc in order to affect
podosome formation and changes in stress filament integrity.
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Previous work by us demonstrated that AFAP-110 aligns strictly with stress
filaments and the cortical actin matrix (34). Deletion of the Lzip motif releases
autoinhibition and enables AFAP-110∆Lzip to activate cSrc and affect significant changes
upon cellular morphology. Our data demonstrate that AFAP-110∆Lzip is able to direct an
increase in cellular tyrosine phosphorylation and confirm that AFAP-110 is able to direct
activation of cSrc. The ability of AFAP-110∆Lzip to activate cSrc was dependent upon its
ability to (a) engage the cSrc SH3 domain and (b) colocalize with cSrc. With regard to
the latter, we had previously shown that deletions in the PH1 domain, as well as point
mutations which prevent SH3 binding to cSrc, were able to abrogate the ability of AFAP110∆Lzip from activating cSrc. Here, we demonstrate that deletions in the PH1 domain
prevent colocalization of AFAP-110∆Lzip with and the subsequent activation of, cSrc. In
vitro kinase data support this hypothesis, as both recombinant AFAP-110 and
recombinant AFAP-110∆Lzip have the potential to activate cSrc, but in cells, only AFAP110∆Lzip can direct cSrc activation. These data indicate that (a) AFAP-110 is capable of
activated cSrc and (b) upon release of the Lzip motif from the PH1 domain, AFAP-110
is then directed to move to and colocalize with cSrc in a fashion dependent upon the
integrity of the PH1 domain. Although we do not know how the PH1 domain facilitates
colocalization, it is well known that pleckstrin homology domains can function as both
protein and lipid binding partners (reviewed in (25)). Thus, it is possible that either a
protein chaperone delivers AFAP-110 to cSrc or conversely, that lipid and/or
membrane-binding properties are revealed that promote colocalization with cSrc. This
mechanism is currently under investigation. Interestingly, the ability of AFAP-110∆Lzip to
direct the formation of, and colocalize with, podosomes is confirmed based on the
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colocalization of AFAP-110∆Lzip and cortactin to these actin-rich, punctuate structures on
the cytoplasmic face of the dorsal membrane. Further, the ability of AFAP-110∆Lzip to
direct the formation of podosomes is dependent upon the presence of cSrc.
We were able to demonstrate that AFAP-110 does modulate PKCα-directed
activation of cSrc using two different techniques. Overexpression of myrPKCα in
murine embryo fibroblasts was sufficient to induce an increase in cellular
phosphotyrosine content and cSrc activation. Using confocal microscopy and
examining scanning Z-planes of 1 µm thickness indicated that all of the phosphotyrosine
signal and cSrc activation is detected on the cytoplasmic face of the dorsal membrane.
This observation is distinct from an examination of Src527F expression in cells, where
phosphotyrosine signals can be detected throughout the cell (Gatesman and Flynn,
unpublished observation), indicating that PKCα may direct activation of cSrc and
subsequent tyrosine phosphorylation of a subset of potential substrates.
Overexpression of mutants of AFAP-110 that fail to bind the cSrc SH3 domain, or fail to
colocalize with cSrc, each blocked myrPKCα from activating cSrc and directing
podosome formation. Given that AFAP-110 does colocalize with cortactin in
podosomes and AFAP-110 always colocalizes with F-actin, podosome formation was
hypothesized based on the presence of AFAP-110 in these punctate structures along
the dorsal membrane. These observations were confirmed using PMA, an activator of
endogenous PKCα. Treatment of cells with PMA resulted in activation of cSrc in an
AFAP-110-dependent manner. The ability of PMA to induce activation of cSrc was
sensitive to the presence of bisindolylmaleimide [I], an inhibitor of PKC that binds to the
catalytic domain. These data confirm that PMA-directed activation of cSrc occurs in a
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fashion dependent upon the catalytic activity of PKC and not upon any other PMAassociated functions. In addition, PMA was able to direct an increase in tyrosine
phosphorylation of endogenous AFAP-110 and was able to direct complex formation
between AFAP-110 and cSrc. Collectively, these data indicate that PKCα directs cSrc
activation in an AFAP-110 dependent manner.
We sought to determine if PKCα could direct activation of cSrc and podosome
formation in the absence of AFAP-110. For this analysis, we utilized a cell line, CaOV3,
which contained AFAP-110 protein expression levels that were at or below the levels of
detection. The data indicate that neither myrPKCα nor PMA were able to induce an
increase in cellular phosphotyrosine content, cSrc activation or podosome formation.
Ectopic expression of AFAP-110∆Lzip was able to direct an increase in cellular
phosphotyrosine content, cSrc activation and podosome formation, indicating that it is
possible to activate these signals in these cells. Ectopic expression of AFAP-110
restored the ability of myrPKCα and PMA to stimulate activation of cSrc, increased
cellular phosphotyrosine content and podosome formation, while mutants of AFAP-110
that fail to activate cSrc, failed to relay these signals. These data confirm that AFAP110 plays an important role in relaying signals from PKCα that direct activation of cSrc
and podosome formation.
Collectively, these data indicate that PKCα directs activation of cSrc via AFAP110. We hypothesize the following model: Activation of PKCα displaces autoinhibitory
interactions between the Lzip motif and the PH1 domain of AFAP-110. This enables
AFAP-110 to move to and colocalize with cSrc in a PH1 domain-dependent manner.
AFAP-110 then initiates activation of cSrc through SH3 binding. Activated cSrc then
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stimulates signals that direct the formation of podosomes. These data are significant for
several reasons. First, they establish a mechanism by which PKCα can activate cSrc.
Second, they establish a mechanism by which PKCα can direct the formation of
podosomes. Podosomes are actin-rich structures that form on the dorsal membrane
and are hypothesized to play an important role in modulating the invasive potential of a
cell. Both PKCα and cSrc activation are sufficient to induce an increase in cell motility
and invasive potential. Indeed, it has been hypothesized that activation of cSrc occurs
concomitant with acquisition of the invasive phenotype (13). Podosomes are rich in
cross-linked F-actin and contain a variety of actin-binding proteins and signaling
proteins, such as actin, cortactin, AFAP-110, and cSrc (26). Interestingly, AFAP-110
may contribute to the formation of podosomes in two ways. Here, PKCα would affect a
conformation change upon AFAP-110 that allows it to colocalize with and activate cSrc,
which our data indicate is sufficient to initiate signals that direct podosome formation. In
addition, the conformational change directed upon AFAP-110 that allows it to activate
cSrc is also sufficient to increase the ability of AFAP-110 to cross link F-actin (35).
Cross-linked F-actin exists in the core of the podosome. Although our analysis does not
distinguish the localization of AFAP-110 in the core or fringe of a podosome, it is
possible that AFAP-110 may be positioned to facilitate actin cross-linking within the
newly formed podosome core. It is also possible that AFAP-110 colocalization to
podosomes may be required to facilitate cSrc colocalization to podosomes, as AFAP110 is a binding partner for activated Src (18).
These data also have implications for signal transduction and possibly cancer
progression. AFAP-110 is a PH1 domain-binding partner for PKCβ, PKCγ and PKCλ

272

(32). Further, AFAP-110 is an SH3 binding partner for Fyn and Lyn, but not c-Yes
(12,17,41). Thus, AFAP-110 may be positioned to relay signals from other PKC family
members that direct activation of a subset of Src family kinases. In each instance, this
may result in the formation of podosomes. Given that PKCα and cSrc expression levels
and activation states are increased in a variety of invasive human cancers that are also
invasive, it may be possible that AFAP-110 expression levels in these same cancers
could facilitate the relay of signals that direct activation of cSrc and acquisition of the
invasive phenotype. These studies are currently under investigation.
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Figure 1. Myristoylated PKCα activates cSrc and alters actin filaments.
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A. SYF/cSrc cells were transiently transfected with Flag-tagged myristoylated PKCα
and labeled with anti-Flag antibody (panels a and e), anti-phosphotyrosine (panel c),
phospho-Src family (Y416) antibody (panel g), and TRITC-phalloidin (panels b and f).
Expression of myrPKCα resulted in the loss of actin filament integrity and the formation
of actin-rich podosome-like structures (arrows, panels b and f). These cells also display
an increase in cSrc phosphorylation at the Y416 position (panel g). B. SYF/cSrc cells
were transiently transfected with Flag-tagged myristoylated PKCα or Flag-tagged
dnPKCα and labeled with anti-Flag antibody (panels i and m), anti-cortactin (panel k),
anti-phosphotyrosine (panel o), and TRITC-phalloidin (panels j and n). Expression of
myrPKCα resulted in the formation of actin-rich podosomes along the ventral surface,
as indicated by the presence of cortactin in these structures (arrow, panels j and k).
Likewise, actin and cortactin are observed to colocalize in the merged image (panel l).
Expression of dominant-negative PKCα (panel m) resulted in no changes in actin
filament integrity (panel n) or immunoreactivity with the anti-phosphotyrosine antibody
(panel o). Anti-Flag mAb was visualized with Alexa Fluor 488 Goat anti-Mouse IgG.
Anti-phosphotyrosine and phospho-Src family (Y416) were visualized with Alexa Fluor
647 Goat anti-Rabbit IgG. Anti-cortactin was visualized with Alexa Fluor 647 Goat antiMouse IgG. Bars represent 20µM.
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Figure 2. Myristoylated PKCα alters actin filament integrity in a cSrcdependent fashion in SYF cells.
Top panels: SYF cells were transiently transfected with both GFP-AFAP-110 (panel a)
and pCMV-cSrc and immunolabeled with EC10 antibody (panel b). In the absence of
myrPKCα, SYF cells have a normal morphology and numerous actin filaments (panel ad). Also, cSrc and GFP-AFAP-110 do not colocalize (panel d). Middle panels: SYF
cells were transiently transfected with both GFP-AFAP-110 (panel e) and Flag-tagged
myrPKCα and immunolabeled with anti-Flag antibody (panel g). In the absence of cSrc,
SYF cells display well-formed actin filaments and have a normal morphology (panel eh). Bottom panels: SYF cells were transiently transfected with GFP-AFAP-110 (panel
i), cSrc (panel j) and Flag-tagged myrPKCα (panel k), and immunolabeled with mAb
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EC10 and anti-Flag antibody. In the presence of both cSrc and myrPKCα, SYF cells
lose actin filament integrity (panel i-k) and instead form actin rich punctate structures
(panel l, gray arrows). GFP-AFAP-110 and cSrc are also observed to colocalize in the
presence of myrPKCα (panel l). EC10 was visualized with Cy5 anti-Mouse IgG, while
anti-Flag polyclonal antibody was visualized with TRITC-anti-Rabbit IgG. Bars
represent 20µM.
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Figure 3. The ability of dominant positive AFAP-110 to activate cSrc correlates
with the colocalization of AFAP-110 with cSrc.
A. SYF cells were transiently cotransfected with cSrc and either GFP-AFAP-110 (panel
a) or GFP-AFAP-110∆Lzip (panel e), and immunolabeled with EC10 (panels b and f) and
anti-phosphotyrosine (panels c and g). Cells co-expressing GFP-AFAP-110 and cSrc
display immunoreactivity with the phospho-specific antibody equivalent to surrounding,
non-transfected cells (panel c), as well as numerous GFP-AFAP-110-decorated actin
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filaments (panel a). Likewise, no colocalization is observed between GFP-AFAP-110
and cSrc (panel d). Cells co-expressing GFP-AFAP-110∆Lzip and cSrc display increased
immunoreactivity to the phospho-specific antibody compared to surrounding, nontransfected cells (panel g), as well as a complete disruption in actin filament integrity
(panel e). Also, GFP-AFAP-110∆Lzip and cSrc are observed to colocalize (panel h).
Transfection of GFP-AFAP-110∆Lzip alone into SYF cells (panel i) resulted in no
alterations in actin stress fiber integrity (panel j), as well as no elevation in cellular
tyrosine phosphorylation (panel k), indicating that AFAP-110∆Lzip activates cSrc, and not
another tyrosine kinase present in SYF cells. B. SYF/cSrc cells were transiently
transfected with GFP-AFAP-110∆Lzip (panel m) and immunolabeled with TRITCphalloidin (panel n) and anti-cortactin (panel o). Expression of the leucine zipper mutant
in SYF/cSrc cells results in a loss in actin stress fiber organization and the formation of
actin-rich podosome structures (arrow, panel n). Cortactin is also present in these
structures (panel o and p). C. SYF cells were transiently cotransfected with cSrc and
either GFP-AFAP-11071A/∆Lzip (panel q), or GFP-AFAP-110∆180-226/∆Lzip (panel u), and
immunolabeled with mAb EC10 (panels r and v) and anti-phosphotyrosine (panels s and
w). Cells co-expressing cSrc and GFP-AFAP-11071A/∆Lzip display immunoreactivity with
the phosphotyrosine antibody equivalent to surrounding, non-transfected cells (panel s).
In the context of the dominant positive leucine zipper deletion, GFP-AFAP-11071A/∆Lzip
and cSrc are observed to colocalize (panel t). Cells co-expressing cSrc and GFPAFAP-110∆180-226/∆Lzip display immunoreactivity with the phospho-specific antibody
equivalent to surrounding, non-transfected cells (panel w). In the context of the
dominant positive leucine zipper deletion, GFP-AFAP-110∆180-226/∆Lzip and cSrc fail to
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colocalize (panel x). EC10 was visualized with Alexa Fluor 546 Goat anti-mouse IgG,
anti-phosphotyrosine was visualized with Alexa Fluor 647 Goat anti-rabbit IgG, cortactin
was visualized with Alexa Fluor 647 Goat anti-Mouse IgG, and actin was visualized with
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Figure 4. Both AFAP-110 and AFAP-110∆Lzip are able to activate cSrc, in vitro.
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Recombinant AFAP-110 and AFAP-110∆Lzip were incubated with cSrc and subjected to
an in vitro kinase assay. Western blot analysis of phosphotyrosine levels and control
protein levels are shown. Blot representative of seven separate experiments.
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Figure 5. PKCα activates cSrc and alters actin filament integrity in an AFAP-110dependent fashion.
A. SYF/cSrc cells were transiently cotransfected with Flag-tagged myrPKCα and either
GFP-AFAP-110 (panel a), GFP-AFAP-11071A (panel d), or GFP-AFAP-110∆180/226 (panel
g), and labeled with Anti-Flag antibody (panels b, e, and h) and anti-phosphotyrosine
(panels c, f, and i). Cells co-expressing GFP-AFAP-110 and myrPKCα display
increased immunoreactivity with the phosphotyrosine antibody compared to
surrounding, non-transfected cells (panel c). Cells co-expressing GFP-AFAP-11071A
and myrPKCα display immunoreactivity to the phosphotyrosine antibody equivalent to
surrounding, non-transfected cells (panel f) as well as contiguous actin filaments
coincident with AFAP-110 (panel d). Identical results were observed upon coexpression of GFP-AFAP-110∆180-226 with myrPKCα (panels g-i). Arrow denotes actinrich punctate structure. Bars represent 20µM. B. SYF/cSrc cells were transiently
cotransfected with Flag-tagged myrPKCα and either GFP-AFAP-110 (panel j), GFPAFAP-11071A (panel m), or GFP-AFAP-110∆180/226 (panel p), and immunolabeled with
Anti-Flag antibody (panels k, n, and q) and phospho-Src family (Y416) antibody (panels
l, o, and r). Cells co-expressing GFP-AFAP-110 and myrPKCα display increased
immunoreactivity with the phospho-Src family (Y416) antibody compared to
surrounding, non-transfected cells (panel l). Arrows denote podosomes. Cells coexpressing GFP-AFAP-11071A and myrPKCα display immunoreactivity to the phosphoSrc family (Y416) antibody equivalent to surrounding, non-transfected cells (panel o) as
well as contiguous actin filaments coincident with AFAP-110 (panel m). Identical results
were observed upon co-expression of GFP-AFAP-110∆180-226 with myrPKCα (panels p283

r). Bars represent 20µM. Anti-Flag mAb was visualized with Alexa Fluor 647 Goat antimouse IgG, while anti-phosphotyrosine and phospho-Src family (Y416) antibodies were
visualized with Alexa Fluor 546 Goat anti-Rabbit IgG.
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Figure 6. PKCα is present in SYF cells.
SYF cells were lysed and 40 µg of protein were separated by SDS-PAGE and western
blotted with isoform-specific PKC antibodies, as listed.
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Figure 7. PMA directs AFAP-110 to colocalize with cSrc, while PKC-inhibitors
block PMA-induced colocalization.
A. SYF cells were transiently cotransfected with either GFP-AFAP-110 (panel a), GFPAFP-11071A (panel e) or GFP-AFAP-110∆180-226 (panel i) and cSrc, treated with 100nM
PMA for 30 minutes, and labeled with mAb EC10 (panels b, f, and j) and antiphosphotyrosine antibody (panels c, g, and k). Upon PMA stimulation, SYF cells
display a loss of actin stress fiber integrity (panel a), as well as an increase in
immunoreactivity with the anti-phosphotyrosine antibody (panel c). PMA was also
observed to induce colocalization of GFP-AFAP-110 and cSrc (panel d). Cells
cotransfected with GFP-AFAP-11071A (panel e) and cSrc displayed immunoreactivity
with the anti-phosphotyrosine antibody equivalent to surrounding, non-transfected cells
(panel g) in response to PMA treatment. Cells cotransfected with GFP-AFAP-110∆180/226
(panel i) and cSrc displayed immunoreactivity with the anti-phosphotyrosine antibody
equivalent to surrounding, non-transfected cells (panel k) in response to PMA treatment.
Bars represent 20µM. B. SYF cells were cotransfected with either GFP-AFAP-110
(panel m), GFP-AFP-11071A (panel q) or GFP-AFAP-110∆180-226 (panel u) and cSrc and
pre-treated with 6µM bisindolylmaleimide [I] for 6 hours, 100nM PMA for 30 minutes,
and then fixed and labeled with EC10 mAb (panels n, r, and v) and antiphosphotyrosine antibody (panels o, s, and w). In the presence of bisindolylmaleimide
[I], PMA treatment of cells co-transfected with GFP-AFAP-110 and cSrc resulted in no
changes in actin filament integrity (panel m). Likewise, bisindolylmaleimide [I] treatment
blocked PMA induced elevation in cellular tyrosine phosphorylation levels (panel o), and
the colocalization of GFP-AFAP-110 and cSrc (panel p). In the presence of
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bisindolylmaleimide [I], PMA treatment of cells cotransfected with GFP-AFAP-11071A
and cSrc resulted in immunoreactivity with the phosphotyrosine antibody equivalent to
surrounding, non-transfected cells (panel s) (panel q). Similar results were observed in
cells cotransfected with GFP-AFAP-110∆180/226 and cSrc (panels u-x). Bars represent
20µM. EC10 was visualized with Cy5 anti-Mouse IgG, while anti-phosphotyrosine was
visualized with TRITC anti-Rabbit IgG.
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Figure 8. PMA stimulates an increase in AFAP-110 tyrosine phosphorylation, as
well as the association between AFAP-110 and cSrc in SYF/cSrc cells.
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A. SYF/cSrc cells were treated with DMSO, 100nM PMA (30 minutes), or 100nM PMA
(30 minutes) and 6µM bisindolylmaleimide [I] (6 hours), and AFAP-110 was
immunoprecipitated from lysates using the F1 antibody and resolved on an 8% SDSPAGE gel. Western blot analysis was preformed using an anti-phosphotyrosine
antibody. Steady state levels are also shown for AFAP-110. B. SYF/cSrc cells were
treated with DMSO, 100nM PMA (30 minutes), or 100nM PMA (30 minutes) and 6µM
bisindolylmaleimide [I] (6 hours), and cSrc was immunoprecipitated from lysates using
the Anti Src (N-18) antibody and resolved on an 8% SDS-PAGE gel. Western blot
analysis was preformed using an anti-phosphotyrosine antibody. AFAP-110 was able to
be co-immunoprecipitated with cSrc in response to PMA treatment, while pre-treatment
with bisindolylmaleimide [I] resulted in an abrogation of this interaction. (Right panel)
Twenty-five µg of cell lysate was resolved and western blot done separately for cSrc
and AFAP-110.
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Figure 9 AFAP-110 is not detected in CaOV3 ovarian cancer cells.
Confluent monolayers of SYF/cSrc, MCF10A, A2780, CaOV3, and CEF cells were
lysed, and 25µg of protein was separated on an 8% SDS-PAGE gel. A. Western blot
analysis was performed using F1 polyclonal antibody to determine AFAP-110 levels and
monoclonal β-actin antibody as a loading control. The blots were done separately and
results combined. B. Western blot analysis was performed using cSrc N-16 polyclonal
antibody and anti-PKCα monoclonal antibody to detect endogenous cSrc and PKCα
protein levels. The blots were done separately and results combined.
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Figure 10. PMA treatment of CaOV3 cells over-expressing cSrc does not result in
a significant increase in cellular tyrosine phosphorylation.
A. CaOV3 cells were transiently transfected with cSrc, and then treated with DMSO,
100nM PMA (30 minutes), or 100nM PMA (30 minutes) and 6µM bisindolylmaleimide [I]

290

(6 hours). After fixation, cells were labeled with mAb EC10 (panels a, e, and i), TRITCphalloidin (panels b, f, and j), and anti-phosphotyrosine antibodies (panels c, g, and k).
DMSO treatment resulted in no change in cellular morphology or actin filament integrity
(panels a and b), and displayed only a slight immunoreactivity to the antiphosphotyrosine antibody compared to surrounding, non-transfected cells (panel c).
Likewise, treatment with PMA resulted in no change in cellular morphology or actin
filament integrity (panels e and f), as well as immunoreactivity to the antiphosphotyrosine antibody comparable to DMSO treatment (panel g). Pretreatment with
bisindolylmaleimide [I] produced similar results (panels i, j, and k). B. myr-PKCα was
transiently transfected into CaOV3 cells and labeled with Anti-Flag mAb (panel m),
TRITC-phalloidin (panel n), and anti-phosphotyrosine antibody (panel o). Expression of
myrPKCα had no effect on cell morphology or actin filament organization (panel n).
These cells also displayed immunoreactivity to the anti-phosphotyrosine antibody
equivalent to surrounding, non-transfected cells (panel o). EC10 and anti-Flag
monoclonal antibody were visualized with Alexa Fluor 488 Goat anti-Mouse IgG and
anti-phosphotyrosine was visualized with Alexa Fluor 647 Goat anti-Rabbit IgG. Actin
was visualized by staining with TRITC-phalloidin. Bars represent 20µM.
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Figure 11. AFAP-110∆Lzip elevates cellular tyrosine phosphorylation and the
formation of actin-rosette structures in CaOV3 cells.
A. CaOV3 cells were transiently transfected with either GFP-AFAP-110 (panel a) or
GFP-AFAP-110∆Lzip (panel e) and cSrc (panels b and f), and immunolabeled with antiphosphotyrosine antibody (panels c and g). Expression of GFP-AFAP-110 and cSrc
resulted in no significant increase in cellular tyrosine phosphorylation (panel c).
Alternately, expression of GFP-AFAP-110∆Lzip resulted in a significant increase in
cellular tyrosine phosphorylation (panel g), as well as the disruption of actin filament
integrity and the formation of actin-rich podosome structures (panel e, white arrow). B.
CaOV3 cells were transiently transfected with either GFP-AFAP-110 (panel i) or GFPAFAP-110∆Lzip (panel l) and cSrc, and immunolabeled with anti-cortactin antibody
(panels j and m). Expression of GFP-AFAP-110 (panel i) does not result in the
formation of podosomes, as indicated by the diffuse cortactin staining (panel j).
Expression of GFP-AFAP-110∆Lzip results in the alteration in actin stress fiber integrity
and the formation of cortactin-rich podosomes (arrow, panel n). EC10 was visualized
with Alexa Fluor 546 Goat anti-Mouse IgG, anti-cortactin antibody was visualized with
Alexa Fluor 647 Goat anti-mouse IgG, and anti-phosphotyrosine was visualized with
Alexa Fluor 647 Goat anti-Rabbit IgG. Bars represent 20µM.
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Figure 12. Expression of AFAP-110 results in an increase in cellular tyrosine
phosphorylation and cSrc activation in response to PMA treatment of CaOV3
cells.
CaOV3 cells were transiently transfected with the dual expression vector pCMV-AFAP110/cSrc, and then treated with DMSO, 100nM PMA (30 minutes), or 100nM PMA (30
minutes) and 6µM bisindolylmaleimide [I] (6 hours). After fixation, cells were
immunolabeled with the AFAP-110 monoclonal antibody 4C3 (panels a, e, i, m, q, and
u), TRITC-phalloidin (panels b, f, j, n, r, and v), and either anti-phosphotyrosine (panels
c, g, and k) or phospho-Src family (Y416) antibody (panels o, s, and w). Treatment with
DMSO resulted in immunoreactivity to the antiphosphotyrosine antibody was equivalent
to surrounding, non-transfected cells (panel c), as well as no elevation if Src kinase
activity (panel o). DMSO treatment also had no affect on actin filament integrity (panels
b and n). Treatment with PMA resulted in the loss of actin stress fiber integrity and the
formation of actin-rich podosome structures (arrows, panels f and r). Likewise, in
response to PMA treatment, transfected cells displayed a great increase in
immunoreactivity to the anti-phosphotyrosine antibody (panel g) and elevated Src
kinase activity (panel s) compared to surrounding, non-transfected cells. Pre-treatment
with bisindolylmaleimide [I] resulted in a complete abrogation of the affects observed
upon treatment with PMA (panels i-l and u-x). 4C3 monoclonal antibody was visualized
with Alexa Fluor 488 Goat anti-mouse IgG, actin was visualized with TRITC-phalloidin,
while anti-phosphotyrosine and phospho-Src family (Y416) antibodies were visualized
with Alexa Fluor 647 Goat anti-rabbit IgG. Bars represent 20µM.
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Figure 13. Mutants of AFAP-110 that abrogate interactions with cSrc or PKCα are
able to block the affects of AFAP-110 in response to PMA treatment in CAOV3
cells.
A. CaOV3 cells were transiently co-transfected with GFP-AFAP-11071A (panels a, e and
i) and cSrc, and then treated with DMSO, 100nM PMA (30 minutes), or 100nM PMA (30
minutes) and 6µM bisindolylmaleimide [I] (6 hours). After fixation, cells were
immunolabeled with EC10 (panels b, f, and j), and anti-phosphotyrosine antibodies
(panels c, g, and k). PMA treatment results in normal cell morphology (panels a, e and
i), as well as no change in cellular tyrosine phosphorylation (panel g) from that observed
upon treatment with DMSO (panel c). Likewise, pre-treatment with bisindolylmaleimide
[I] and PMA also resulted in no elevation in cellular tyrosine phosphorylation above
background (panel k). Identical results were obtained upon expression of GFP-AFAP110∆180-226 and cSrc upon treatment with PMA. EC10 was visualized with Alexa Fluor
546 Goat anti-mouse IgG, while anti-phosphotyrosine antibody was visualized with
Alexa Fluor 647 Goat anti-rabbit IgG. Bars represent 20µm.
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